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This is a study of the diagnosis and treatment of adults with
obstructive airways disease in general practice and is in two parts
Part 1 - The diagnosis
The aims of this section were to assess, firstly, whether
patients diagnosed by their general practitioners as having asthma or
chronic bronchitis could be separated by their symptom complexes,
secondly, whether the patients' airways reversibility could be
predicted from this complex and, thirdly, whether patients with
demonstrable airways reversibility were undertreated.
The findings demonstrate that,although patients diagnosed as
having asthma or chronic bronchitis could be separated by their
symptom complexes, there was considerable overlap between the two
groups. In practice differentiation using the symptomatic history
would be difficult in about a third of patients. There was a poor
correlation between the symptom complex and the bronchodi lator and
corticosteroid reversibility, though the latter occurred more
frequently in those with an asthmatic symptomatology. The majority of
patients in whom corticosteroid reversibility was demonstrated had
been undertreated.
These findings are of importance to general practitioners in
demonstrating that the symptomatic history cannot be used as a
reliable basis for diagnosis or to predict airways reversibility.
Trials of bronchodi lators and corticosteroid therapy are therefore
warranted in any patient with troublesome airways obstruction
regardless of the symptomatic history.
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Part 2 - The treatment
The aim of this section was to undertake a comparative study
of the management of patients with obstructive airways disease in
several general practices and a specialist clinic and to identify the
main problems of drug therapy.
Approximately a fifth of patients seen in general practice
had also recently been reviewed by a specialist clinic. Although
patients who attended specialist clinics had a similar severity of
symptoms to those attending their general practitioners alone, there
were noticeable differences in therapy between these groups. Inhaled
unlike oral therapy was underused by general practitioners.
Prophylactic therapy was underprescribed and underused; compliance
with this form of therapy was a major problem. Trials of oral
corticosteroid therapy were underused in patients diagnosed as having
chronic bronchitis. It is concluded that many patients in general
practice receive sub-optimal treatment for their airways obstruction
because of a combination of poor compliance and inadequate
prescribing.
These findings demonstrate a need to educate general
practitioners in the use of appropriate treatment for obstructive




There are two main problems in the management of obstructive
airways disease in general practice, firstly that of making a correct
diagnosis and secondly that of giving optimal treatment. In this
Thesis these two problems are assessed separately.
The diagnosis-
There is an impression that chronic asthma is often
misdiagnosed as chronic bronchitis in general practice, because of
the similarity of symptoms in these two conditions. Chronic
bronchitis has been associated previously with irreversible and
untreatable airways obstruction. A patient given this diagnosis,
therefore, may be undertreated. It has been stated that the diagnosis
given to the patient is unimportant in clinical practice as the
physician usually moves from a symptom complex directly to therapy
and provided that adequate treatment is given for reversible airways
obstruction, the name attached to the condition is irrelevant (Gross
1980). These statements may be individually true but collectively
their validity depends upon the ability to predict airways
reversibilty from the symptom complex. Gregg has demonstrated how
simple reversibility studies can be undertaken in order to identify
those patients who respond to therapy and who are likely to be
asthmatic (Gregg 1964). There is little information, however, as to
how useful such studies are in the diagnosis and management of
patients with airways obstruction in general practice.
The aims of the first part of the survey were to assess
1) Whether patients diagnosed by their general practitioners as
having asthma or chronic bronchitis could be separated by their
symptom complexes.
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2) Whether the patients airways reversibility could be predicted
from this complex.
3) Whether patients with demonstrable airways reversibility were
undertreated.
The Treatment-
Despite the introduction of efficient bronchodilating and
prophylactic drugs there has been little improvement in the death
rate from asthma over the past 30 years {OPCS-Mortality statistics).
During the same period the hospital admission rate for asthma has
almost doubled (OPCS- Hospital inpatient enquiry). Enquiries into the
circumstances of asthma deaths have suggested that bronchodilators
and corticosteroids were often underprescribed and underused in
severe unstable asthma (British Thoracic Society 1982). These
findings have been confirmed in studies of new hospital outpatient
referrals (Stellman et al 1982). The continuing use of old,
potentially addictive, barbiturate containing bronchodilators
continues to be a source of concern (Seaten 1978), especially as they
are of doubtful efficacy when compared with newer agents (Paterson
and Shenfield 1974). Unfortunately some patients find aerosol
inhalers difficult to use (Patersen and Crampton 1976), though the
magnitude of this problem in the community is unknown. Dry powder
inhalers and the spacer device have been developed because of this
problem but there is little information as to how often they are
used.
A previous study on the treatment of wheezy children in the
community suggested an underuse of bronchodilating drugs and that
this was probably related to a reluctance to use the diagnostic
label- asthma (Speight 1978). Although the need to improve the care
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of asthmatics in the community has been realised (Editorial 1981b),
there have been few studies concerning this problem in adults. Colmer
and Pereira Gray (1983), and Shee et al (1980) have both studied
asthma care in single general practices in Exeter and London
respectively. The latter group demonstrated the underprescription of
effective therapy. However, neither study has given insight into the
problems of management in this group of patients, and both studies
suffer from the fact that when examining a single general practice
individual prescribing habits may become a dominant feature of the
study and, therefore, may not be representative of general practice
care.
The aims of this part of the survey are:-
1) To study the drug therapy of patients with obstructive airways
disease in several general practices.
2) To identify the main problems associated with the use of these
drugs and to assess whether such problems are due to inappropriate
prescribing or to the patient's misuse of treatment.
3) To compare the management in general practice to that observed in
a specialist clinic.
The Thesis is divided into eight chapters. Chapter 1 gives a
historical perspective and describes the development of drug therapy
for obstructive airways disease. It also gives insight into the
difficulties of diagnosis in such patients. Chapter 2 describes the
structure of the study and the techniques involved. Chapter 3
includes details of the patients involved. Chapters 4 and 5 describe
the symptom complexes and airways reversibility of patients diagnosed
by their general practitioners as asthmatic and chronic bronchitic.
Chapters 6 and 7 describe the problems associated with the management
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b) Modern drug therapy for obstructive airways disease
c) The classification of obstructive airways disease
d) Epidemiology




The modern word asthma is derived from the Greek o< <y oC
meaning "to pant". Though Hippocrates (4th century B.C.) referred to
the condition, it was Aretaeus in the 2nd century A.D., who gave the
most vivid and surprisingly accurate description (Adams 1856)-
"The symptoms of its approach are heaviness in the chest,
sluggishness to one's accustomed work and to every other exertion....
but if the evil gets worse the cheeks are ruddy, eyes protruberant as
if from strangulation; a rale during the waking state, but the evil
much worse in sleep; voice liquid and without resonance, a desire of
much and of cold air."
In contrast his explanation of its aetiology based on a disorder of
the spirit or "pneuma" is perplexing to modern ears. Galen believed
that the condition was caused by excessive thick secretions draining
from the base of the brain on to the lungs. This led Aetius (5th
century A.D.) to recommend cautery to the head for the treatment of
asthma. In order to thin these secretions Paulus Aegineta in the 7th
century A.D. (Adams 1844) recommended the use of attenuent and
detergent medicines with:
"continued purging with drastic medicines and vomiting from radishes"
The account of Aegineta suggests that the term asthma may have been
used as a description rather than a disease state; this is
illustrated in the following passage in which he differentiates
asthma from orthopnoea:
"Those who breathe thick without fever, like those 'who have run fast,
are said to be asthmatic, that is to say pant for breath: and from
their being obliged to keep their chest erect for fear of being
suffocated, they are called orthopnoeic"
-Early English Descriptions
The classical Greek theory of asthma, especially the
teachings of Galen dominated medical practice in Europe until the
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17th century. This is illustrated by an account of a famous
consultation in 1 552 between John Hamilton, an influential bishop of
St. Andrew's, who suffered from asthma, and Jerome Cardan, Professor
of Medicine at Pavia. He attempted to purge the brain by applying
ointments to the coronal suture (luckily he also advised the patient
not to sleep on a feather bed, and unwittingly cured his patient by
antigen avoidance!) (Dana 1921).
Van Helmont in the mid 17th century was the first to dispute
the theories of Galen, stating that in asthma:
"nothing rains down from the head to the lungs"
and that:
"remedies are badly applyed to the head in an asthma"
However, his theory of the aetiology of asthma being an imbalance of
the body's vital force is as puzzling as that of Galen (Van Helmont
1662).
Thomas Willis was the first to associate asthma with
bronchial obstruction (Willis 1679); Sir John Floyer agreed with this
basic defect and listed its causes under the titles: air, diet,
exercise, and passions. The treatment he advised, however, including
emetics, bleeding and blisters, was as uncomfortable as those of
ancient Greece (Floyer 1698).
During this period there was a trend to use the term asthma
to describe any breathless patient. William Cullen, the famous
Edinburgh physician, strongly disapproved of this, stating that the
term "asthma" should depend on the presence of particular symptoms
and a "particular proximate cause" (Cullen 1784).
Charles Badham was the first to describe chronic bronchitis
and, as today, chronic cough and expectoration were the hallmarks of
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this condition (Badham 1808). The famous French physician, Laennec,
preferred the term "pulmonary catarrh" to bronchitis. He described a
condition of "dry pulmonary catarrh" in which attacks of shortness of
hreath could occur (Laennec 1846). One wonders how he differentiated
such patients from asthmatics.
Laennec rightly thought that bronchial narrowing was caused
by spasmodic contraction of muscular fibres in the bronchial wall,
controlled by nervous stimulation. In 1842 the French physiologist,
Longet, demonstrated this innervation by stimulating the Vagus nerve.
Curing this period two substances which could block the actions of
this nerve were in use: Belladonna and Datura Stramonium. These were
the first specific anti-asthmatic drugs but other medications
remained popular. Dobell listed 39 formulations for inhalation and 44
preparations in tablet or powder form (Dobell 1886). Their main
constituents were: potassium nitrate, datura stramonium, lobelia,
cannabis indica, belladonna, arsenic, potassium iodide, coffee, and
tobacco. Henry Hyde Salter admitted that such treatments were "of
very irregular and uncertain operation" and that no single successful
remedy existed (Hyde Salter 1868).
-Modern Descriptions of Asthma and Chronic Bronchitis
Knowledge of the aetiology of asthma had, however, improved;
in 1819 Bostock gave the first account of hayfever and its
relationship to asthma. Later Blackley published a classical account
of hayfever and hayasthma; relating the symptoms to pollen exposure
he designed a method of pollen counting using glycerine on a glass
slide (Blackley 1873).
Hie term "anaphylaxis" was introduced by Richet after noting
the change in reaction of dogs to repeated injections of a
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preparation of sea anemone (Richet 1908); Von Pirquet used the term
allergy for a similar reaction. Asthma was thought to be a phenomenon
of anaphylaxis after the discovery that "toxalbumin" of pollen
injected into normal subjects had no effect, whereas in asthmatics it
could provoke airways obstruction (Meltzer 1910). Modification of
clinical reactions by the repeated injection of small quantities of
such substances was investigated by Noon and Cooke, and was the basis
of desensitization therapy (Noon 1911, Cooke 1918). The term atopy-
was later used to describe patients who were unusually sensitive to
substances in the environment and who had a well defined group of
clinical disorders, such as asthma, hayfever, and childhood eczema
(Coca and Cooke 1923). This trait was later found to be associated
with the capacity to develop antibodies (IgE) to various external
substances (or allergens) (Ishizaka and Ishizaka 1971).
Only a proportion of asthmatics, however, were found to have
evidence of atopy, and Rackemann classified asthma as extrinsic or
intrinsic depending on whether there was evidence of an allergic
aetiology or not (Rackemann 1947). He thought that the intrinsic type
had a variety of aetiologies from the psychosomatic to infection.
Unfortunately the aetiology of non-allergic asthma remains poorly
understood.
Surprisingly, it was not until the 1950's that the true
impact of smoking on the development of chronic bronchitis and
obstructive airways disease was realised (Oswald et al 1953). Later
it was demonstrated that the progression of airways obstruction was
independent of the severity of cough and expectoration and was the
major cause of morbidity (Fletcher et al 1976).
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b) MODERN DRUG THERAPY FOR AIRWAYS OBSTRUCTION.
There has been a great change in attitude to the management
of airways obstruction in the later part of this century with a
greater emphasis on drug therapy. In the 1930's asthma was often
considered a psychosomatic disorder and the doctors' attitudes were
not always as constructive as they might have been. In the absence of
more effective therapy patients were often taught breathing
exercises. Children were separated from their families and taught in
special schools. Until recently parties of asthmatics were sent to
Davos in Switzerland with the help of the British Red Cross (Morrison
Smith 1983). It was the development of efficient drug therapy that
changed attitudes to the management of asthma.
Bronchodilator drugs
Sympathomimetic Agents-
In 1895 the potent effects of suprarenal gland extracts in
man were reported (Oliver and Schafer 1895). Shortly after this the
main active principal, adrenaline, was isolated. A group of related
amines were later discovered with comparable but not identical
physiological actions (Barger and Dale 1910); these substances were
called "sympathomimetic".
A dried tablet form of the suprarenal gland was originally
used in asthma with seme success, however, it was the injectable form
of adrenaline that revolutionised the therapy of asthma (especially
of the acute attack). Earlier in this century it was often considered
the one valuable treatment in asthma (Rackemann 1927).
The development of another sympathomimetic drug called
ephedrine occurred at a similar time in the West, though it had teen
used by the Chinese as a herbal remedy called "Ma Huang" for many
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centuries. Ephedrine was first isolated in Japan by Nagai in 1887,
and initial clinical studies took place in that country. An oral
preparation was later marketed for use in asthma; though it did not
achieve instant success probably because initially recommended doses
were incorrect.An early therapeutic trial, however, found it of value
in over half the patients treated (Leopold and Miller 1927).
Herxheimer described the development of tolerance to the
bronchodilator effects of ephedrine used over 2-4 days (Herxheimer
1946). This tolerance was overcome by the use of higher doses, but at
the risk of inducing side effects such as excitement and urinary
retention. Because of these side effects at higher doses, ephedrine
in low dose was often combined with theophylline and a barbiturate
(the latter drug presumably added to counteract the central nervous
system effects). Such combination tablets continue to be used though
there is little evidence to support their effectiveness (Paterson and
Shenfield 1974).
In 1 940 a synthetic sympathomimetic agent was developed and
found to be more potent than adrenaline. In Britain it was called
isoprenaline. In 1 948 Ahlquist introduced a theory that
sympathomimetic drugs exerted their effects by actions on two
different types of receptors in the body, called c* and ft receptors
(Ahlquist 1948). Unlike adrenaline, isoprenaline was thought to
activate only preceptors and therefore had actions specific to the
bronchi, heart and peripheral vasculature. Used by inhalation in
therapeutic doses the actions were almost specific to the bronchi.
Isoprenaline was unsuccessful when taken orally because of rapid drug
metabolism.
In the 1960's other sympathomimetic agents were discovered,
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which had selective actions on the bronchi (and peripheral
vasculature) with a relative sparing of cardiac effects. Because of
the selectivity of these preceptor actions Tands proposed the theory
of having two types of preceptor: ^31 and[Q with the bronchi having
fl2 receptors (Lands et al 1967). Several drugs with varying degrees
of fl 2 rather than /31 actions have been developed and are new the
mainstay of modern asthma therapy. They include orciprenaline,
isoetherine, terbutaline, salbutamol, fenoterol and rimiterol and are
usually available in both oral and inhaled forms.
Anticholinergic Agents-
Atropa Belladonna and Datura Stramonium were used in various
powders for asthma throughout the 19th century. The chief
constituents of these drugs, atropine, was first isolated by Mein in
1832. It has been in regular use both as an injection and as an
inhalant since then. As an inhalant, atropine is still occasionally
used in combination with adrenaline or isoprenaline, the
bronchodilating effects of atropine being slower in onset but more
prolonged than the latter two agents. Crompton found that chronic
bronchitics were relatively more responsive to atropine than to
sypathomimetic drugs; the reverse being true in the asthmatic
(Crompton 1968). In 1973 a more selective anticholinergic agent was
developed called ipratropium bromide (Poppius and Salorinne 1973).
This drug has fewer central anticholinergic effects and has now
virtually replaced atropine.
The development of inhaled therapy-
The earliest form of inhaled therapy was from smoke derived
from burning various powders and until recently asthma cigarettes
were sold "over the counter" at chemists. In 1910 adrenaline was
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sprayed directly down a bronchoscope, with benefit in asthma (Graeser
1939). Since that time various atomisers and sprays have been
developed to deliver drugs singly, or in combination. Seme of the
combination solutions for inhalation are still available, such as
"Brovon" (containing adrenaline, atropine, and papaverine). Even in
1929 it was noted that inhalation therapy was associated with far
fewer side effects than oral or parenteral treatment (Camps 1929).
Until the 1950's the equipment used for inhalation, however, was
bulky and often fragile and the introduction of small pressurised
aerosol inhalers was a major advance.
Unfortunately aerosol inhalers were later implicated as a
cause of an epidemic of asthma deaths in the 1960's (Speizer et al
1968). The isoprenaline inhaler was considered by many to be the
major culprit as the rise and fall of its sales in the 1960's in
England and Wales was mirrored by a similar rise and fall in asthma
deaths (Inman and Melstein 1969). Before 1967 such inhalers were
available without prescription and therefore were possibly more open
to abuse. However, isoprenaline may not have been the sole cause of
excess asthma mortality. Although a similar epidemic of asthma deaths
occurred in Australia, these were not as closely related to
isoprenaline aerosol sales (Gandevia 1973). A recent review of asthma
deaths in this country has suggested that underuse of drug therapy
was more common than overuse (British Thoracic Association 1982). It
is possible that,following the epidemic of deaths in the 1960's,
there may be now underuse of aerosol inhalers in the community
because of fear of their untoward effects (Stableforth 1983).
Recently it has become evident that some patients are unable
to use aerosol inhalers properly (Paterson and Crompton 1976, Epstein
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et al 1979). This has resulted in the development of the dry powder
inhaler and spacer devices which may be easier to use efficiently.
The methylxanthines-
For many years the stimulant and diuretic properties of the
methylxanthines (theophylline, caffeine and theobromine) have been
used as infusions as in tea, coffee and cocoa. In the 19th century
strong coffee was often recommended for asthma. Unfortunately
theophylline, the most potent bronchodilator of the methylxanthines,
caused severe gastric irritation and was unsuitable for parenteral
use. In the 1940's a combination of theophylline and ethylene diamine
was found to be chemically stable and could be given intravenously;
this drug was called aminophylline (Herman et al 1937). Later oral
forms of theophylline were introduced which caused less gastric
irritation. Unfortunately, theophyllines have a narrow therapeutic
range and there is a wide individual variation in drug metabolism
(Turner-Warwick 1957). For maximum benefit, therefore, the dosage has
to be manipulated to achieve an optimal drug level. Despite these
drawbacks, and their moderate potency when compared with
sympathomimetic agents (Palmer et al 1971), theophyllines have become
popular recently, probably because of the introduction of
slew-release preparations which maintain stable serum levels
throughout the day.
Prophylactic drugs
The word prophylactic is derived from the Greek meaning "keep
guard before". In medical terminology it refers to preventative
therapy. Although seme of the antispasmodic bronchodi lators may be
used in this way, only drugs whose action is primarily preventative
will be discussed under this heading.
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Corticosteroid drugs-
The discovery of the potent effects of adrenocorticotropic
hormone (Bordley et al 1949) and cortisone (Randolph and Rollins
1950) was to fundamentally change the outlook of patients with
chronic asthma. There was, however, considerable disagreement as to
how these drugs should be used. Initial studies suggested that
corticosteroids were of little value as a maintenance therapy in
chronic asthma (Medical Research Council 1956). Fortunately, these
drugs were not abandoned, and their undoubted benefits were later
emphasised (Rees and Williams 1 962). The high incidence of side
effects with systemic corticosteroids was quickly realised (Editorial
1958) and because of this inhalation therapy was investigated at an
early stage. Early studies of inhaled hydrocortisone were
disappointing because of the high systemic absorption of the drug
with only moderate local effects. In 1971-4 two corticosteroid drugs
with high topical activity but with little systemic absorption were
introduced in aerosol and, shortly after, in dry powder form for
inhalation (Morrow Brown et al 1972). These drugs were beclcmethasone
diproprionate and betamethasone valerate. Such inhaled
corticosteroids have now replaced the need for the systemic form in
most asthmatics.
Sodium Crcmoglycate-
The discovery of sodium cromoglycate in 1 965 opened an
entirely new therapeutic avenue in asthma care. Although an
oversimplification, it has been labelled a mast cell stabilizing
agent with anti-allergic properties. Altounyan discovered the
substance whilst investigating khellin, a constituent of an ancient
remedy from the eastern Mediterranean countries (Altounyan 1967).
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Sodium cromoglycate was prepared in powder form for treatment by
inhalation; a specially designed turbine type of inhaler was
introduced to deliver the powder (the spinhaler). The drug has been
found to be especially useful in paediatric practice (Godfrey 1983a),
though beneficial results have been recorded in adult asthma
(Bernstein 1981, Northern General Hospital, Brompton Hospital and MRC
collaborative trial 1976). Because of the lack of systemic absorption
sodium cromoglycate has been found to be an extremely safe drug. A
few patients have found the powder spinhaler delivery troublesome,
but recently an aerosol inhaler has been introduced which, for some,
may be preferable.
c) THE CLASSIFICATION OF OBSTRUCTIVE AIRWAYS DISEASE
The Ciba Guest Symposium (1959) introduced the first major
classification of obstructive airways disease. Asthma was defined as
an abnormality of function, namely variable airways obstruction,
rather than using aetiological or physiological terms
"Asthma refers to the condition of subjects with widespread narrowing
of the bronchial airways, which changes its severity over short
periods of time either spontaneously or under treatment and is not
due to cardiovascular disease."
they continued:-
"The clinical characteristics are abnormal breathlessness, which may
be paroxysmal or persistent, wheezing, and in most cases relief by
bronchodilator drugs (including steroids)."
Alternatively, the Symposium defined chronic bronchitis in
symptomatic terms
"Chronic bronchitis refers to a condition of subjects with chronic or
recurrent excessive mucous secretion in the bronchial tree."
they continued
"The diagnostic criterion is clinical, and is chronic or recurrent
cough with expectoration."
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They defined chronic or recurrent cough as that occurring on most
days for at least three months in the year during at least two years.
The definition did not, therefore, include airways obstruction which
is often the main cause of morbidity in the condition. The large
group of patients in when airways obstruction was the dominant
feature and which was unresponsive to bronchodilators were defined as
having "Irreversible or Persistent Generalised Obstructive Lung
Disease" (Chronic Obstructive Airways or Lung Disease is a similar
term in use today).
Efriphysema was defined by the pathological presence of dilated
airspaces distal to the terminal bronchioles; such a definition
implied that a clinical diagnosis could only be speculative. Before
this symposium, emphysema was a term frequently used for patients
with chronic expectoration (and therefore chronic bronchitis) who
became breathless. Though changes of emphysema often co-exist with
chronic bronchitis further study in these patients has indicated that
dyspnoea may occur without co-existent emphysema (Burrows et al
1966).
In 1965 a further report on the classification of chronic
bronchitis was published (Medical Research Council 1965) splitting
the condition into three main categories:-
1) Simple chronic bronchitis, implying mucoid sputum
expectoration.
2) Chronic mucopurulent bronchitis, implying recurrent
bronchial infection.
3) Chronic obstructive bronchitis, where expectoration was
combined with persistent widespread narrowing of the intrapulmonary
airways causing resistance to airflow.
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The pathogenesis of airways obstruction in smokers with
chronic expectoration remains poorly understood. However, in patients
with this condition the mucous derives mainly from the central
airways (from mucous gland hypertrophy), whereas the main site of
airflow obstruction appears to be in the peripheral airways (Hogg et
al 1 968). Epidemiologically it has been shown that the progression of
airways obstruction is unrelated to the degree of chronic
expectoration or the number of infective exacerbations (Fletcher et
al 1976). It would seem logical, therefore, to follow the advice of
Fletcher and Pride and abolish the term chronic obstructive
bronchitis and only use the term chronic bronchitis to describe
simple chronic expectoration (Fletcher and Pride 1984).
What term could be used in its place? Perhaps we are wrong to
distinguish such patients from those with asthma. Some workers have
propounded the theory that those smokers with chronic cough and
expectoration who develop airways obstruction have an underlying
"asthmatic predisposition" and, therefore, have a variant of asthma
(Orie et al 1 961 ). Because of their country of origin this has become
known as the "Dutch hypothesis". Bronchial hyper-reactivity is
considered by some workers to be the cardinal abnormality in asthma
(Bronchial reactivity is usually assessed by the concentration of
histamine or methacholine required to cause a given increase in
airways obstruction). In support of the Dutch hypothesis is the
finding that smokers with airways obstruction may show increased
bronchial reactivity (Taylor et al 1985), and in one prospective
study of 34 patients with mild chronic bronchitis there was a
correlation between the rate of decline in FEV1 over 5 years and the
degree of methacholine reactivity and reversibility to isoprenaline
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(Barter and Campbell 1976). Reviewing many studies of bronchial
reactivity in chronic bronchitis (defined by chronic cough and
expectoration) Fanta and Ingram concluded that in these patients
there was a range of reactivity from normal to the hyper-reactivity
normally occurring in the young asthmatic (Fanta and Ingram 1981).
Unfortunately, it is not clear whether those smokers with airways
obstruction who demonstrate bronchial hyper-reactivity also had this
feature when asymptomatic in youth. As the degree of response to
histamine or methacholine may depend upon the initial airways calibre
there is some concern that the increased reactivity may be a
consequence rather than a cause of the airways obstruction in smokers
(Fanta and Ingram 1981).
lite role of allergy in smokers who develop airways
obstruction is more controversial. In the large study by Fletcher and
co-workers the incidence of allergic features was not increased in
those patients who developed airways obstruction (Fletcher et al
1976). However, in a study of a younger cohort of men from the group
originally analysed by Fletcher's group an association was found
between the rate of decline in FEV1 and presence of allergic features
(Connellan et al 1982). Barter and Campbell, in their prospective
study of chronic bronchitis, found that those patients who developed
airways obstruction were more likely to have sputum eosinophilia
(Barter and Campbell 1976).
Although non-specific terms such as chronic obstructive
airways (or lung) disease have been criticised as being unhelpful
(Scadding 1971 ), they do describe the abnormality causing the
morbidity and mortality. Such terms are now becoming increasingly
popular and "chronic obstructive lung disease" is new included in the
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most recent "International Classification of Diseases" as used by
General Practitioners (World Health Organisation 1978).
Hie 1959 Ciba Guest Symposium definition of asthma did not
include any reference as to the degree of change in airways
obstruction required to diagnose asthma, nor the period of time in
which this change should take place. The second major problem is hew
to differentiate quantitatively between patients with asthma
(variable or reversible airways obstruction) and those with
"Irreversible airways obstruction". Unfortunately there are
difficulties with the use of airways reversibility to bronchodilators
and corticosteroids as a disease characteristic. The response to
these drugs depends upon the type and dose of drug used, and how the
response is measured. The problems of reversibility studies will be
discussed in detail later in the thesis. As yet there is no agreement
as to what degree of airways reversibility is required to diagnose
asthma (Porter and Birch 1971).
A further problem in the use of symptoms and airways
reversibility in definitions is that these features may change with
time. It is well known that an asthmatic may present with episodic
airways obstruction but later develop irreversible airways
obstruction which is unresponsive to bronchodilators and
corticosteroids (Brown et al 1984). This is especially likely to
occur in asthma presenting in middle age. Scadding has proposed that
previous evidence of variable airways obstruction in such patients
justifies a diagnosis of asthma (Scadding 1983). Patients with a
history of heavy cigarette smoking often give a long history of
chronic cough and expectoration and do not notice impaired exercise
tolerance unless they have a chest infection. Only a minority
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(between 10-20%) develop symptomatic airways obstruction, and this
usually progresses with age (Fletcher et al 1976).
It is likely that those patients with truly "irreversible"
airways obstruction have primarily emphysema, as the defect in such
cases is in the alveoli rather than in the bronchi. Unfortunately,
this is a difficult diagnosis to make in life and a recent review has
emphasised the poor correlation between clinical, radiological and
physiological changes on the one hand and the pathological changes of
emphysema on the other (Flenley and Warren 1980).
d) EPIDEMIOLOGY
Epidemiological surveys of adults with airways obstruction
are hampered by diagnostic difficulty between chronic bronchitis and
chronic asthma in the middle aged and elderly. Estimates of
prevalence vary depending on the definitions used and hew the
disorder is identified in the survey. Asthma is an intermittent
condition and therefore, the use of current prevalence (all patients
experiencing the condition at a given time) underestimates the
incidence of the disease. Period prevalence (all patients having a
history of the condition during a given period) or cumulative
prevalence (patients having a history of the condition at scmetime in
their life) may be more representative of disease frequency, but the
addition of historical information leads to inaccuracies, especially
when one is dependent upon the patient's memory. Variations in
disease prevalence between authors in diverse geographical locations
may well be due to difference in study design rather than in disease
frequency.
Asthma-
The current prevalence of asthma in adolescents and adults
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has been reported between 0.9% and 5.4% in several recent surveys. In
these studies the male/female ratio has varied between 1.1/1 to
2.8/1 .In approximately a half of patients the disease commences belcw
10 years of age (Gregg 1983a).
Fry estimated that the annual prevalence of asthma in his
practice was 1.5%; this prevalence peaked in two agegroups around 10
and 60 years (Fry 1983). Using these figures there would be about 40
asthmatics with ongoing symptoms in an average practice of 2,500
patients. Of these, however, Fry has stated that only a third would
attend for treatment in any one year. An assessment of consultation
rates (per thousand population) for asthma and chronic bronchitis in
England and Wales can be obtained from the General Practice Morbidity
Survey 1971-1972 (Royal College of General Practitioners 1979). These
consultation rates are illustrated in figure 1.
Chronic Bronchitis-
In the single most useful study of the epidemiology of
chronic bronchitis in this country the prevalence was found to be 17%
in men and 8% in women for the age group 40-64 years (College of
General Practitioners 1961). It is likely that many of these cases
were of simple chronic bronchitis without any associated airways
obstruction. Using the criterion of chronic cough and expectoration,
and breathlessness on the level (when the presence of airways
obstruction was likely) the prevalence was lower: 8% in men and 3% in
women. The prevalence increased throughout the age range 40-64 years;
this being especially marked in males. The male/female ratio rose
from 1.2/1 at the age 40-44 years to 2.4/1 at the ages 60-64 years.
This is in contrast to a study of chronic bronchitics in chest




5.2/1 at ages 60-69 years (Medical Research Council 1959). Mortality
studies have revealed similar figures to the chest clinic survey
suggesting that chronic bronchitis is a more severe condition in
males.
Fry estimated that in a general practice of 2,500 with a
typical age/sex structure there would be 200-300 patients with
chronic bronchitis. However, only about one hundred of these would
attend their general practitioner in any one year and 60 of these
would have simple chronic bronchitis with no or minimal airways
obstruction (Fry 1983). The variation of consultation rate by age as
derived by the general practice morbidity survey is illustrated in
figure 1.
e) THE DIAGNOSIS OF OBSTRUCTIVE AIRWAYS DISEASE
Clinical history-
In some patients the history is almost diagnostic of asthma;
this is especially common in the child or young adult with episodic
breathlessness and associated atopic symptoms. In the older patient,
however, the history may be less helpful. The following features have
been described in teaching texts as being useful in differentiating






















There is little information, however, as to hew helpful these
symptoms are in differentiating between the two conditions. As
previously described chronic bronchitis has been defined by chronic
cough and expectoration. It is well known that patients with asthma
may present with the symptom of cough and occasionally there may be
recurrent expectoration (Fletcher 1971). Whether these patients
should be described as bronchitic is debatable.
Examination-
suggest diffuse airways obstruction, examination of the chest is
relatively unhelpful both in differentiating between chronic
bronchitis and asthma and assessing the severity of disease (Hetzel
and Clark 1983). For this reason no analysis of clinical examination
in the diagnosis and assessment of airways obstruction has been
undertaken in this survey.
Tests of respiratory function-
In 1846 the first spirometer was used to measure vital
capacity (Hutchinson 1846). Hcwever, it was not until the 1950's that
Though the presence of wheeze and chest hyperinflation may
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the measurement of airways obstruction by the forced expiratory
volume in one second (FEV1) and the farced vital capacity (FVC) using
a spirometer was widely used. In 1959 details of a portable meter for
measuring the peak expiratory flew rate (PEFR) were published (Wright
and McKerrow 1959). Whilst the PEFR is more dependent on patient
effort than the FEV1, it gives similar information, is easy to
perform, and the meter required for its measurement is portable. In
short the measurement of the PEFR is ideal for general practice
(Gregg 1964). In 1978 a smaller, cheaper PEFR meter (the mini-Wright
peak flow meter) was introduced (Wright 1978) and such devices have
become increasingly popular.
There are no absolute normal values for FEV1, FVC, and PEFR
because these values vary with age, sex and height. Normal ranges of
these measurements, taking these variables into account are available
(Cotes 1979), and indeed graphs of predicted normal PEFR are
provided with each mini-Wright peak flow meter based on a study of
normal non-smoking adults in London (Gregg and Nunn 1973). The FEV1,
FVC, and PEFR may be recorded, therefore, as absolute values or
percentages of the predicted norm. Of course, such norms are means of
normal distributions, and in theory measurements are only "abnormal"
if they are outside the 95% confidence limits for the normal
distribution. Recently the problem of short term variability in FEV1
recordings has been emphasised (Tweeddale et al 1984). Such
variability may make the assessment of small changes at lew initial
values difficult. It is likely that PEFR recordings are similar in
this respect.
There is some controversy as to hew many "blows" should be
made to make a recording of an FEV1 or PEFR. If patients undertake
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repeated "blcws" during a single period, these measurements have a
normal distribution (Ullah et al 1983), suggesting that the use of
the mean of several recordings would be scientifically valid. In
practice, however, the best of three "blows" is often used (Hughes
and Empey 1972) and certainly this method is more suitable for
general practice.
It has been shown that most patients are capable of taking
their own PEER recordings at home (Hetzel et al 1979). Such repeated
recordings are valuable in the diagnosis of asthma as they may
demonstrate variable airways obstruction both spontaneously and as a
result of therapy (Prior and Cochrane 1980).
Reversibility studies-
Ihe value of FEV1 and FVC measurements in assessing response
to drug therapy was recognised in the 19501 s (Hume and Gandevia
1957); such assessments have been called reversibility studies.
Similar studies can easily be undertaken in general practice using a
peak flow meter (Gregg 1964). Aerosol sympathomimetic agents rapidly
reach peak effects. For salbutamol this is approximately 15 minutes
after delivery, though about 80% of the response occurs within the
first 5 minutes (Tattersfield 1983). Therefore, measurements may be
taken before and 10-15 minutes after a dose of such a drug. Usually a
standard therapeutic dose from a metered dose inhaler is used, though
in some patients a larger response is achieved using higher doses
(Prior and Cochrane 1982).
The effects of oral corticosteroids on airways obstruction do
not occur for at least 9 hours (Ellul Micallef et al 1974) and the
maximal effects may not be apparent for 6-8 days (Shenfield et al
1975, Webb et al 1981a). Because of the suitability of PEFR
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recordings for heme use, repeated measurements may be undertaken
during a course of prednisolone to assess the response. Various other
measurements such as the FVC and "the 12 minute walk" may be more
sensitive in demonstrating a response to corticosteroids (Williams
and McGavin 1 980), but these are not easily undertaken in general
practice.
At present there are no dose response data for the effects of
oral corticosteroids on airways obstruction and the dose used is,
therefore, arbitrary. A review of 17 different studies on the effects
of corticosteroids on chronic bronchitis illustrates this point; in
10 of these studies prednisolone or prednisone was used in starting
doses ranging from 15-60mg daily (Sahn 1978). Lew doses of 5mg daily
appear to have no effects on patients with chronic airways
obstruction (Evans et al 1974). At the present time most workers
advise 30-40mg of prednisolone daily to assess corticosteroid
responsiveness (Crofton and Douglas 1983).
The expression and interpretation of the reversibility of airways
obstruction-
There are a number of ways in which the reversibility of
airways obstruction may be expressed:
a) Firstly the change in a measurement after treatment may be
expressed in absolute terms. Thus:-
If
Initial measurement = X1
Measurement after treatment = X2
Then
Reversibility = X2-X1
TVeeddale et al found a short term variability in the measurement of
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airways obstruction using the FEV1. When this variability was
expressed as an absolute change it was independent of the degree of
airways obstruction. Because variability expressed as a percentage
change would increase with decreasing FEV1, absolute change may be a
more reliable as a measure of bronchodilator response (Tweeddale et
al 1984). It is likely that measurements of PEFR are similar in this
respect.
b) In practice the Improvement after treatment is expressed commonly
as a percentage of the initial or baseline recording. Put simply:-
Reversibility = 100(X2-X1)/X1%
c) Cotes (1979) has stated that the difference term (X2-X1) is
correlated inevitably with the initial value X1. In order to avoid
this error he has suggested expressing the improvement as a
percentage of the mean of the two values between the measurements




Although this expression may be theoretically correct it is not used
commonly in clinical practice.
d) Nicklaus et al have suggested expressing the improvement term
(X2-X1) as a percentage of the patient's predicted norm (Nicklaus et
al 1969). Thus:-
If
Predicted norm = X3
Ihen
Reversibility = 100(X2-X1)/X3%
With this expression small changes in a measurement at low initial
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values assume less importance, and this may be relevant when there is
important short term variation in measurements of airways obstruction
as in the FEV1.
Asthma is defined by reversible airways obstruction (either
spontaneously or as a result of treatment). No guidelines exist,
however, as to the degree of reversibility or variability that
constitutes a diagnosis of asthma. Crofton and Douglas (1983) and
Crampton (1980) have stated that at least 20% or 25% reversibility
(the improvement expressed as a percentage of the initial
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a) THE PRACTICES
Because of the nature of the survey it was not possible to
choose the practices at random. The general practitioners were asked
to provide the names of patients given therapy for airways
obstruction and had to be prepared for the author to undertake
interviews of these patients in their premises. Obviously
considerable co-operation was required and because of this the
practices were selected as those likely to comply with the needs of
the study. Of course, the use of random samples of general
practitioners would have been preferable but technically difficult to
undertake.
Patient management in general practice may be influenced by
the local specialist clinic and, therefore, 3 different cities with
different available specialist referral centres were chosen.
Five practices were selected, one each in Bradford and
Wakefield and three in Leeds. Two practices working from the same
health centre and serving a similar population were analysed together
because of the small numbers obtained in each practice. Information,
therefore, was analysed in four separate practice centres, the
details of which are included in table 1.
b) PATIENT ENTRY CRITERIA
1) The patient should be between the ages 16-80 years.
2) The patient should be able to attend his or her general
practitioner's surgery.
3) The patient should be currently taking therapy for airways
obstruction.
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1 2 3 4
Wakefield Leeds Bradford Leeds
central central central suburb
5 6 3 5
11,200 10,000 6,200 11,000
yes yes no yes
yes yes no yes
yes no no no
Table 1
C) PATIENT SELECTION
One of the most efficient ways of identifying patients with a
particular disorder in general practice is by the use of a diagnostic
index. Unfortunately, only a minority of practices have this
facility. In this study one general practice had a diagnostic index
and this was used to identify every adult patient taking therapy for
airways obstruction in the diagnostic categories asthma and chronic
bronchitis during the period January 1981 to June 1981. There was no
diagnostic category "Chronic obstructive lung disease" in the
classification used (World Health Organisation ICD 1971). No patient
had been given a single diagnosis of emphysema.
In the other practices without this facility the general
practitioner was asked to record all adults given a prescription (new
or repeat) for airways obstruction during an arbitrary two month
period (which varied between the practices).
d) THE INTERVIEWS
The practices were visited shortly after the collection of
these names and the patients were sent a letter (see Appendix I)
asking then to attend their practices for a half hour interview. All
interviews were undertaken by the author at times suitable for the
patients and the practices, including periods in the early evening
and occasionally on Saturday mornings in order to accommodate working
men and wcmen. If initial times given to the patient were unsuitable
the patient was invited to rebook at a more convenient time.
Thankfully practice receptionists were extremely helpful in rebooking
appointments. Postal addresses of defaulters were checked but no
further follow up of this group was undertaken as it was thought
likely that failure to attend or contact the surgery indicated a wish
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not to participate in the study.
e) THE PATIENT GROUPS
Patients were split into two main groups depending cxi their
general practitioners' most recent diagnosis. Asthmatics were classed
as group A, and chronic bronchitics and all other categories of
obstructive airways disease as group B. In nearly all cases the
diagnoses were obtained from the patients' records, though if not
available it was asked of the patient. Rarely patients were given
double diagnoses, for example- asthma and chronic bronchitis. In this
case if the term asthma was included at all this was the diagnosis
recorded and the patient was classed as group A.
In order to analyse seme areas of management, patients in
groups A and B were further subdivided into those who had recently
attended a specialist clinic (within the previous 12 months) A-OPD
and B-OPD, and those who had not A-GP and B-GP.
f) THE HOSPITAL GROUP
In order to compare therapeutic practice in a specialist
centre with that of the general practitioners a consecutive series of
asthmatics attending a "follow up" specialist clinic were similarly
interviewed. This group of patients were classed as group H.
Unfortunately not enough patients with chronic bronchitis attended
the clinic to form a valid comparison for the general practice group
B.
g) THE QUESTIONNAIRE
All interviews were completed between 1/8/1982 and 31/1/1983.
A copy of the questionnaire is included in Appendix II. This was
designed in a format aiding computerisation of the data with
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numerical cedes for each answer. The final draft of the questionnaire
was produced after trial interviews with in-patient asthmatics. Not
all questions were analysed for the report, and scnie require
amplification. The following section includes explanatory notes on
the structure of the questionnaire.
Patient number- Each patient was given a three digit code.
Questions 1-3 -Age, sex, and social class.
(Social class was identified as in the Classification of
Occupations ( Office of Populations, Censuses and Surveys 1970). In
the case of minors the fathers occupation was recorded).
Question 4 - Are you troubled with wheeze?
(The symptom "wheeze" was often poorly understood by
patients. It was amplified to whistling noises on breathing. As
nearly all patients answered this question positively it was not used
further in the analysis).
Question 5 -Hew long have you been troubled with wheeze?
(It was obvious from the outset that this question failed to
provide sufficient information concerning the age of onset of
symptoms. Because of this a further question (5a) was added at the
bottom of page 1).
Question 5a -How old were you when your wheeze or shortness of breath
became noticeable?
(In this and all subsequent questions concerning wheeze
shortness of breath was added as in many patients this feature was by
far the dominant symptom).
Is the wheeze (and /or shortness of breath)
Question 6 -Continuous (occurring most days out of the year) or
episodic (with symptom free periods)?
Question 7 -Seasonal or perennial?
Question 8 -If seasonal is it most marked in summer or winter?
Question 9-10 -Associated with occupations past or present?
Question 11 -Associated with hobbies?
Question 12 -Associated with animal contact?
Question 13 -Associated with upper respiratory tract infections?
Question 1 4 -Do/did you suffer from hayfever?
Question 15 -Do/did you have eczema?
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Question 16 -Have you a family history of hayfever or eczema?
Question 17 -What time of day is your wheezing worse:- morning, day,
evening, night, or no change?
Question 18 -Have you had cough and expectoration most days for at
least three months out of the year for the past two years?
Question 19 -Do/did you smoke regularly?
(Regularly was defined as at least daily for a year).
Question 19a -What form of tobacco do/did you smoke mostly:-
Cigarettes, pipe or cigars?
Question 20 -How many daily if a cigarette smoker?
Question 21 -Did/does smoking affect your wheeze?:- Better, worse, no
change or don't knew.
(Questions 6-21 were formulated in order to obtain a symptom
history from each patient. The symptoms of patients diagnosed as
asthmatic were then compared with those diagnosed as chronic
bronchitic).
Question 22 -Have ycu been warned about smoking by your doctor?
Question 23 -If you have stopped smoking, why?
Have you attended a hospital/chest clinic with your wheeze
Question 24 -As an inpatient?
Question 25 -As an outpatient?
Question 26 -Frequency of inpatient hospital admissions (total)?
Question 27 -Frequency of outpatient attendances (in the past year)?
(Questions 24-27 were designed to ascertain the proportion of
patients in general practice who attended specialist clinics. The
frequency of inpatient admissions was used as a marker of disease
severity. In those chapters dealing with the therapeutic management
of the patients, those who had attended a hospital or chest clinic
within the previous 12 months were compared with those who had not).
Question 28 - What chest condition do you have? - asthma, chronic
bronchitis, emphysema, 00AD, don't know.
Question 29 -General Practitioner diagnosis?
Question 30 -Hospital Diagnosis?
(Only the general practitioner's diagnosis was used in this
report. The most recently recorded diagnosis was used).
Question 31 -Are you satisfied with your wheeze control?
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Question 32 -Is your condition static, deteriorating, or improving?
(These two questions were not used further in this report).
Question 33 -How often have you seen your general practitioner in the
past six months?
(This excluded emergency visits).
Question 34 -What is the frequency of emergency house calls made by
your general practitioner in the past six months for wheeze?
Question 35 -Have you required injections from your general
practitioner in the past six months for wheeze?
Question 36 -How many weeks off school/work have you had in the past
year?
(This latter question did not provide sufficient information.
If the patient had retired early or received long term sickness
benefit because of his/her chest condition this information was added
in longhand and analysed separately).
Question 37 -If episodic, how many episodes of wheeze lasting more
than one hour have you had in the last month?
Question 38 -If you have morning tightness how long does it normally
last?
Question 39 -Do you have more severe wheeze on exercise continuing
after the exercise has ceased?
(This question was designed to identify patients with
exercise induced asthma. It was stressed that this did not indicate
shortness of breath on exertion which quickly improved after rest.
The latter could occur with any form of lung disease).
Question 40 -Does this regularly interfere with your activities?
Question 41 -Do you regularly participate in sport?
(This question was not included further in the analysis).
(Questions 31 -40 were designed to assess the severity of
disease and its control. This information was used in conjunction
with symptom scores and peak flew rates to compare severity in
groups A,B and H).
DRUG THERAPY
Questions 42-57 -Each patient was asked which drugs he or she was
taking or had taken for wheeze.
(Each drug was given a two digit code as shown in Appendix
III. Both the drug name and coding were entered on the
questionnaire).
Qj.estions 58-61 -Do you take any of the following regularly? Beta
blockers, aspirin, antibiotics, cough suppressants, expectorants or
antihistamines.
(This information was normally obtained from the patients'
records).
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Question 62 -Which method of therapy do you prefer? Oral, aerosol
inhaler, dry powder inhaler, don't know.
Inhaler use-
Question 63 -Are you using an aerosol inhaler?
Questions 64-65 -Were you shown how to use your inhaler by your
general practitioner or by the pharmacist?
Question 66 -Do you think you use the inhaler correctly?
Question 67 -Inhaler technique score- efficient, doubtfully
efficient, inefficient?
(This simple assessment was described by Paterson and
Crompton (1976))
Questions 68-72 -Inhaler technique- Was the cannister shaken and held
upright? Was there co-ordination between activation and inspiration?
Was the breath held after inspiration? Was the mouth held open or
pursed around the inhaler?
Bronchodilators-
Question 73 -Are/were you using a bronchodilator aerosol inhaler?
Question 74 -(The drug code(s) was/were inserted here).
Question 75 -Is the drug used regularly without regard to wheeze?
Question 76 -Is the drug used on demand?
Question 77 -What is the average daily dose?
Question 78 -Do you use the drug before exercise?
Question 79 -Is it beneficial when used before exercise?
Question 80 -How long does relief from the inhaler last?
Question 81 -How long does an inhaler normally last?
(Questions 79-81 were not used in this report).
Questions 82-84 -Have you noticed the side effects: tremor,
palpitations, others?
Questions 85-93 -(These refer to the past use of inhalers and why the
drug was stopped).
Questions 94-107 -(These refer to the use of dry powder inhalers and
are of a similar format to questions 73-93).
Questions 108-129 -(These refer to the use of oral bronchodilator
drugs and again are of similar format to questions 73-93).
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Questions 130-133 -(These refer to the use of aminophylline
suppositories. These preparations were not used frequently enough to
warrant analysis and were not used in this report).
Prophylactic drugs-
Question 134 -Are you using (have you used) sodium crcmoglycate?
Question 135 -Do you take the drug regularly without regard to
wheeze?
Question 136 -Dose?
(This question refers to the prescribed dose and was obtained
from the patients' records if possible.If not recorded it was
obtained from the patient).
Question 137 -Are doses missed? Rarely, once per week, once per day
or at least twice per day.
Question 1 38 -Is it used on demand for wheezing attacks?
Question 139 -Is it helpful when used on demand?
Question 1 40 -Do you use sodium crcmoglycate before exercise?
Question 141 -Is it beneficial used in this way?
Question 1 42 -Does sodium cromoglycate protect against wheeze or
treat the wheeze once it is present?
Question 1 43 -Were you shown how to use the spinhaler?
Question 144 -Do you find the spinhaler technique easier, harder, or
the same as an aerosol?
Question 1 45 -Have you noticed side effects such as coughing or
wheezing after sodium cromoglycate?
Question 146 -Was the drug coamenced by the patient's general
practitioner or a hospital doctor?
(Questions 139, 140, 143 and 144 were not used in this
report)
Questions 147-152 -(These refer to the past use of sodium
cromoglycate and why the drug was stopped)
Questions 153-167 -(These questions were concerned with the use of
inhaled corticosteroids and were of a similar format to those
concerning sodium cromoglycate)
Oral corticosteroids-
Question 168 -Are you taking/have you taken oral corticosteroids for
wheeze?
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Question 169 -Was the drug first prescribed by the general
practitioner or a hospital doctor?
Question 170 -Hew long have you been taking oral corticosteroids?
Question 171 -What dose of oral corticosteroids do you take (in
prednisolone equivalent)?
Question 172 -Do you alter your corticosteroid dosage with respect to
your wheeze?
Question 173 -Is this on your doctor's recommendation -usually,
rarely, always?
Question 174 -By hew much do you usually increase your corticosteroid
dosage for an exacerbation of wheeze (in prednisolone equivalent)?
Question 175 -For hew long do you normally take the raised dose?
Question 176 -When lowering the dose to baseline treatment, do yen
use a reducing schedule?
Question 177 -Does your wheeze relapse after reducing the dose?
Question 178 -Hew often do you take raised courses per year?
Questions 179-181 -Have you noticed side effects since commencing
corticosteroid therapy? -Weight gain, indigestion, or change in
facial appearance. (Other side effects were entered in longhand on
the sheet and analysed separately)
Question 182 -If yen are not on a corticosteroid inhaler, have you
ever been?
Questions 184-191 -(Refer to the past prescription of short courses
of oral corticosteroids lasting less than six weeks. They are of a
similar format to questions 173-178).
Questions 192-200 -(Refer to the previous use of long courses of oral
corticosteroids and why they were stopped).
Questions 201-210 -(Refer to the use of ketotifen.As very few
patients used this drug, no analysis of this section was undertaken).
Question 211 -Hew many courses of antibiotics have you had for your
chest in the past year?
Question 212 -Have you had a course of desensitizing injections for
your chest?
Question 21 3 -Do you take expectorants or antihistamines for your
chest or have you taken them within the past six months?
Questions 214-216 -(This was the only part of the questionnaire which
was completed by the patient, after explanation by the author)
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Question 214 -(This was a visual analogue scale assessment and was
not used in this report).
CXiestion 215-216 -Please grade your wheeze as an average in the month
before interview.
Question 215 -
0. No wheeze -able to do all activities.
1. Slight wheeze -able to do most activities.
2. Moderate wheeze -activities limited regularly by frequent wheeze.
3. Severe wheeze -activities constantly curtailed by wheeze.
Question 216 -
0. No nocturnal wheeze.
1. Slight nocturnal wheeze -woken occasionally, but less than once
per week by wheeze.
2. Moderate nocturnal wheeze -woken frequently i.e. 1-3 times per
week by wheeze.
3. Severe nocturnal wheeze -woken very frequently i.e. more than 3
times a week with wheeze.
(Questions 215-216 were used to formulate a symptom score. These
scores were modified from a published diary card for asthma
assessment (Stark 1980)
Questions 217-221 -(These questions were used to record the PEFR
recordings and the reversibility studies undertaken with each
patient).
h) PEFR RECORDINGS AND REVERSIBILITY STUDIES
All baseline and post-bronchodi lator recordings of the PEFR
were undertaken using a single mini-Wright peak flow meter. This
meter was calibrated by comparing recordings by myself and
colleagues against a Wright peak flow meter which itself was
maintained and calibrated at the Leeds Chest Clinic.
The best of three PEFR recordings was documented and
expressed as a percentage of the patient's predicted PEFR
standardised by age, sex, and height (Cotes 1979).
h2
Bronchodilator reversibility-
If the patient's PEFR was below 80% of the predicted value
the PEFR recordings were repeated 10 minutes after an inhalation of
200 meg (2 puffs) of salbutamol via a standard aerosol inhaler. If
the inhaler technique had been shown to be inadequate the aerosol was
activated by the author.
The level of 80% predicted was chosen for simplicity, but in
theory a recording of the PEFR would be "abnormal" only if it was
outside two standard deviations from the predicted norm. As two
standard deviations is approximately 100L/min (Cotes 1979), it is
accepted that seme patients with low predicted PEFRs could have
values below 80% predicted and still be normal.
Reversibility was expressed, firstly, as the change in PEFR
as a percentage of the initial PEFR, and secondly, as the change as a
percentage of the predicted PEFR. The first expression was chosen as
it is the one most commonly used in clinical practice. However, as
mentioned in the introduction, reversibility expressed as the change
in PEFR as a percentage of the mean of the initial and post
bronchodilator PEFRs may have been scientifically more valid. The
second expression of reversibility (the change in PEFR as a
percentage of the predicted PEFR) was chosen in order to lessen the
impact of small changes at low initial values. This was important in
the section of the study comparing patients with asthma and chronic
bronchitis, as the latter often had very low initial PEFRs. Analysis
of reversibility as expressed by absolute changes in PEFR was not
undertaken because this does not take into account the patient's
predicted PEFR. For example, if two patients both record PEIFRs of
200L/min but one had a predicted PEFR of 400L/min and the other
'*3
600L/min, one would not expect both patients to have the same
capacity for change.
The results of reversibility were recorded in longhand on the
questionnaire and an extra question 219a was added in which the
bronchodilator reversibility was expressed by a two digit code.
Corticosteroid reversibility-
If the patient's PEFR was equal to or below 60% of the
predicted value he or she was offered a trial of corticosteroid
therapy.If accepted the patient was supplied with two identical
bottles of tablets labelled A and B. In week one the patient took
placebo tablets from bottle A. In week two the patient took
prednisolone 5mg tablets, two four times daily (40mg daily) from
bottle B. The patient was also taught to user and was provided with, a
mini-Wright peak flew meter and a standard hospital respiratory
function chart (see appendix 1V). Patients recorded the best of three
peak flow readings morning and evening (not less than four hours
after a dose of bronchodilator) throughout the two week period. Each
peak flew meter was checked before use by the author measuring his
cwn PEFR. The patient was only aware that he had been prescribed
"steroid therapy".
Corticosteroid reversibility was assessed by comparing the
mean PEFRs of the last 5 days (10 recordings) during placebo and
prednisolone therapy. Only 5 days recordings were used to lessen the
possible effects of placebo responses. The change in mean PEFR was
expressed as a percentage of the mean inital PEFR during placebo
therapy. Paired t tests were also undertaken on the untransformed
data for morning and evening recordings separately as some patients
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exhibited marked diurnal variation in PEFR.
Patients with a recent exacerbation of symptoms or a history
of recent (within the past 6 months) treatment with oral
corticosteroids were excluded, as were patients with the following
medical complications:- 1) Ischaemic heart disease (current history
of angina or previous myocardial infarction), current treatment for
congestive cardiac failure or hypertension 2) Diabetes mellitus 3)
Known old tuberculosis 4) Indigestion or previous peptic ulcer
disease 5) Mental illness 6) Pregnancy 7) Malignancy 8)
Inter-current chest infection.
i) ETHICAL CONSIDERATIONS
Full consent was obtained from all patients before interview.
Consent was similarly obtained from involved general practitioners
and local hospital consultants. The plan of this study was passed by
the local medical research ethical committee.
j ) COMPUTING AND STATISTICS.
Computing was undertaken using the Statistical Package for
Social Sciences (S.P.S.S.) on the AMDAHL computer of the University
of Leeds. The data were programmed by Mrs Valerie Binns from the
Department of Community Medicine and General Practice, University of
Leeds. The majority of data analysis was achieved by question
crosstabulation. Not all data were computerised and a small amount of
information was correlated by longhand.
Discrete variables were analysed by the chi-squared test, and
continuous variables with a non-parametric distribution by the Mann
Whitney U test. A linear multivariate analysis (Armitage 1971 ) was
used to assess the value of various symptoms in distinguishing
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"asthma" and "chronic bronchitis", as diagnosed by the general





a) Patient attendance rates
b) The diagnostic groups
c) Age and sex distributions
d) Social class distributions
e) A comparison of peak expiratory flew rates and symptom scores
between the diagnostic groups




a) PATIENT ATTENDANCE RATES
Of the 397 patients requested to participate in the general
practice study, 314 attended for interview (79% attendance rate).
Table 2 gives an analysis of the insignificant difference in
attendance rates between practice centres. In order to assess whether
non-attenders were similar to attenders, an analysis of sex (in all
practices), age and social class (practice centre 1 ) of patients in
these two groups was undertaken (table 3). No significant difference
in these features was found.
b) DIAGNOSTIC GROUPS
201 patients were diagnosed by their general practitioners as
being asthmatic and were classified as group A. 107 were diagnosed as
having chronic bronchitis and 5 chronic obstructive airways disease;
these latter patients were classified as group B (no patient was
given a primary diagnosis of emphysema). The number of patients in
these two diagnostic groups in each practice centre is shown in table
4. Most patients were obtained from practice centre 1 which had a
disease index. In all practice centres except number 2, more
asthmatics than bronchitics were obtained.
C) AGE AND SEX DISTRIBUTION
The age and sex distributions of patients in groups A and B
are shown in table 5. In group A there were approximately equal
numbers of men and wcmen; but there were twice as many men as wemen
in group B. Over a half of group A were belcw 50 years of age,
whereas over 90% of group B were above this age. In group A there
were more males than females in those under 30 years of age; this
trend was reversed in the 51-70 years age group. There was no
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The difference in attendance rates





















140(83%) 62(70%) 45(82%) 67(79%) 314(79%)
28(17%) 27(30%) 10(18%) 18(21%) 83(21%)
Table 2.
The difference in sex (all practices),
age and social class (practice centre 1)






X1 1 .3 DF1 NS



















I and II 38(27%) 4(14%)
III 81(58%) 16(57%)
IV and V 20(14%) 8(28%)
Tbtal 139* 28
X1 4.3 DF2 NS
* one missing observation
Table 3.
The number of patients in groups
A and B in each practice centre.
Practice Group A Group B Total
1 84 56 140
2 30 32 62
3 33 12 45
4 54 13 67
"Cable 4.
The age and sex distribution of patients
in groups A and B.
Group A Group B
Sex
Male Female Total Male Female Total
99(49%) 102(51%) 201(100%) 75(66%) 38(34%) 113(100%)
Age groups (years)
<30 37(37%) 23(23%) 60(30%) 0(0%) 1(2%) 1(1%)
30-50 24(24%) 28(27%) 52(26%) 4(5%) 3(8%) 7(6%)
51 -70 28(28%) 40(39%) 68(34%) 47(63%) 25(66%) 72(63%)
>70 10(10%) 11 (11%) 21 (10%) 24(32%) 9(24%) 33(30%)
Total 99(100%) 102(100%) 201(100%) 75(100%) 38(100%) 113(100%)
Thble 5.
significant difference in the age of asthmatics between the practice
centres (table 6).
d) SOCIAL CLASS
There was a significant difference in social class between
groups A and B. Unlike the asthmatics, the chronic bronchitics were
predominately from the lower social classes. Table 7 illustrates this
distribution and includes the average for England and Wales for
comparison. There was a marked difference in social class between the
practice centres, varying from 13% to 85% of group A in social
classes I and II (see table 8).
The difference in age, sex, and social class distribution
between group A and the asthmatics attending a hospital clinic (group
H) is illustrated in table 9. Although these patients were of similar
age and sex more patients in group H were from the lower social
classes.
e) A COMPARISON OF PEAK EXPIRATORY FLOW RATES AND SYMPTOM SCORES
BETWEEN THE DIAGNOSTIC GROUPS
Peak expiratory flow rates (PEFR)-
All patients (apart from two who were unable to undertake the
manouevre) provided PEFR recordings (the best of three blows being
documented). An analysis of the patients' baseline PEFRs expressed as
a percentage of the predicted value (Cotes 1979) is included in
tables 10, 11 and 12. The asthmatics (group A) had significantly
higher PEFRs than the chronic bronchitics (group B) despite
differences in age. In patients over 50 years of age the median PEFRs
were 60.5% and 44% predicted for groups A and B respectively
(p<0.001). Younger asthmatics had significantly higher PEFRs than the
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Hie age distribution, of asthmatics (group A)
between the practice centres.
Practice
1 2 3 4
Agegroup
(years)
<30 25(30%) 6(20%) 12(36%) 17(31%)
30-50 27(32%) 6(20%) 7(21%) 12(22%)
51-70 22(26%) 16(53%) 12(36%) 18(33%)
>70 10(12%) 2(7%) 2(6%) 7(13%)
Total 84(100%) 30(100%) 33(100%) 54(100%)
X2 8.8 DF9 MS
T&ble 6.
The difference in social class between
groups A and B
Social class
I II Ill IV V
Group*
A 28(14%) 56(28%) 95(47%) 16(8%) 5(2%)
B 2(2%) 13(12%)






































The age, sex, and social class distribution



































X* 9.9 DF4 p<0.01
1 missing observation.
Tbble 9.
The peak expiratory flow rates (PEFR) (% of the predicted value)
of patients in groups A and B.
Groups
A B
Number of 201 111
patients





Hie difference in peak expiratory flow rates (PEFR)
(% of the predicted value) of asthmatics (group A) by age group.
Age group(years)
<30 30-50 >50
Number of 60 52 89
patients
Median % PEFR 83%(67%,96%) 81.5%(60%,96%) 60.5%(39%,74%)
(25th,75th centiles)^ ^ /
p=0.62 NS p<0.001
Table 11.
older; unfortunately not enough young chronic bronchitics were seen
to make similar comparisons.
Within group A, patients who had recently attended hospital
or chest clinics (within the previous 12 months) - group A-OPD, were
compared with those who had attended only their general practitioner
-group A-GP. Group A-OPD had significantly lower PEFRs than group
A-GP, with group H having an intermediate range of recordings (see
table 12).
Symptom scores-
The highest score of 0-3 for day or night time symptoms was
recorded for each patient. The distribution of scores for patients in
groups A and B are illustrated in table 13. More chronic bronchitics
complained of severe symptoms than asthmatics with a third grading
their symptoms as severe. However, there was no significant
difference in symptom scores between asthmatics in groups H, A-OPD,
and A-GP (see table 14). Between 1 in 4 and 1 in 5 patients in these
groups graded their symptoms severe.
The relationship between symptom score and PEFR in patients
in groups A and B is illustrated in table 15. Of those patients with
PEFRs greater than 70% predicted nearly two thirds had scores of 0 or
1 indicating mild symptoms and less than 1 in 10 gave a symptom score
grade of 3 indicating severe symptoms: conversely, of those with
PEFRs below 50% predicted nearly half gave a score of 3, indicating
severe symptoms.
f) A COMPARISON OF OTHER MARKERS OF DISEASE SEVERITY BETWEEN THE
DIAGNOSTIC GROUPS
The incidence of several other markers of disease severity
was analysed in the different groups including:
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The peak expiratory flow rate (PEFR) (% of the
predicted value) of patients in groups A-GP, A-OPD, and H.
Groups
A-GP A-OPD H
Total number 150 51 48
of patients
Median PEFR 74%(50%,93%) 63%(37%,82%) 68%(46%,87%)
(%predicted) I' * 1 '— ** —' J





The distribution of symptom scores for patients in








XX 16.5 DF2 p<0.001
Table 13.
The distribution of symptom scores for patients





0-1 27(53%) 80(53%) 26(54%)
2 10(20%) 45(30%) 10(21%)
3 14(27%) 25(17%) 12(25%)
Total 51 (100%)
Xz 4.9 DF4 NS
150(100%) 48(100%)
Ibble 14.
ibe association between symptom scores and
peak expiratory flow rates (PEFR) (% of predicted value)
Symptom score
PEFR 0-1 2 3 Total
>70% 78(62%) 35(28%) 12(9%) 125(100%)
50-70% 35(52%) 17(25%) 15(22%) 67(100%)
<50% 30(25%) 42(35%) 48(40%) 120(100%)
Total 143(100%) 94(100%) 75(100%) 312(100%)
X2 38.6 DF4 p<0.001
Table 15.
a) The frequency of emergency housecalls in the previous six months.
b) The number of weeks off work in the previous year.
c) The number of episodes of wheeze lasting longer than one hour in
the previous month.
d) The length of morning tightness.
e) The number of previous hospital admissions.
An analysis of these features in groups A and B is included
in table 16. Similar numbers of asthmatics and chronic bronchitics
had had emergency housecalls in the previous six months, though more
asthmatics had had multiple housecalls. The majority of chronic
bronchitics were not working, usually because of retirement as most
were men. Nearly 1 in 10 received long term sickness benefit, and of
the few that did work a half had had a period of at least one week
absent from work because of their chest complaint in the previous
year.
Approximately 1 in 4 asthmatics had had at least one wheezing
attack lasting longer than an hour in the previous month and 1 in 6
had regular morning tightness lasting an hour or longer. About a
third of asthmatics and a quarter of the chronic bronchitics had had
at least one previous hospital admission in the past.
In order to examine whether patients in groups A-OPD, A-GP,
and H were of similar severity the above indices are analysed in
table 17. The most marked difference in severity between patients
attending hospital clinics (A-OPD and H) and those attending their
general practitioner alone (A-GP) was the greater frequency of
hospital admissions in the former. Patients in group H also had a
greater frequency of emergency housecalls by their general
practitioners, though this did not apply to patients in group A-OPD.
The numbers of patients in groups A and B exhibiting





















Frequency of 0 84(42%) 13(11%)
weeks off work 1 17(8%) 6(5%)
in the previous >1 28(13%) 5(5%)
year* invalided 3(1%) 10(9%)
not 69(34%) 79(70%)
working
Frequency of 0 131(65%) 41(36%)
wheezing attacks <5 26(13%) 6(5%)
lasting >1hr in >5 25(12%) 4(4%)
the previous never had 19(9%) 62(55%)
month* wheezing
attacks
The length of 0 80(40%) 37(33%)
morning tightness <1hr 88(43%) 59(29%)
experienced in >1hr 33(16%) 17(15%)
the previous month





Xi 5.5 DF3 NS







The number of patients in groups A-GP, A-OPD, and H
























Number of 0 68(45%)
weeks off 1 15(10%)










































Xi 47.3 DF6 p <0.001
Thble 17.
Other features of severity were similar in all groups.
g) DISCUSSION.
It was assumed that a representative sample of patients
attending their general practitioners with airways obstruction was
seen. Although it was not possible to assess the severity and control
of disease in the non-attenders, the latter were of similar age, sex
and social class to attenders. A response rate of 79% was thought to
be satisfactory, especially as patients had been requested to attend
their surgeries for an interview with an unknown doctor. Response
rates may be higher when interviews take place in the patients own
home by a known doctor (Colmer and Pereira Gray 1983).
By using the prescription of therapy as a selection criterion
it is likely that this study is biased towards patients with more
severe disease. The proportion of asthmatics and chronic bronchitics
studied in relation to the expected number in this general practice
population can be approximated from previous epidemiological data.
Ihe expected number of asthmatics is:
77% X 38,400 = 29,500
(% of population (practice
between 16-80) population)
29,500 X 3%(prevalence of asthma) = 885
(Accepting an asthma prevalence of 3%, and an age distribution of the
practice population similar to the average for England and Wales).
As 201 asthmatics were studied this represents a 23% selected
sample of the total number expected. Fry (1983), however, in his
general practice found an annual prevalence of 1.5% in which case 46%
of the expected number of asthmatics in the practice population were
seen. He has stated that only a half of a population of adult
asthmatics would attend their general practitioner in any one year;
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if this is so then nearly all asthmatics expected to attend their
general practitioners in a single year in this population were seen.
The proportion of asthmatics seen in relation to the number expected
varied from 13-32% between the practice centres (using a proposed
prevalence of 3%). As expected practice centre 1 using the diagnostic
index produced the largest sample.
It is more difficult to assess the proportion of chronic
bronchitics seen; this study selected only those with associated
airways obstruction and there are few prevalence data on this
subgroup. However a comparison can be made with the General Practice
Survey (1961 ). They found a prevalence of chronic bronchitis with
breathlessness of 5.5% (average for men and women) in patients 40-64
years old. In this age group we would have expected:
29% X 38,400 = 11,136
(% population (practice
aged 40-64 yrs) population)
11,136 x 5.5% = 612
prevalence
As we analysed 113 patients between 16-80 years it is likely
that only 10-15% of cases of chronic bronchitis with airways
obstruction were seen.
Asthma is more common in males in childhood and adolescence
(Gregg 1983a); this may explain the higher consultation rates of male
asthmatics than females under the age of 30 years. There is an
impression that late onset asthma is more common in females. Though
Gregg has disputed this, stating that there is a tendency to
misdiagnose middle aged males as bronchitic rather than asthmatic.
Certainly consultation rates are higher in female than male
asthmatics over 25 years old (Royal College of General Practitioners
OPCS 1979), a fact substantiated by this study. As expected, the
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hospital asthmatic group (H) had a similar age and sex distribution
as group A. In keeping with previous experience the chronic
bronchitics were middle aged or elderly with twice as many males
studied as females.
Asthma has been associated traditionally with the upper
social classes, though there are few data to support this notion and
consultation rates are similar in all social classes (Royal College
of General Practitioners OPCS 1979). In this study the asthmatics
seen in general practice were biased towards the upper social
classes. This is likely to be due to the difference in social class
structure of the practices concerned. In contrast the hospital group
of asthmatics were of a similar class structure to the national
pattern. Chronic bronchitis is a disorder of the lower social classes
and in the morbidity survey (Royal College of General Practitioners
OPCS 1979) consultation rates in social class V were nearly tenfold
those of social class I. The trend towards the lower social classes
in this study was present but not as marked, probably because of the
higher social class structure of the practices.
Interestingly, there was a variation in the ratio of chronic
bronchitics to asthmatics seen in the four practice centres. There
are three possible explanations for this. Firstly, if the incidence
of chronic bronchitis is increased in the lower social classes, and
the incidence of asthma is independent of social class, one would
expect the number of chronic bronchitics to increase in relation to
those with asthma in practices with more patients from the lower
social classes. Unfortunately, without a formal assessment of social
class structure in each practice this feature is difficult to
examine. However, the centre with the highest ratio of chronic
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bronchitics to asthmatics was an inner city practice in an area of
high unemployment. Whereas, the practice with the smallest ratio of
chronic bronchitics to asthmatics was situated in a wealthy, suburban
area of Leeds. In this latter practice 85% of patients seen in the
study were from social classes I and II. Secondly, practitioners may
be biased in their diagnoses by the social class of the patient,
tending to diagnose asthma in patients from the upper social classes
and, conversely, chronic bronchitis in patients from the lower social
classes. Thirdly, different methods of selecting patients from the
practices may alter the number of asthmatics and chronic bronchitics
obtained. In practice 1 a diagnostic index was used to identify
patients, whereas in the other practices patients were identified by
the prescription of therapy. A difference between practice 1 and the
others would occur if attendance rates varied between patients with
asthma and chronic bronchitis. The use of the diagnostic index was a
more efficient way of identifying patients and was less dependent on
attendance rate.
Asthma is, by definition, an episodic disorder and the
assessment of its severity, therefore, is most accurately undertaken
by repeated measurement of lung function (such as the PEFR) and a
diary card completed over a period of time (Stark 1980). Such
continuous assessment was impractical for this study and yet it was
desirable to obtain some objective measurement of the patients'
disease severity so that patient groups and their therapy could be
compared. By using single recordings of peak flew rates it is
accepted that unrepresentative assessments of seme patients with
episodic symptoms may have been made. The symptom score was adapted
from a diary card and was used to grade symptoms over a period of one
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month. A single retrospective score was obtained, therefore, rather
than multiple prospective assessments as with a diary card. Obviously
such a score was subjective and in the author's opinion there was a
tendency for patients to underestimate their symptoms.
The section for assessing breathlessness in the MRC
questionnaire on respiratory symptoms (a copy is included in Fletcher
et al 1976) was considered for inclusion in the author's
questionnaire. This being
"14a) Are you ever troubled by shortness of breath when hurrying on
the level or walking up a slight hill?
14b) Do you get short of breath walking with other people at an
ordinary pace on the level?
14c) Do you ever have to stop for breath when walking at your own
pace on the level?"
This assessment was thought to be inappropriate for asthma which in
many patients is episodic with symptom free periods. However, many
asthmatics in the study had continuous symptoms and in retrospect the
inclusion of this simple assessment would have been valuable.
In this study the chronic bronchitics were more
incapacitated than the asthmatics, with lower peak flew rates and
higher symptom scores. The fact that few young chronic bronchitics
with mild disease were seen suggests that either such patients do not
present to their general practitioners, or if they do are not treated
for airways obstruction. It might be expected that asthmatics who
attended hospital clinics would have more severe disease than those
attending their general practitioners alone. Though the peak flow
rates of those attending hospital clinics were slightly lower, these
two groups were surprisingly similar in terms of severity of
symptoms. The main difference between the two groups was the greater
frequency of inpatient treatment in hospital clinic attendees. This
may indicate more severe underlying disease in patients attending
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hospital clinics, but of course hospital clinic attendance often









This chapter deals with groups A and B only. It investigates
whether patients diagnosed by their general practitioners as
asthmatic and chronic bronchitic can be separated by their symptom
complexes.
a) UNIVARIATE ANALYSIS
Those symptoms identified from the questionnaire as being
potentially helpful in differentiating asthma (group A) and chronic
bronchitis (group B) are summarised in figure 2 (the data from which
this figure was derived is included in table 18 of the chapter
appendix). For simplification 5 patients diagnosed as having chronic
obstructive airways disease are included with the 107 diagnosed as
chronic bronchitic forming group B. All 5 of these patients fulfilled
the M.R.C. criteria for chronic bronchitis (M.R.C. 1965). Because it
is likely that differentiation between these two groups would be more
difficult in the older patient, a separate analysis of these symptoms
in patients over 50 years of age is included in table 18 of the
chapter appendix. The symptoms are placed in order according to the
level of significance found with the chi-squared test. Figure 3
analyses the incidence of these symptoms in the asthmatics in three
different age groups (the full data from which this figure was
obtained is included in table 19 of the chapter appendix).
Unfortunately not enough young chronic bronchitics were seen to
enable a similar analysis to be made.
Some of these symptoms are considered in detail in the
following section:-
Chronic cough and expectoration-
This symptom was identified using the M.R.C. criteria for
chronic bronchitis (M.R.C. 1965) "Have you had cough and
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THE INCIDENCE OF VARIOUS SYMPTOMATIC FEATURES IN
ASTHMATICS (GROUP A) AND CHRONIC BRONCHITIS (GROUP B)
Group A (n 201) Group B (n 113)
100% 80% 60% 40% 20%
Chronic cough and expectoration _
MRC Criteria for chronic bronchitis
W
All time non-smokers.
Onset of symptoms under.
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FIGURE 2
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FIGURE 3.
expectoration, most days for at least 3 months out of the year for the
past 2 years". A third of those diagnosed by their general
practitioners as having chronic bronchitis did not complain of
chronic cough and expectoration, whereas a fifth of the asthmatics
did (see figure 2). The incidence of this symptom did not vary with
age (see figure 3).
Examination of the whole group (A and B) showed that
significantly more patients with a smoking history (past or present)
gave a history of chronic cough and expectoration (83 out of 185,
45%) than those who were all-time non-smokers (27 out of 129, 20%)(X1
19.1, DF1, p<0.001). However, a similar proportion of asthmatics with
a smoking history complained of chronic cough and expectoration (19
out of 86, 22%), as all-time non-smokers (18 out of 115, 16%)(Xa1.3,
DF1, NS).
Smoking history-
A smoking history was defined as having had at least one
cigarette daily for at least one year. Only 1 in 8 of the chronic
bronchitics were all-time non-smokers in comparison with nearly 6 in
10 asthmatics. The incidence of a smoking history in the asthmatics
was similar in all social classes (see table 20).
The effects of smoking on patients airways obstruction was
assessed by asking if smoking made their wheeze worse (see table 21).
Significantly more asthmatics than chronic bronchitics felt that
their wheeze worsened on smoking.
Exercise induced wheeze and episodic rather than continuous symptoms-
Both these features were more common in the younger
asthmatics, but even in the over 50 years age group they were still
useful differentiating symptoms between the two groups.
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The incidence of smoking in group A in the upper
and lower social classes
Social class
I&II III,IV&V








The effect of smoking upon the patients' symptoms
in groups A and B.
Groups
A B
Number of cigarette 86 99
smokers (current and ex-)




X* 6.3 DF2 p<0.05
Tctble 21.
Allergic history-
Histories of hayfever, eczema, wheeze in contact with
animals, and the presence of asthma or hayfever in a close relative
were all more common in the younger asthmatic. Only a history of
hayfever was a useful differentiating feature between groups A and B
in patients over 50 years old. A history of eczema and wheeze in
contact with animals were unusual symptoms in this age group.
Seasonal and diurnal variation of symptoms-
These features were of little value in differentiating
between groups A and B. Although more young than old asthmatics had
troublesome symptoms in summer, this difference was not statistically
significant.
Age of onset of symptoms-
Only a fifth of asthmatics over 50 years of age had an early
onset of symptoms (before 20 years of age). This was only a slightly
greater proportion than that found in chronic bronchitics (8%).
b) MULTIVARIATE ANALYSIS
The value of various symptoms in discriminating between
patients diagnosed by their general practitioners as having asthma or
chronic bronchitis has been described using a univariate analysis.
Such analysis has the disadvantage of assessing each symptom
independently, whereas in reality seme of the symptoms (e.g. chronic
expectoration and smoking) are likely to be related. If one feature
is present, therefore, the other may add little discriminating value.
In order to investigate this problem a linear multivariate
discriminant analysis using a stepwise process was undertaken
(Armitage 1971) using the S.P.S.S. progranme (Nie 1975). In this
analysis the symptom which most successfully differentiated between
6i
groups A and B was identified and then further factors were added in
order of importance, ensuring that each subsequent factor was
statistically valuable in the separation of the two groups.
Using the best single factor in discriminating between groups
A and B, the presence of chronic cough and expectoration, 81% of
group A and 65% of group B were correctly identified (see table 22).
The relative risk of being diagnosed as asthmatic given that chronic
cough and expectoration was absent was 2.29.
The 11 factors described in table 18 were included in the
multivariate analysis. As it was hoped to examine the separation of
groups A and B without details of age, sex, or social class, these
factors were excluded from the analysis initially. A significance
level of 5% was set and this resulted in a discriminant function
using 6 factors. In order of importance these were:-
a) Chronic cough and expectoration.
b) Hayfever.
c) Exercise induced wheeze.
d) Episodic or continuous symptoms.
e) An early or late onset of symptoms.
f) Stroking history.
Slight simplification of the numerical coding of the responses in the
questionnaire was made for the discriminant analysis, the formulation
of which is outlined overleaf:-
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Factor Question Score
A Have you had chronic
cough and expectoration
most days for at least
3 months out of the
























E Hew old were you
when your wheeze












In comparison with the first 4 factors, the latter 2 added
relatively little to the power of discrimination. Using the
discriminant function each patient was given a predicted diagnosis.
Table 23 illustrates the effectiveness with which groups A and B were
separated using the discriminant function; in 83% of the asthmatics
and 88% of the chronic bronchitics the predicted and general
practitioner diagnoses were matched (relative risk 7.22). The
discriminant function can be compared with the use of the best single
discriminating factor, chronic cough and expectoration, with which
81% of group A and 65% of group B were identified correctly. A study
of the stacked histogram of the discriminant functions of the whole
group (figure 4) shews that lew values were characteristic of group B
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The value of the symptom "chronic cough and expectoration"
in differentiating between groups A and B.
No chronic Chronic cough Relative
Group cough and and risk
expectoration expectoration
A 163(81%) 38(19%) 2.29
B 40(35%) 73(65%)
Table 22.
The value of the discriminant function in















The value of the discriminant function when obtained
from one half of the patients in groups A and B
















The value of the discriminant function in
differentiating between patients in groups A and B
over 50 years old.
Groups Predicted Predicted Relative
group A group B risk
A 73(82%) 16(18%) 5.38
B 16(15%) 89(85%)
Thble 25.










































































































































(group mean -1.3), whereas high values were characteristic of group A
(group mean 0.73). It is likely that chronic bronchitics with high
scores and asthmatics with low scores either had unusual symptoms for
the diagnoses or were misdiagnoses.
Using the above function in practice would give less
satisfactory results because it was applied to the data in an optimal
way to achieve maximal separation of the patients. To investigate the
expected loss of accuracy, half of groups A and B (the odd numbered
patients) were used to obtain another discriminant function which
then was applied to the other half of the data set (the even numbered
patients). This discriminant function identified only 4 of the 6
factors previously found to be helpful. These were:-
1) Chronic cough and expectoration.
2) Hayfever.
3) Age of onset of symptoms.
4) Smoking history.
Using the same coding of responses this discriminant function was
obtained using the following formula-
Discriminant function^ 1.8A-0.8B-0.55E+0.36F-0.94
When this function was used to predict the diagnoses in the other
half of the data set, in 76% of asthmatics and 79% of the chronic
bronchitics the predicted and general practitioner diagnoses were
identical (see table 24). In this case, therefore, separation of the
two groups by symptoms was less successful, and this latter analysis
is likely to be more representative of its value when used on other
groups of patients.
In clinical practice the differentiation of asthma and
chronic bronchitis is more difficult in the middle aged and elderly.
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Because of this a discriminant analysis was undertaken using only
patients over 50 years old (this age limit was chosen
arbitrarily).The analysis led to the formulation of another function
which identified the following factors-
1) Chronic cough and expectoration.
2) Hayfever.
3) Exercise induced wheeze.
4) Smoking history.
The formula of this function was-
Discriminant function = 1.29A-1.44B-1.01C+0.56F+1.6
82% of the asthmatics and 85% of the chronic bronchitics were given
the same predicted diagnoses (see table 25). The separation of these
patients can be seen on the stacked histogram illustrated in figure
5.
Other factors were included in a discriminant analysis of the
whole group including morning tightness, the effects of smoking on
wheeze, bronchodilator reversibility, sex, age, and social class.
Only the last two factors were found to be of any additional
discriminating value.
c) DISCUSSION.
This analysis suggests that patients diagnosed by their
general practitioners as having asthma or chronic bronchitis could be
separated by their symptom complexes. These findings are in keeping
with a previous community survey of asthma characteristics in
wheezing patients (Burr et al 1975), though the latter dealt with an
age group in which differentiation between the two groups may have
been easier (20-44 years). However, the discriminant analysis
provided a mathematical function from symptomatic features to produce
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maximal separation of the patients with asthma and chronic bronchitis
and despite this there was still considerable overlap between the two
groups. Observation of the stacked histogram of the discriminant
function (figure 4) suggests that in about a third of patients the
differentiation between the two conditions using the symptomatic
history would be difficult. This group is slightly larger when
considering patients over 50 years of age. The difficulties of
differentiating asthma from chronic bronchitis in the elderly have
been described previously (Burr et al 1979, Lee and Stretton 1972).
In some patients the differentiation between asthma and
chronic bronchitis may be artificial as both disorders may co-exist.
A fifth of the asthmatics in this study complained of chronic cough
and expectoration, fulfilling the criteria for chronic bronchitis
(M.R.C. 1965). The incidence of chronic expectoration has been
considered greater in older asthmatics (Burr et al 1979, Lee and
Stretton 1972), though this study found only a slight increase in
this symptom with age. Interestingly, in asthmatics there was no
relationship between this symptom and smoking.
The fact that there is a group of patients in whom
symptomatic differentiation between asthma and chronic bronchitis is
difficult lends support to the Dutch hypothesis. Thus, in any large
group of patients with airways obstruction there will be a spectrum
of patients. At one end of the spectrum there will be patients with
purely asthmatic symptoms and at the other there will be those with
symptoms associated with atmospheric pollution (usually cigarette
smoking). Between these two poles there will be patients with a
mixture of symptoms, perhaps because some of the smokers with chronic
expectoration who develop airways obstruction have underlying asthma.
66
There is controversy about the nomenclature of non-asthmatic
airways obstruction (Fletcher and Pride 1984). This study has
illustrated the problem well, as the general practitioners use the
term chronic bronchitis in a wider sense than the MRC criteria of
chronic cough and expectoration (over a third of those diagnosed as
chronic bronchitic did not complain of this symptom). In the past it
was thought that one could be specific with a clinical diagnosis of
chronic bronchitis and emphysema. Dornhors^in 1956,identified two
main types of patients with non-asthmatic chronic airways obstruction
and these two clinico-pathological types were later described in
detail (Burrows et al 1966). The first type of patient (type A) was
considered pathologically to have predominantly emphysema (dilatation
of the distal air spaces with wall destruction), and the second type
(type B) predominantly chronic bronchitis (mucous gland hypertrophy
in the bronchial walls). These two pathological types were thought to
have quite well defined clinical profiles. The type A patient had
radiological evidence of emphysema, was severely short of breath but
maintained normal gas exchange. The patient did not produce much
sputum and rarely experienced cor pulmonale. Physiologically the
lungs were hyperinflated with an increased total lung capacity and a
reduced diffusion coefficient. The type B patient had no radiological
evidence of emphysema, usually produced large amounts of sputum and
often had a reduced arterial oxygen saturation and hypercapnia. This
type of patient was subject to recurrent episodes of cor pulmonale.
As mentioned in the introduction, there is now considerable doubt as
to the validity of these two clinico-pathological groups (Flenley and
Warren 1980). Put simply, many clinicians believe that it is
difficult to assess the contribution of emphysema to airways
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obstruction in life. Unfortunately therefore, patients with
predominant emphysema do not have characteristic symptoms to
differentiate them from those with predominant chronic bronchitis and
it is impossible to predict hew many patients who were labelled as
chronic bronchitic by the practitioners in this study were in fact
predominantly emphysematous. This is unfortunate as the ability to
predict the presence of severe emphysema is clinically important as
one would not expect patients with this condition to respond to
bronchodilators or corticosteroids.Despite being non-specific, terms
such as chronic obstructive airways disease are realistic in that
they do not assume a clinical ability to differentiate between
chronic bronchitis and emphysema.
The incidence of smoking in the asthmatics (a fifth) was
similar to that found in previous outpatient studies (Higenbottam et
al 1980, Connolly 1983). In keeping with previous experience
(Higenbottam 1980), surprisingly few asthmatics who smoked felt that
this made their wheezing worse (a fifth). There is evidence, however,
that the rate of decline in the FEV1 is greater in atopic than
non-atopic smokers (Cornelian et al 1982). It is likely, therefore,
that the rate of decline in the FEV1 is greater in smoking
asthmatics, and it follows that they should be dissuaded from
smoking. The majority of the chronic bronchitics had a smoking
history and the relationship between this disorder and smoking is
well known (Oswald et al 1953). As expected few chronic bronchitics
felt that smoking made their wheezing worse, indeed more felt that it
was improved.
Exercise induced asthma has been recognised at least since
the 17th century (Floyer 1717). However, only recently has this
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reaction been recognised as having diagnostic and therapeutic
implications. In the early 1960's it was demonstrated that airways
obstruction occurred in young children after 8-12 minutes of exercise
and was most severe 1-5 minutes after the exercise (Jones et al
1962). This response was abolished by prior treatment with
isoprenaline. Later sodium cromoglycate was found to have a similar
protective effect (Godfrey 1983a). The incidence of this reaction in
asthmatics depends en the type of exercise involved (Fitch and Morton
1971) and hew the airways response is measured. Godfrey (1983b) found
that 89% of asthmatic children had a 10% fall in PEFR after exercise.
The incidence is probably lower in adults and Poppius et al (1970)
found an incidence of 42% in this group (though he used the stricter
criterion of a 25% fall in PEFR after exercise). This study
substantiates the high incidence of exercise induced wheeze in young
asthmatics (83%), however, even in those over 50 years of age a half
complained of this symptom. Chronic bronchitics do not develop this
response to exercise (Godfrey 1983b) and yet in this study
approximately a quarter complained of this symptom. It is possible
that some of these patients represented misdiagnoses and were
asthmatics. However, the question concerning exercise induced
symptoms may not have been specific enough to differentiate
accurately between exercise induced airways obstruction and the
shortness of breath on exercise which may occur with many forms of
lung disease.
Although asthma is defined by the presence of episodic
airways obstruction (Ciba Foundation 1957), it is well known that
many patients with "late onset asthma" have continuous symptoms
(Rackemann 1947), like those with chronic bronchitis. In this study
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less than a third of asthmatics over 50 years of age had episodic
wheeze with symptom free periods. This factor, therefore, is of less
diagnostic value in the older patient.
A history of atopy in a patient with airways obstruction may
be a useful indicator that the latter is due to asthma. Skin testing
has demonstrated the presence of atopy in 90% of patients whose
asthma commenced before the age of 10 years, whereas this applied to
only 30% of those whose asthma commenced over the age of 30 years
(Pepys 1975). Using the clinical manifestations of atopy (asthma,
hayfever and eczema) and skin testing, Pearson (1968) estimated that
55% of asthma in patients aged between 15-29 years was allergic in
aetiology; this applied to only 32% of asthmatics aged between 45-60
years. The prevalence of atopic features in asthmatics in this series
was entirely compatible with those previous studies. The prevalence
of atopic manifestations in the chronic bronchitics was slightly
higher than expected. The prevalence of hayfever in the community is
approximately 6% (Broder et al 1962) whereas 10% of the chronic
bronchitis in this study gave such a history.
Turner-Warwick (1978) has suggested that a family history of
asthma is as camion in atopic as non-atopic asthmatics, unlike the
family histories of hayfever and eczema which are more common in the
former. This explains the similar frequency of family history of
hayfever and asthma in both older and younger asthmatics.
Unfortunately the family histories of hayfever and asthma were not
considered separately in this study. Chronic bronchitis is often
associated with a strong family history (Oswald 1953). It is possible
that the high incidence of family history of hayfever and asthma in
this study is related to the misdiagnosis of asthma for chronic
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bronchitis in relatives. Consequently the presence of a family
history of wheezing chest disorders may be of little diagnostic
value. Interestingly Burr et al (1975) found a family history of
allergy (asthma, hayfever and eczema) in 24% of their control group
when undertaking a survey of asthma characteristics in the community.
Asthma has traditionally been associated with troublesome
symptoms at night (Editorial 1983). There is a circadian rhythm of
airways calibre in normal individuals, and asthma probably represents
an exaggeration of this rhythm, with maximal airways obstruction
occurring between 4-6 a.m.(Hetzel and Clark 1980). Asthmatics who
have troublesome airways obstruction in the early hours have been
called "morning dippers" (Turner-Warwick 1977). This has been
estimated to occur in a third of asthmatics (Connolly 1979). In this
study approximately a third of asthmatics thought the night to be
their most troublesome period. In contrast chronic bronchitics have
been found to have little diurnal variation in airways obstruction
(Dawkins and Muers 1981) and such patients are thought normally to
have restful nights. It was a surprise, therefore, to find that a
fifth of the chronic bronchitics thought that the night was their
most troublesome period.
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The number of patients exhibiting various symptoms in groups








Chronic cough 37(18%) 73(65%)






























Wheeze in contact 62(31%) 7(6%)































Not seasonal 97(48%) 60(53%)
X2 15.0 DF2
Childhood eczema 41(20%) 5(4%)
X* 14.8 DF1
Family history of 106(53%) 38(34%)
hayfever/asthma X2 10.6 DF1



















The number of patients exhibiting various symptoms in














































X1 12.6 DF2 p<0.01
50(83%) 33(63%)
X1 35.6 DF2 p<0.001
40(67%) 29(55%)
X2 12.2 DF2 p<0.01
30(50%) 21(40%)




X1 3.4 DF4 NS
22(36%) 12(23%)
X2 18.6 DF2 p<0.001
36(60%) 29(56%)
Xz 3.0 DF2 NS

































REVERSIBILITY STUDIES IN THE DIAGNOSIS OF
OBSTRUCTIVE AIRWAYS DISEASE.
a) Bronchodilator reversibility studies
b) Corticosteroid reversibility studies
c) The treatment of patients with documented reversibility
d) Discussion.
72
a) BRCMCHODILATCR REVERSIBILITY STUDIES
PEER recordings were undertaken before and 10 minutes after
200 meg of salbutamol delivered by aerosol in 120 asthmatics (group
A) and 95 chronic bronchitics (group B) (all patients with a baseline
PEER below 80% of the predicted value). Bronchodilator reversibility
was expressed as the change in PEER both as a percentage of the
initial value and of the predicted value for that patient. The
distributions of bronchodilator reversibility expressed in these two
ways are illustrated in figures 6 and 7. There was no significant
difference in reversibility between the asthmatics and chronic
bronchitics when the change in PEER was expressed as a percentage of
the initial value. When this change was expressed as a percentage of
the predicted PEER the difference between the asthmatics and chronic
bronchitics was significant, but examination of the distribution (see
figure 7) shows considerable overlap and only values over 20% were
specific for asthma. This occurred in 16(13%) asthmatics.
Figure 8 illustrates the relationship between the baseline
and post bronchodilator PEER. Only a few patients with mild airways
obstruction (>60% predicted PEER) reached their predicted values with
a bronchodilator, and there was no obvious relationship between
response and the degree of initial impairment. Neither was there a
significant difference in reversibility between older and younger
asthmatics (see table 26).
In the previous chapter each patient was given a predicted
diagnosis using a discriminant function equation. Using this function
more negative values were characteristic of group B and positive
values of group A. Figure 9 illustrates the relationship between
bronchodilator reversibility (the change in PEER being expressed as a
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BRONCHODILATOR REVERSIBILITY (THE CHANGE IN PEFR EXPRESSED
AS A PERCENTAGE OF THE INITIAL VALUE) IN ASTHMATICS (GROUP A)
AND CHRONIC BRONCHITIS (GROUP B).




















Median (25th, 75th centiles)
FIGURE 6.
BRONCHODILATOR REVERSIBILITY (THE CHANGE IN PEFR
EXPRESSED AS A PERCENTAGE OF THE PREDICTED NORM) IN
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Median (25th, 75th centiles)
FIGURE 7
THE RELATIONSHIP BETWEEN BASELINE AND POST
BRONCHODILATOR PEAK FLOW RATES IN ASTHMATICS
(GROUPA) AND CHRONIC BRONCHITICS (GROUP B)
Baseline PEFR % predicted
Figure 8
The median (25,75th centiles) bronchodilator reversibility
(change in the PEFR expressed as a percentage of the predicted norm)
in groups A and B in two agegroups.
Median (25th,75th centile)
reversibility.
(n=number of patients involved)
Groups
A B






♦Number too small for comparative statistics
**p<0.05 Mann-Whitney U test
ihble 26.





































• Spearmancorrelationcoefficient pcO'OOl 30%
40%
Bronchodilatorreversibility(changeiPEFRexpr sseapercentag ofpredictedPEFR) FIGURE9
percentage of the predicted value for each patient) and the
discriminant function. Although this correlation was significant
(Spearman's test p<0.001 ) examination of the plot reveals a wide
scatter and only a reversibility greater than 20% was specific for a
discriminant function "predicted" diagnosis of asthma.
An arbitrary level of bronchodilator reversibility was
chosen and those with values equal to or above 10% were compared with
those below 10% (change in PEFR as a percentage of the predicted
value). The characteristics and symptoms of patients in these two
groups are illustrated in figure 10 (the data from which this figure
is derived are included in table 27 of the chapter appendix). Of
those who had good reversibility (»10%) significantly more were
non-smokers, had episodic symptoms, troublesome nocturnal wheeze and
were female. However, observation of figure 10 suggests that none of
these differences was great enough to be clinically valuable. A
discriminant analysis was undertaken between those with poor (<10%)
and those with good reversibility (>A 0%) using the same features
described in the previous chapter (but including age and sex). Only
sex, and the season and time of day in which the symptoms were most
severe were of discriminating value. Using this discriminant function
less than two-thirds of patients were grouped correctly by
reversibility (see table 28). Observation of the stacked histogram of
this discriminant function in figure 11 emphasises the poor
separation of patients.
50% of group A and 39% of group B had reversibilities of 10%
or greater. Table 29 illustrates that the discriminant function did
not help in predicting "good" bronchodilator reversibility.
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,The incidence of various factors in patients with
bronchodilator reversibility (the change in PEFR
expressed as a percentage of the predicted norm) equal
to or above 10%, or below 10%




Symptoms worse in the
evening or night
Patients greater than

















The value of the discriminant function in predicting
bronchodi lator reversibility by patient characteristics
and symptoms
Predicted Predicted Total













Bronchodilator reversibility by the general practitioner
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b) CORTICOSTEROID REVERSIBILITY STUDIES.
145 patients (67 asthmatics and 78 chronic bronchitics) had a
PEER less than 60% of the predicted value. 18(12%) of these already
took oral corticosteroid therapy. 17(12%) had taken oral
corticosteroids in the past and did not wish to take a further
course.
37(34%) of the remaining 110 patients were given a trial of
oral corticosteroids. Other patients were excluded for the following
reasons
1) 25(23%) Congestive cardiac failure, hypertension, ischaemic heart
disease.
2) 13(12%) Peptic ulceration or severe indigestion.
3) 6(5%) Known old tuberculosis.
4) 3(3%) Mental illness.
5) 3(3%) Diabetes Mellitus.
6) 4(4%) Miscellaneous medical disorders (intercurrent chest
infection, epilepsy, malignancy)
7) 4(4%) A history of a previous adverse reaction to oral
corticosteroids.
8) 4(4%) An inability to comply with taking PEER recordings.
9) 11(10%) An unwillingness to take oral corticosteroids.
Of 37 patients given a trial of oral corticosteroids 1 failed
to attend for follcw up (despite 3 appointments made for him), and
another 2 patients returned having failed to take all the tablets
(They did not complain of having had side effects but were worried
about taking corticosteroid therapy,). The remaining 34 patients took
the full course of placebo and prednisolone tablets. This treatment
was well tolerated though 2 patients complained of feeling bloated
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and one of hot flushes throughout the prednisolone therapy. No
serious side effects were encountered.
26 of the 34 (76%) patients completed a peak flew graph on
their chart entirely correctly including all 28 recordings (twice
daily for two weeks). A further 2 patients provided all recordings
but did not complete the graph correctly. 3 patients omitted one
recording, and a further 2 omitted up to half the recordings. In only
one patient could no valid assessment be made from the peak flow
chart.
Tables 30 and 31 illustrate the symptomatic characteristics
and reversibility of the 33 patients who undertook a full trial of
oral corticosteroids. In this group there were 15 females and 18
males, their mean age was 57.3 years (range 23-73 years). 15 were in
group A, and 18 in group B. In 4 cases diagnosed by their general
practitioners as asthmatic, the discriminant function had given a
"predicted diagnosis" of chronic bronchitis. 13 of the 18 patients in
group B and 4 of the 15 in group A fulfilled the M.R.C. criteria for
chronic bronchitis with chronic cough and expectoration.
Corticosteroid reversibility was assessed by two methods:
1) By comparing the mean PEFRs of the last 5 days (10 recordings)
during placebo and prednisolone therapy (the change in mean PEER
being expressed as a percentage of the mean initial PEER during
placebo therapy).
2) By undertaking paired t tests on the untransformed data on both
morning and evening recordings separately.
The most significant of the two t tests for each patient is included
in table 31. In 3 patients t tests revealed a significant response



































The characteristics of 33 patients undertaking
a trial of oral corticosteroid therapy.
Age Sex Chronic Smoking Hay- Exercise
(yrs) cough and history fever induced
expect'n wheeze
35 F no no yes yes
56 F yes yes no no
23 F no no no yes
65 F no ex no no
72 F yes no yes yes
25 M yes ex yes yes
67 M no yes no no
64 F yes ex no yes
52 M yes ex no yes
67 M yes yes no no
70 M yes ex no no
73 M no yes no yes
55 F yes yes no no
60 M yes yes no no
62 F no yes yes no
67 M yes ex no no
46 F no yes no yes
72 M yes yes no no
49 F no ex no yes
66 F yes ex no no
55 F no yes no no
51 M no ex no no
28 F no no no yes
73 M no ex no no
60 M yes yes no no
66 M no no no yes
60 F no no no yes
62 M no no no yes
66 M yes ex no no
60 F no ex no no
63 M yes ex no yes
28 M yes no yes yes





































The reversibility of 33 patients given a trial
of oral corticosteroid therapy.







































































occurred in both morning and evening recordings. The use of t test
significance (p<0.05) and a change in mean PEFR of 15% or greater as
response criteria gave entirely similar results apart from 2 patients
(numbers 18 and 23).
The symptoms indicated in table 30 were analysed in both
responders and non-responders (change in PEFR ^15% and <15%
respectively), there was no significant difference in the incidence
of any of these symptoms between the two groups.
The use of the discriminant function "predicted diagnosis"
did not change the number of responders between the diagnostic
groups. Approximately 6 in 10 asthmatics and 1 in 4 of the chronic
bronchitics had "good" corticosteroid reversibility (see table 32).
The relationship between corticosteroid and bronchodi lator
reversibility is illustrated in figure 12. The correlation between
these two responses was significant (r= 0.403, p<0.05 Spearman's
test).
In order to assess whether there was a placebo response
during the corticosteroid trials, the means of the first and last 4
recordings during the placebo week were compared (morning and evening
recordings on days 1-2 and 6-7 respectively). The mean difference
between these periods in the whole group was 13.6. Though this
difference was not significant (t=1.92 DF32 N.S.) the graphs of two
patients (illustrated in figure 13) revealed marked individual
placebo responses.
The importance of diurnal variation was assessed by
expressing the difference in mean morning and evening recordings for
each patient as a percentage of the mean peak flow during the whole
placebo week. Paired t tests were undertaken on the untransformed
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The number of corticosteroid responders (an
improvement of 15% or greater) by the general practitioner
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data in order to ascertain whether morning and evening recordings
were significantly different in each patient. The results are
analysed in table 33. The mean evening recordings were significantly
higher than those in the morning (t=2.58 DF29 p<0.05). The mean
difference in PEFR was slightly less in group A (4.9%) than in group
B (5.5%). When examining individual patients, 3 asthmatics and 3
chronic bronchitics were found to have significantly higher (p<0.05)
evening than morning recordings. In 4 of these (1 asthmatic and 3
chronic bronchitic), this difference in peak flew rate was greater
than 20%. There was no correlation between diurnal variation measured
in this way and corticosteroid reversibility (r= -0.028).
c) THE TREATMENT OF PATIENTS WITH DOCUMENTED REVERSIBILITY.
The therapy of those patients responding (by 15% or more) to
the corticosteroids trial was examined. Of the 13 responsive
patients, 3 took inhaled corticosteroids (2 in group A and 1 in group
B) and 2 sodium cromoglycate (both in group A). 4 out of the 5
patients using inhaled prophylaxis were prescribed below standard
doses (<400mcg beclcmethasone diproprionate or <4 capsules of sodium
cromoglycate daily or equivalents) despite scores of 2 or 3 for day
or night time symptoms.
12 out of the 13 responsive patients had scores of 2 or 3 for
day or night time symptoms, suggesting that in nearly all this group
prophylactic therapy with at least standard doses of inhaled
corticosteroid was warranted.
45 patients (32 in group A and 13 in group B) were shewn to
have good bronchodilator reversibility (15% or greater of the
predicted PEFR) but did not have a trial of oral corticosteroids.
24(53%) of these patients (15 in group A, 9 in group B) had scores of
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The diurnal variation during the placebo week of
the corticosteroid trials.
Pat Group Mean '■lean Difference
No AM PM of mean AM &
PEER PEER PM PEER
as % of
mean PEFR
1 A 171 168 -2%
2 B 125 128 2%
3 A 118 140 17%
4 B 121 131 8%
5 A 480 475 -1%
7 B 310 321 3%
8 B 74 85 11%
9 B 198 212 7%
10 B 154 205 27%
11 B 160 158 -1%
12 B 147 146 -1%
13 B 128 166 26%
14 B 205 250 20%
16 A 185 201 8%
17 A 193 224 15%
18 B 204 206 1%
20 B 134 136 1%
21 B 120 136 12%
22 A 188 178 -5%
23 A 177 244 32%
24 A 302 319 5%
25 B 240 250 4%
26 A 171 166 -3%
27 A 105 91 -14%
28 A 138 143 3%
29 B 115 117 2%
30 B 98 30 -20%
31 B 240 234 -3%
32 A 273 283 4%
33 B 247 250 1%



































2 or 3 for day or night time symptoms. The treatment of this
symptomatic group is illustrated in table 34. All 6 symptomatic
patients on inhaled corticosteroids and 3 out of the 5 on sodium
cromoglycate took below standard dosage of these drugs.
c) DISCUSSION
When bronchodilator reversibility was expressed as the change
in PEFR as a percentage of the initial value, there was no
significant difference between the asthmatics and chronic
bronchitics. However, the chronic bronchitics had lower initial PEFRs
than the asthmatics, and when reversibility is expressed in this
manner responses at low initial values may be exaggerated (Nicklaus
et al 1969). In an attempt to increase the specificity of the
reversibility studies the change in PEFR was expressed as a
percentage of the predicted PEFR. Bronchodilator reversibility
expressed in this manner was significantly higher in the asthmatics
but again there was a great overlap with the chronic bronchitics.
Using this method a reversibility of 15% has been found to be
specific for asthma (Nicklaus et al 1969). In this study only a
reversibility greater than 20% was specific for asthma (general
practitioner and predicted diagnoses).
The degree of reversibility found in the chronic bronchitics
in this study may be considered to be surprising; however, Curtis et
al (1966) found that 84 out of 100 patients with chronic bronchitis
and emphysema showed improvement with isoprenaline, and although the
FEV1 declined in this group over a 5 year period this reversible
element remained. Crompton (1968) examined the effects of
bronchodilators and corticosteroids on 18 asthmatics and 18 chronic
bronchitics and found that the mean reversibility to isoprenaline was
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The treatment of symptomatic patients with
bronchodilator reversibilty equal to or greater
than 15% (the change in PEFR being expressed as
a percentage of the predicted norm) in whan
a corticosteroid trial was not undertaken.
Diagnostic group
A B
Number of patients 15 9
Number of patients using











32% (of the initial value). It has been considered that a
reversibility greater than 25% is suspicious of asthma (Crompton
1980) and yet 11 out of the 18 chronic bronchitics in Cronpton's
study demonstrated this degree of reversibility to isoprenaline.
A comparison of symptoms in patients with good and poor
bronchodilator reversibility emphasises the poor correlation between
the two, and that reversibility cannot be predicted from the
symptomatic history. Why was there such a poor relationship between
the practitioners' diagnoses or the symptomatic "predicted" diagnoses
and the bronchodilator reversibility? Hume and Rhys-Jones (1960) have
stated that the response of an asthmatic to a bronchodilator depends
upon the degree of initial airways obstruction present. If this were
true then each patient would have a range of bronchodilator
reversibility depending on the degree of initial airways obstruction.
In this study patients with severe airways obstruction had similar
responses to those with mild obstruction. This may have been due to
the fact that all the patients seen were in a stable state, despite
the fact that seme had severe airways obstruction. The observation by
Hume and Rhys-Jones was undertaken on a very small number of
asthmatics and more work is required to examine the reproducibility
of the bronchodilator reversibility in airways obstruction. If a
single study is an unreliable measure of response, perhaps the
specificity of bronchodilator reversibility to asthma could be
enhanced by undertaking repeated studies over a period of time and
documenting the mean of several results.
Very few patients reached their predicted PEFR with standard
doses of salbutamol, and it is possible that the specificity of these
tests could be increased by the use of higher doses of
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bronchodilator. Certainly sane asthmatics require higher than
standard doses of a |J2 stimulant to demonstrate maximal reversibility
(Prior and Cochrane 1982). Unfortunately it is not known whether
patients with chronic bronchitis respond to a similar degree with
higher doses of ^2 stimulants as those with asthma.
The idea of a trial of oral corticosteroid therapy in chronic
asthma to assess which patients would benefit from long-term therapy
was described nearly 30 years ago (Walsh and Grant 1966) and it is
now standard practice. Although the effect of corticosteroids in
chronic bronchitis is more controversial (Sahn 1978), it is new
recommended that a trial of such therapy should be given to any such
patients with disabling symptoms (Royal College of Physicians 1981,
Editorial 1980).
Corticosteroid trials were used in this study, firstly, to
investigate whether there was a relationship between the general
practitioners' diagnoses or the "predicted" symptomatic diagnoses and
the reversibility to corticosteroids, and secondly, to demonstrate
how many patients with disabling airways obstruction, despite
treatment from their general practitioner, could benefit from this
form of therapy. None of the patients studied had an acute
exacerbation of symptoms; this is important as there is new evidence
that corticosteroids are valuable in acute exacerbations of chronic
bronchitis (Albert et al 1980).
Because the corticosteroid trials were undertaken
independently of the general practitioners' management, strict
criteria were used to exclude patients with associated medical
conditions which might be worsened by such treatment. High dose
corticosteroids may cause fluid retention, increase the blood
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pressure, disturb glucose homeostasis, induce acute psychosis and
cause peptic ulceration (this latter effect remains unproven)
(Cochrane 1983). Despite such side effects, the results of this study
confirm the safety of short courses of oral corticosteroids. Used in
this manner there is little suppression of adrenal function (Webb and
Clark 1981b) and the course may be terminated abruptly without risk.
It was surprising how many patients in this study were excluded from
having a corticosteroid trial because of associated medical
conditions. Such conditions are only relative contraindications,
however, and in normal clinical practice more trials could have been
undertaken if considered medically justified.
The majority of patients completed their peak flow charts
correctly. Hetzel suggested that patients found it easier merely to
record the peak flew values numerically on a chart rather than
produce a graph (Hetzel et al 1979). In this study only 9% were
unable to formulate a graph and the omission of recordings was a more
frequent error.
Although no statistically significant placebo response was
demonstrated in the group as a whole, seme patients demonstrated a
marked response to placebo highlighting some of the pitfalls in the
interpretation of therapeutic trials in obstructive airways disease.
Most previous workers (Webb et al 1981a, Stokes et al 1982, Lam et al
1983) have also failed to demonstrate a placebo response, whilst
others think it important (Mitchell et al 1984). At present few chest
physicians routinely use placebo tablets, and one could not expect
this of the general practitioner.
There are few guidelines for the assessment of corticosteroid
trials. In keeping with previous experience (Webb et al 1981a)
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undertaking paired t tests on the data offered little advantage over
the much simpler analysis of calculating the mean percentage
improvement. Many workers determine the corticosteroid response by
visual assessment of the PEFR chart. In order to clarify the trends
in the PEFR, the use of cusum (cumulative sum) analysis has been
suggested (Clarkson et al 1978), and was considered in this study,
using the mean of the first two days recordings on placebo therapy as
the reference value. The use of this analysis in a small selected
sample did not appear to improve on mere visual inspection of trends
in PEFR on the charts. Because it is highly subjective, visual
assessment of the peak flew charts was not documented.
Some patients improved symptomatically on oral corticosteroid
therapy but not by recordings of the peak flow chart. Such patients
are difficult to assess. They may have been experiencing the
non-specific euphoria, which occurs with corticosteroid therapy.
However, some patients fail to respond by PEFR or FEV1, but shew
Improvement in the FVC or measurements of exercise capacity such as
the 12 minute walk (Williams and McGavin 1980). In others, there is a
reduction in total lung capacity because of a decrease in the
hyperinflation of the lungs which occurs in obstructive airways
disease (Turner-Warwick 1977). It is impossible, without further
assessment, to knew hew many patients in the study with a symptomatic
response to corticosteroids had derived a physiological benefit from
the drug.
Two young patients in the study (numbers 1 and 32) with
typical asthma (atopy and episodic wheezing) had little response to
corticosteroids as measured by the PEFR. Perhaps higher doses or
longer courses of corticosteroids were required. In assessing the
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time course of response to corticosteroids (using the same dose of
prednisolone as in this study) Webb et al (1981a) found that 10 out
of 13 responsive patients had reached their maximum response within 7
days. It is accepted therefore, that some responders may have been
missed. Prednisolone treatment for one week was chosen as a
compromise between that most likely to identify responders and that
least likely to incur side effects.
The proportion of responders was similar by both the general
practitioner and the "predicted" symptomatic diagnoses. The latter
did not help, therefore, in predicting reversibility. Although
corticosteroid responsiveness was more likely to occur in those with
an asthmatic symptomatology with 7 out of 11 responders, there were 6
out of 22 responders in those with symptoms of chronic bronchitis.
Previous workers have found that a history of wheezing attacks and a
short duration of symptoms (Petty et al 1970), a variability of
symptoms (Lam et al 1983) and sputum eosinophilia (Shim et al 1978)
have all been associated with a good response to corticosteroid
therapy. However, this study suggests that there is a range of
corticosteroid responsiveness in obstructive airways disease which is
poorly correlated with symptoms.
As with the bronchodilator studies this may be due to
inadequacies in the tests and the expression of the results. However,
the reason for the poor correlation between the symptomatic diagnosis
and the bronchodilator and corticosteroid reversibility may be more
fundamental than this. In the introduction it was noted, in a
discussion of the Dutch hypothesis, that bronchial reactivity in
patients with typical chronic bronchitis ranged from normal to the
hyper-reactivity usually associated with asthma. This heterogeneity
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of response to histamine or methacholine in chronic bronchitis also
applies to the response to drug therapy. Thus there is a range of
reversibility from that usually associated with asthma to the minimal
response of fixed airways obstruction. One would expect, therefore,
an overlap in reversibility between patients with asthma and chronic
bronchitis. This may be due to the fact that the underlying mechanism
of airways obstruction is similar despite the differing causative
factors such as allergy and smoking. Although unproven, those
patients with little airways reversibility may have predominant
emphysema. As mentioned earlier this is a difficult diagnosis to make
accurately in life. Although corticosteroid reversibility has been
considered previously to be a universal feature of asthma, it is now
recognised that there are some patients with a typical history of the
disorder who are resistant to the drug (Carmichael et al 1981). In
this study, as previously described, there were two young patients
with typical asthma who did not respond to corticosteroids.
Asthmatics (Hetzel and Clark 1980) unlike chronic
bronchitics (Dawkins and Muers 1981) have large diurnal variations in
airways obstruction, so much so that an amplitude greater than 20%
from the mean has been considered to be a useful screening test for
asthma (Hetzel and Clark 1980). However, such studies have used
oosinar analysis to identify the diurnal rhythm, which is
impracticable in clinical practice. As asthma is often associated
with an increase in airways obstruction in the early morning
(Turner-Warwick 1977) it was thought worthwhile to examine whether
twice daily recordings of PEFR could help in the differentiation
between asthma and chronic bronchitis. In this study the mean evening
peak flew rates were significantly higher than the morning values by
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5.3% (of the mean peak flew rate). This was similar to previous
experience (Webb et al 1981), though it was surprising that the
variation was slightly higher in the chronic bronchitics than the
asthmatics. There was no relationship between corticosteroid
reversibility and diurnal variation, and this type of simple analysis
wnuld appear to be of dubious value.
In practice the main aim of undertaking a corticosteroid
trial is to identify those patients who would benefit from long term
treatment with this drug. Once responsiveness has been demonstrated,
many of these patients can be maintained on inhaled therapy alone
(Toogood et al 1978). However, it is likely that there are degrees of
responsiveness and in some patients the documented improvement
obtained during a corticosteroid trial may be impossible to maintain
even with long term oral corticosteroids (Stokes et al 1982).
In this study the corticosteroid trials identified a group of
symptomatic yet responsive patients, none of whan had been taking
satisfactory maintenance therapy. It is likely that the majority
would have benefitted from inhaled corticosteroid in adequate dosage.
Though bronchodilator reversibility need not imply corticosteroid
responsiveness (Carmichael et al 1981), the findings of this study
and other workers suggest that there is a relationship. It is
possible, therefore, that those patients with good bronchodilator
reversibility in whom a corticosteroid trial was not undertaken may
also have improved on inhaled corticosteroids.
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The number of patients exhibiting various characteristics
and symptoms with bronchodi lator reversibility (the change
in PEFR expressed as a percentage of the predicted



























X* 10.9 DF1 p<0.001
32(27%) 41(42%)
X* 5.4 DF1 p<0.05
24(20%) 33(34%)
X1 5.1 DF1 p<0.05
27(23%) 34(35%)
X1 3.8 DF1 p<0.05
93(79%) 66(68%)
X2 3.2 DF1 NS
53(45%) 34(35%)
X* 2.1 DF1 NS
15(13%) 15(15%)
X2 0.3 DF1 NS
60(51%) 53(55%)
X2 0.3 DF1 NS
31(26%) 28(29%)
X2 0.2 DF1 NS
20(17%) 17(18%)
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a) GENERAL ASPECTS OF MANAGEMENT
Hospital or chest clinic outpatient attendance-
141 (70%) patients in group A and 64(57%) in group B had
attended a hospital outpatient department or chest clinic with
symptoms of airways obstruction at sometime; 51 (25%) in group A and
23(20%) in group B had attended within the previous 12 months.
General practice surgery attendance-
Hie number of times patients in groups A and B had attended
their general practitioner in the previous six months is indicated in
table 35 (visits for repeat prescriptions without seeing the doctor
and emergency housecalls are excluded). Patients in groups A and B
had similar attendance rates with approximately two thirds attending
at least twice in the previous six months. The differences in
hospital clinic attendance, frequency of visits to the general
practitioner, and the proportion who were satisfied with the control
of their symptoms between the four practice centres are illustrated
in table 36. Approximately a quarter of patients were currently
attending hospital outpatient clinics, this proportion was similar in
all practice centres. There were insignificant differences in the
rates of attendance with the general practitioner and the proportion
satisfied with the control of their symptoms between the practice
centres. However, it is noticeable that the practice with the lowest
attendance rates had the smallest number of patients who were
satisfied with their symptom control.
A similar proportion of hospital outpatient attenders in
groups A and B frequently (greater than 5 attendances in 6 months)
visited their general practitioner (11 out of 74, 15%) as those who
did not attend hospital outpatients (39 out of 240, 16%).
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Attendance at the general practice surgery.
The number of patients attending their general practice surgery





2-5 times 83(44%) 68(60%)
>5 times 33(16%) 17(15%)
Number of patients 201 113
Table 35.
Hospital clinic and general practice surgery
attendance between the general practice centres.
Practice centre 1234
Number of patients 140 45 62 67




f<Jumber of patients attending their general practice surgery
in the previous 6 months.
Never 10(7%) 5(11%) 2(3%) 6(9%)
Once 31(22%) 21(47%) 10(16%) 23(34%)
2-5 times 76(54%) 17(38%) 35(56%) 28(42%)
>5 times 23(16%) 2(4%) 15(24%) 10(15%)
The number of patients satisfied with the control of
their symptoms.
116(83%) 30(67%) 46(74%) 48(72%)
Thble 36.
b) THE PRESCRIPTION OF BRQNCMX>ILATCRS.
284 out of 314 (90%) patients in groups A and B and all
patients in group H used a bronchodilator. 28 of the remaining
patients in groups A and B used a prophylactic drug alone (including
19 using sodium cromoglycate, 7 inhaled corticosteroids, and 2
systemic corticosteroids). 18 of these 28 patients (64%) used their
prophylactic drug on demand for wheezing attacks, suggesting the need
for bronchodilator therapy. A further 2 patients had recently stopped
all therapy.
Hie different types of bronchodilator delivery prescribed to
the 284 patients in groups A and B are summarised in table 37.
Significantly more chronic bronchitics used oral therapy than
asthmatics, this difference continued to apply in a separate analysis
of patients over 50 years of age, and there was little difference in
bronchodilator delivery between asthmatics over and under 50 years of
age. There was also a significant difference in the use of inhaled
and oral drugs between those asthmatics attending hospital clinics
(groups A-OPD, and H) and those attending their general practitioner
alone (group A-GP) with more of the latter using oral bronchodilators
(see table 38). When the type of bronchodilator delivery was examined
in the asthmatics between the four practice centres, again
differences were found with between 2-36% using oral therapy alone
(see table 39).
c) INHALED BRONCHODILATCRS.
The types of inhaled bronchodi lators prescribed to patients
in groups A, B, and H are illustrated in table 40. The great majority
used fl stimulant inhalers with ipratropium bromide being used mainly
by chronic bronchitics. There was little difference in the type of
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The number (%) of asthmatics (group A) and chronic
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Hie number(%) of asthmatics (group A) using the various types



















53(74%) 21(84%) 20(77%) 43(98%)
19(36%) 4(16%) 6(23%) 1(2%)
X4 12.3 DF3 p<0.01
liable 39.
ihe types of inhaled bronchodilators prescribed






















Number(%) using the following drugs:






inhaler used between groups A and H.
Regular or demand use of inhalers-
Asthmatics attending hospital outpatient clinics (groups
A-OPD, and H) were more likely to take regular therapy than those
attending their general practitioner alone (group A-GP). This
difference continued to apply when analysing only patients with
moderate or severe day time symptoms in whom two thirds of groups
A-OPD and H took regular therapy in contrast to only a seventh of
group A-GP (see table 41). Similar findings were obtained in the
chronic bronchitics, with more of those patients attending hospital
clinics within the previous 12 months (group B-OPD) taking regular
inhaled therapy than those who attended their general practitioner
alone (group B-GP) (see table 42).
Dosage of bronchodilator inhalers-
Ihe dosages of bronchodilator inhalers used are included in
table 43. The majority of patients (81%) used salbutamol. In group A
10 out of 29 patients (34%) taking more than 8 puffs daily of their
bronchodi lator inhaler did not use inhaled corticosteroid or sodium
cromoglycate. 26 of these 29 patients had scores of 2 or 3 for day or
night time symptoms. All patients in group H using these doses also
took such prophylactic therapy. Only 7 patients (3%) in groups A and
B used more than 16 puffs daily.
In groups A and B 17 patients (8% of inhaler users) were
regarded as underusing their inhalers (taking less than 2 puffs daily
despite scores of 2 or 3 for day or night time symptoms).
Significantly more patients (p<0.001) underusing aerosol inhalers had
a poor inhaler technique (11 out of 17,65%) compared with those








The regular use of bronchodilator inhalers in






Number of inhaler 22
users with scores of 2 or 3








The regular use of bronchodilator inhalers











X1 5.4 EF1 p<0.05
Number of bronchodilator inhaler 14
users with a score of 2 or 3
for daytime symptoms
Number(%) taking regular doses 13(93%)
28
11(39%)
X* 10.9 DF1 p<0.001
Thble 42.
Hie dosages of inhaled bronchodilators used








>16 puffs 0(0%) 6(4%) 1(2%)
9-16 puffs 11(23%) 23(16%) 8(13%)
<9 puffs 36(77%) 113(80%) 52(85%)
<2 puffs despite 0(0%) 7(5%) 10(16%)
a score of
2 or 3 for daytime
symptoms
For simplicity, in this table IRotacap = 2puffs. Unless the patient




Only 36 of 85 patients (42%) in groups A and B and 9 out of
27 patients (33%) in group H who had troublesome wheeze on exercise
and an available bronchodilator inhaler ever used this form of
therapy before exercise.
Inhaler technique-
All 44 patients using an aerosol bronchodilator in group H
demonstrated an efficient inhaler technique and all had been taught
this by a doctor. 52 out of 192 patients (27%) in groups A and B
using an aerosol bronchodilator inhaler had poor inhaler techniques.
Using the classification of Paterson and Crampton (1976), 30(16%)
were doubtfully efficient and 22(11%) were totally inefficient. There
was little difference between those who had recently attended a
hospital clinic (groups A-OPD and B-OPD) and those who attended their
general practitioner alone (groups A-GP and B-GP), in whom 14 out of t
59 (24%) and 38 out of 133 (29%) had poor techniques respectively.
In groups A and B the following points were noted with regard
to inhaler technique-
1) Fewer patients using aerosol corticosteroid or sodium
cromoglycate (with or without an aerosol bronchodilator) had poor
techniques (19 out of 89, 21%) than those using a bronchodilator as
their only aerosol (39 out of 116, 34%) (X^ 3.9 DF1 p<0.05).
2) Fewer using an aerosol as their only bronchodilator had
poor techniques (23 out of 128, 18%) than those using aerosol and
oral bronchodilator therapy combined (29 out of 64, 45%) (X^- 16.2 DF1
p<0.001 ).
3) Fewer patients who had been instructed by their doctor had
poor inhaler techniques (30 out of 141, 21 %) than the untutored (21
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out of 46, 46%) (Xz 10.4 DPI p<0.01).
4) The importance of age can be demonstrated by examining
only tutored patients, more patients over 50 years of age had poor
techniques (24 out of 74, 32%) than those 50 years and under (6 out
of 67, 9%) (XZ11.6 DPI p<0.001).
The differences in levels of tuition and inhaler techniques
between the practice centres are illustrated in table 44, between 63%
and 85% of patients had been taught inhaler technique, and the
practice with the lowest incidence of inhaler tuition had the lowest
incidence of good inhaler technique.
Problems with the use of aerosol inhalers-
Table 45 outlines the main problems in the use of aerosol
inhalers in patients in groups A and B. Failure to co-ordinate
activation and inhalation was the most common problem (occurring in
nearly a third of users).
Alternative inhaler devices-
In groups A and B 13 patients used alternative inhaler
devices other than aerosols, including one using a tube spacer
inhaler, one a small hand nebuliser, and 11 the dry powder
"Rotahaler", 9 of the latter had previously used aerosol inhalers and
7 of these preferred the "Rotahaler" to the aerosol inhaler.
d) ORAL BRONCMXJELATORS.
The number of patients using the various types of oral
bronchodilators are analysed in table 46. A separate analysis of the
over 50 years age group is included in table 47. Both methylxanthines
and oral adrenergic drugs were prescribed more frequently in the
chronic bronchitics in all age groups. Methylxanthines were usually
prescribed in combination with other bronchodilators, in contrast to
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Aerosol inhaler technique and the number receiving
















55(63%) 19(76%) 29(81%) 47(85%)
X2 9.5 DF3 p<0.05
Number(%) with good
inhaler technique
55(63%) 22(88%) 23(64%) 47(85%)
X3, 12.1 DF3 p<0.05
Table 44.
Problems associated with the use of aerosol inhalers.
Number of patients using aerosol inhalers 205
(prophylactic or bronchodilator)
in groups A and B
Number (%) of patients failing to:
Shake the cannister 28(14%)
Hold the cannister upright 6(3%)
Coordinate activation and inhalation 56(27%)
Hold breath after activation 45(22%)
Table 45.
The number(%) of patients in groups H, A, and B



















: X2 1.7 DF1 NS




























* Xz 29.2 DF1 p<0.001
** X2 6.1 DF1 p<0.05
*** X2 8.8 DF1 p<0.05
**** Xz 1.0 DF1 NS
The single number in brackets being the number of
patients using this drug as their sole bronchodilator.
Table 46.
The use of oral bronchodilators in groups A and B
in patients over 50 years old.
Groups


















*X2 1.3 DF1 NS
**X2 8.8 DF1 p<0.01
0.1 DF1 NS
Table 47,
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the oral adrenergics which were prescribed more often as the sole
bronchodi lator. In group H methylxanthines were the only commonly
used oral bronchodilator therapy (in a quarter of patients) and these
were invariably prescribed in combination with inhaled
bronchodi lators. Group H may not have been typical of drug therapy in
hospital clinics, however, as there was little difference in
prescribed oral bronchodilator therapy between groups A-OPD and A-GP
(see table 48).
As well as there being a significant difference in the number
of patients using oral bronchodilator therapy between the practice
centres, there were also differences in the use of individual drugs.
An analysis of oral bronchodi lator usage in asthmatics between the
practice centres is included in table 49. In one practice more
patients used mixed oral drugs (containing ephedrine and a
methyIxanthine, with or without a barbiturate) than methylxanthines
alone: in another a third of patients using oral therapy used
methylxanthines but none used mixed oral drugs.
The use of methylxanthines-
All 12 patients in group H, and 58 out of 60 in groups A and
B using methylxanthines took a slew release preparation. All patients
in group H took regular therapy in contrast to patients in groups A
and B in which 10 (17%) used therapy entirely on demand and a further
7 (12%) who were otherwise regular users took extra doses on demand
(all these patients used the slow release preparation). More patients
using methylxanthines as their only bronchodilator took therapy on
demand (10 out of 17, 58%) than those using methylxanthine combined
with another bronchodilator (7 out of 43, 16%) (X2 10.8 DF1 p<0.001).
Of 22 asthmatics in group A using adrenergic drugs in combination
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The variation in the use of oral bronchodi lator therapy















8(11%) 9(36%) 7(27%) 4(8%)
16(22%) 3(12%) 7(27%) 2(4%)
10(14%) 0(0%) 2(8%) 3(6%)
Table 49.
The number(%) of patients in groups A and B experiencing










*X2 4.2 DF1 p<0.05






with methylxanthines, 11 did not use associated prophylactic therapy
(sodium cromoglycate or inhaled or oral corticosteroids). 7 of these
had scores of 2 or 3 for day or night time wheeze.
The dosages of methylxanthines (in mg of theophylline daily
or equivalent) prescibed to patients in groups A and B are
illustrated in figure 14. In groups A and B only 17% of patients
using raethylxanthines were prescribed more than 400mg daily (of
theophylline or equivalent), whereas this applied to 7 out of 12
patients in group H using this drug.
Oral short acting adrenergic drugs-
No patient in group H used these drugs. In groups A and B
they were combined with adrenergic stimulant inhalers in 1 7 patients
(7% of those using a bronchodilator). Significantly more patients
using oral short acting adrenergic drugs took regular therapy (46 out
of 63, 73%) than those using adrenergic inhalers (44 out of 195, 23%)
(X2 53.4 DF1 p<0.001). In a separate analysis of chronic bronchitics
28 out of 35 (80%) patients using oral short acting adrenergic drugs
took regular therapy, in contrast to 27 out of 54 (50%) using
adrenergic inhalers (X2- 8.1 DF1 p<0.01).
The use of slew release oral agents for relief of nocturnal symptoms-
Only 9 out of 39 (23%) patients with grade 3 scores for
nocturnal symptoms were prescribed a slew release methylxanthine or
adrenergic drug for relief of such symptoms.
e) SIDE EFFECTS OF BRONCBODILATQR THERAPY.
A comparison of the incidence of side effects between inhaled
and oral bronchodilator therapy is included in table 50. Oral therapy
was associated with approximately twice the incidence of side effects
than that occurring with inhaled therapy. The most common adverse
94
THE DOSAGE OF 60 PATIENTS IN GROUPS
A AND B USING ORAL METHYLXANTHINES
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Patients in groups A and B were also asked what forms of
bronchodilator therapy they had had in the past and why such therapy
had been discontinued. Twice as many patients had received oral
rather than inhaled bronchodilators in the past, and very few
patients had tried the dry powder "Rotahaler". Again side effects had
been twice as common with oral rather than inhaled therapy. Although
few patients admitted to difficulty in the use of aerosol inhalers,
nearly a half stopped this form of therapy because of a lack of
benefit, suggesting that many may have been using the devices
incorrectly. These findings are summarised in table 51.
f) PATIENT PREFERENCE.
Patients were asked which form of bronchodilator delivery
they preferred. 27(13%) asthmatics and 23(20%) chronic bronchitics
preferred oral therapy, 104(52%) asthmatics and 36(32%) chronic
bronchitics preferred inhaled therapy and 70(35%) asthmatics and
54(48%) chronic bronchitics were unable to judge between the two
methods of delivery or had no preference. Of the 81 patients using
oral therapy alone 66(81%) had never had inhaled therapy in the past.
g) OTHER FORMS OF THERAPY FOR OBSTRUCTIVE AIRWAYS DISEASE.
14(7%) asthmatics and 14(12%) chronic bronchitics used cough
suppressants, expectorants, or antihistamines regularly. 30(15%)
asthmatics and 38(34%) chronic bronchitics had taken one of these
drugs within the previous six months.
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The number(%) of patients having received bronchodilator








Cause unknown 16(35%) - 49(48%)
Difficulty in use 7(15%) 3(50%) -
Lack of benefit 19(42%) 2(33%) 37(36%)
Side effects 3(7%) 1(16%) 18(18%)
"Eable 51.
f) DISCUSSION
It has been stated that in the care of asthmatics a regular
continuity of follow up is essential until self management is
satisfactory (Gregg 1983b). Although it is recognised that this study
was biased in the selection of those who frequently attended their
general practitioners, it was reassuring to see that approximately
two thirds of the patients had been seen at least twice in the
previous six months by their general practitioner. It might be
expected that patients who attended hospital clinics would visit
their general practitioner less frequently but this was not the case,
and the fact that only a quarter of the patients had attended a
hospital clinic in the previous twelve months emphasises the
4
important role of the general practitioner. There are many arguments
in favour of maintaining this dominant role (Editorial 1981b),
including continuity of care and a more personal approach to
management. However, this places the challenge of prescribing
suitable and efficient drug therapy firmly with the general
practitioner.
Branched!lators are considered the cornerstone of therapy for
obstructive airways disease (Hetzel and Clark 1983) and it was a
surprise to find that nearly 1 in 10 of patients in groups A and B
used sodium cromoglycate or corticosteroid alone. Over a half of
these patients used therapy on demand, suggesting the need for
bronchodilators.
The benefits of inhaled rather than oral bronchodilator
drugs, including rapidity of action and lack of side effects (Walker
et al 1972), are such that a recent editorial (Editorial 1981a) has
stated:
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"Nowadays, recourse to oral bronchodilator drugs should seldom be
necessary."
In this study about 8 out of 10 asthmatics used inhaled
bronchodilators, which is a similar proportion to that found in a
recent asthma clinic audit (Connolly 1983) and a study of patients
dying from asthma (British Thoracic Association 1982). However, oral
bronchodi lators were also commonly used, especially in the chronic
bronchitics. This study has demonstrated that those patients
attending a hospital or chest clinic were more likely to use inhaled
drugs than those attending their general practitioner alone. The fact
that the majority of patients taking oral drugs alone had never been
prescribed inhalers and that the majority who were able to choose
preferred inhalers, suggests that it is the doctor rather than the
patient who is responsible for this prescribing trend.
Patients with chronic bronchitis and chronic asthma often
require regular bronchodi lator therapy and yet only a half of the
former with adrenergic inhalers used these regularly. In contrast 80%
of those using oral short acting adrenergic drugs used this therapy
regularly. This suggests that the doctor or patient associate oral
therapy with regular use but inhaled drugs with symptomatic
treatment. There is no obvious rationale for this pattern of
prescribing as inhaled adrenergic drugs have similar bronchodilator
capacities ard lengths of action as their oral counterparts (Walker
et al 1972) and the use of regular rather than demand inhaler therapy
may improve the control of asthma (Shepherd et al 1981). Patients
attending hospital clinics were more likely to take regular inhaled
treatment than those attending their general practitioner alone,
despite the similarity of PEFR and symptom scores between the two
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groups.
Aerosol bronchodilators may be liable to abuse (Pratt 1982).
Although this problem may have been underestimated by such patients
defaulting from interview, little evidence of this problem was found.
It is likely that the use of greater than average doses of inhaled
hronchodilators was associated with uncontrolled asthma requiring
prophylactic therapy rather than with drug abuse. Underuse of inhaled
bronchodi lators was more common than overuse, in keeping with a
recent study of asthma fatalities (British Thoracic Association
1982). Contrary to previous opinion (Crompton 1983), poor inhaler
technique was associated with inhaler underuse rather than overuse.
Despite the efficacy of inhaled adrenergic drugs in protecting
against exercise induced wheeze (Andersen et al 1976), such therapy
was often underused both by the general practitioner and in hospital
clinics.
The proportion of patients in general practice receiving
tuition was impressively high - in two practices over 80%. The
proportion with poor techniques was only slightly worse than that
found in a previous hospital study (Paterson and Crcmpton 1976).
However, poor inhaler technique remains a major cause of therapeutic
inefficiency. Although improved by tuition this study suggests that
older patients are less capable than the younger in this respect. In
keeping with previous work (Epstein et al 1979) regular users (those
using prophylactic inhalers) were more efficient than those using
bronchodilator inhalers. More patients using aerosol and oral
bronchodilators in combination had poor inhaler techniques than those
using aerosols alone, suggesting that the oral therapy may have been
added because of a poor response to the aerosol. Perhaps such
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combinations could have been avoided by tuition on inhaler technique.
Hie excellent figures of group H, in which all patients used their
aerosol inhalers correctly, may not have been representative of
hospital outpatient care as this particular clinic had a rigorous
policy of inhaler tuition; indeed there was little difference between
groups A-GP and A-OPD in respect of the incidence of poor inhaler
technique. Incoordination between activation of the aerosol and
inhalation is the main problem associated with aerosol inhaler use.
Because of this other inhaler devices such as the dry powder
"Rotahaler" and tube spacer have been designed (Anonymous 1981); such
systems were underused in this study.
There were considerable differences in the prescription of
oral bronchodilators between the practices, though in general oral
short acting adrenergic drugs were as popular as the methylxanthines.
There has been concern in New Zealand about the current trend to use
methylxanthines rather than inhaled corticosteroids or sodium
cromoglycate when adrenergic drugs have failed to control asthma in
adults (Wilson et al 1981 ). Though the numbers are too small to
assess prescription trends, half the asthmatics (group A) in this
study using adrenergic drugs and methylxanthines did not use inhaled
corticosteroids or sodium crcmoglycate and most of these were poorly
controlled. The same workers were concerned as to the dangers of
using slew release methyIxanthines on demand; nearly a third of
patients in groups A and B using these drugs took doses on demand,
often because a more suitable bronchodilator had not been prescribed.
In the low doses prescribed it is unlikely that many of the
patients achieved maximal bronchodilatation from the methylxanthine.
Some may have benefitted from higher doses, although lew dose regimes
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have the advantage of a lew incidence of side effects (Weinberger and
Hendeles 1983). The role of the methylxanthines in the control of
adult asthma remains controversial (Hetzel and Clark 1983). The
general practitioners did not measure plasma levels of theophylline
and in these circumstances efficient use of these drugs may be
difficult. However, there is some evidence that low dose theophylline
can be useful in combination with adrenergic drugs (Wolfe et al
1978). Both the slow release methylxanthines and adrenergic drugs
have been shown to be of value in protecting against nocturnal wheeze
(MiHedge and Morris 1979) and in this circumstance were
underprescribed.
Despite a lack of objective evidence as to their value
(Paterson and Shenfield 1974), mixed oral drugs (containing ephedrine
and theophylline with or without a barbiturate) continue to be used
(though there was a considerable variation in the use of these drugs
between the practice centres). The popularity of mixed oral drugs,
despite their relative lack of potency, has been described
previously.
Cough suppressants, expectorants and antihistamines are of
little value in obstructive airways disease or chronic expectoration.
Although such agents were conmonly used by patients in this study
many are available without prescription and, therefore, their use




a) The prescription of prophylactic drugs
b) The use of prophylactic inhalers
c) The use of systemic (oral) corticosteroids
d) Discussion
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This chapter investigates the use of prophylactic drugs-
inhaled and systemic corticosteroids, and sodium cromoglycate.
a) THE PRESCRIPTION OF PROPHYLACTIC DRUGS
Patients were split into 3 grades depending on their PEFRs at
interview. The number of patients in each grade and the proportion
using prophylactic drugs are illustrated in table 52. There was no
significant difference in the proportion of patients using a
prophylactic drug between the 3 PEER grades. Approximately one sixth
of the asthmatics (group A) had scores of 2 or 3 for day or night
time symptoms but did not use a prophylactic drug; nearly a half of
these had PEFRs below 50% of the predicted value. Nearly all patients
in group H (43 out of 48, 90%) were prescribed a prophylactic drug.
An analysis of the prophylactic drugs used by patients in
groups A and B is shown in table 53. As expected more asthmatics than
chronic bronchitics used this form of therapy. Those asthmatics
attending a hospital clinic (A-OPD and H) were more likely to use
inhaled or oral corticosteroids than those attending their general
practitioner alone (A-GP), the reverse was true of sodium
cromoglycate (see table 54). Very few patients in either group used
ketotifen. In groups A and B sodium cromoglycate was more likely to
have been prescribed initially by the patient's general practitioner
(in 37 out of 53 cases, 70%) than inhaled corticosteroid, which was
more frequently commenced by a hospital doctor (in 53 out of 98
cases, 55%)(X1 7.9 DF1 p<0.01). Of 33 patients using oral
corticosteroids, in 24(73%) this was initially conmenoed by a
hospital doctor. The mean ages of patients taking sodium
cromoglycate, inhaled corticosteroids and oral corticosteroids were
36.5 years, 53.5 years, and 58.2 years respectively. More patients
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The number(%) of asthmatics (group A) and chronic
bronchitics (group B) using prophylactic drugs
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GROUP B n=21 n=21 n=70 n=112*
"Jumber(%) using 2(10%) 6(29%) 15(21%) 23(21%)
prophylaxis
* One asthmatic and one chronic bronchitic unable to provide PEFR
recordings.
Table 52.
Hie number(%) of patients using the different types
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* X1 3.05 DF2 NS
** X234.9 DF2 p<0.001
Table 54.
using sodium cramoglycate had high PEFRs (>70% predicted) than those
using inhaled corticosteroids (see figure 15), though the range of
symptom scores was similar between patients using these two drugs
(see figure 16). As expected more patients using oral corticosteroids
had severe disease with higher symptom scores and lower PEFRs.
There were considerable differences in the use of these drugs
in the asthmatics between the practice centres (see table 55). The
practice with the greatest proportion using sodium crcmoglycate
(centre 3) had the fewest using inhaled corticosteroid, and the
reverse trend was seen in practice centre 4. These differences in
prescribing could not be explained by variation in the severity of
disease in the patients between the practices (as seen by the
proportion of patients with PEFRs below 50% predicted).
In groups A and B 27 patients used combinations of sodium
cromoglycate, inhaled and oral corticosteroids, including 19 taking
the latter two drugs, and 8 taking the former two drugs. In group H
only the combination of inhaled and oral corticosteroids was used
(by 18 of 48 patients). Of 98 patients who used inhaled
corticosteroids 12(12%) used the dry powder form of delivery. 53
patients used sodium cromoglycate, of whom 31 (58%) used the compound
of sodium cromoglycate and isoprenaline, 18(34%) the plain
formulation, and 4(8%) the aerosol preparation.
b) THE USE AND PRESCRIPTION OF PROPHYLACTIC INHALERS
56(39%) of those patients using prophylactic inhalers were
poorly compliant (poor compliance was defined as the omission of at
least one treatment daily from the prescribed dose). The dose most
likely to be omitted was the lunch time treatment of a TID or QID
regime.
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19(23%) 8(27%) 13(39%) 10(18%)
29(34%) 11(36%) 7(21%) 32(59%)
16(19%) 3(10%) 7(21%) 3(6%)
X4* 17.2 DF6 p<0.01
Number(%) with a PEFR
<50% predicted
14(17%) 14(47%) 9(27%) 11(20%)
Table 55.
Of these 56 poor conpliers, 16 (11% of prophylactic inhaler
users) took treatment entirely on demand, 10 took seme regular
treatment but also extra doses on demand, the remaining 30 took only
regular treatment but omitted doses. A further 27 patients took
regular therapy at full dosage but took extra doses on demand
depending on symptoms. Moore patients using sodium cromoglycate
compound took treatment on demand (either totally or partially) (19
out of 31, 61%) than those using sodium crcmoglycate plain (8 out of
22, 36%)or inhaled corticosteroid (26 out of 98, 27%)(X2* 12.3 DF2
p<0.01).
Inhaler technique was classed as efficient, doubtfully
efficient and inefficient (Paterson and Crompton 1976). 12(13%)
patients were found to be doubtfully efficient and 7(8%) inefficient.
A summary of the incidence of poor compliance, demand usage
and poor inhaler technique and the proportion of these patients who
had scores of 2 or 3 for day or night time symptoms is included in
figure 17. In group H there were significantly fewer poor compilers
(9 out of 42, 21%) than in groups A and B (56 out of 142, 39%) (X2
4.6 DF1 p<0.05); very few (2 out of 42, 5%) used their prophylactic
inhalers entirely on demand. However, recent hospital attenders in
groups A and B (A-OPD and B-OPD) were similar in their incidence of
poor compliance (13 out of 39, 33%) as those who attended their
general practitioners alone (groups A-GP and B-GP) (43 out of 103,
42%) (X2 0.8 DF1 NS).
Patient knowledge of prophylaxis-
All patients using a prophylactic drug were asked if this
protected then against wheeze (or shortness of breath), or treated
these symptoms once they were present. 84 out of 142 (59%) chose the
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first correct response. The proportion of patients who realised the
protective nature of the drugs varied insignificantly between the
practices as did the number of poor compliers (see table 56).
Patients who used their inhalers regularly but always took less than
the prescribed dose had a good level of knowledge (24 out of 30, 80%
gave correct responses). These patients differed from those who used
their inhalers on demand (either totally or partially) in whcm there
was a poor level of knowledge (20 out of 53, 38% gave correct
responses) (X^ 13.7 DF1, p<0.001).
Although more compliant, patients in group H had a similar
level of knowledge as those in groups A and B with 26 out of 42 (62%)
realising the prophylactic nature of the drugs.
Problems with the prescription of prophylactic inhalers-
In groups A and B 17 compliant patients (12% of inhaler
users) were prescribed below standard doses (< 400 meg of
beclomethasone diproprionate or <4 capsules of sodium cromoglycate
daily) and 28(20%) standard doses, despite both groups having scores
of 2 or 3 for day or night time symptoms, suggesting that additional
therapy may have been beneficial. The prescribed doses of inhaled
prophylaxis are illustrated in figure 18. The highest prescribed dose
of inhaled corticosteroid in groups A and B was 12 puffs (600mcg
beclomethasone diproprionate) daily. In group H only 1 out of 42
patients was prescribed less than standard dosage and 17 out of 40
using inhaled corticosteroid were prescribed at least 800 meg daily
of beclcmethasone diproprionate.
Combining the problems of prophylactic inhaler use and
underprescribing 74 out of 142 (52%) of patients in groups A and B
either had a poor inhaler technique, omitted at least one treatment
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The number(%) of patients in groups A and B using prophylactic
inhalers who understood the protective nature of the drug
and the number(%) who were non-compliant









1 2 3 4 Total
n=53 n=24 n=21 n=44 n=142
31(58%) 10(42%) 11(52%) 32(73%) 84(59%)
X2 6.8 DF3 NS
19(36%) 6(25%) 11(52%) 20(45%) 56(39%)
X 4.5 DF3 NS
Tbble 56.
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daily from the prescribed regime, or were fully compliant but were
prescribed a below standard dose despite a score of 2 or 3 for day or
night time symptoms. Fewer patients in group H took inefficient therapy
(9 out of 42, 21%) than those in groups A and B (74 out of 142, 52%) (X*
12.3 DF1 p<0.001). However when comparing groups A-OPD arid B-OPD with
those in A-GP and B-GP a similar proportion were found to take
inefficient therapy (22 out of 39, 56% and 52 out of 103, 50%
respectively). Of the 74 patients in groups A and B using inefficient
therapy 43(58%) had scores of 2 or 3 for day or night time symptoms.
Side effects of prophylactic inhalers-
The incidence of sore throat, hoarseness, and previous
treatment for oral thrush in patients using inhaled corticosteroids is
analysed in table 57. More patients in group H using this drug reported
side effects than those in groups A and B, with a fifth of patients in
group H having had previous treatment for oral thrush.
25 of the 49 patients (51%) using the spinhaler for sodium
cromoglycate complained of coughing after inhalation. A similar
proportion using the plain preparation complained of coughing (9 out
of 18, 50%) as those using the compound with added isoprenaline (15 out
of 31, 48%).
c) THE USE OF SYSTEMIC (ORAL) CCRTICDSTEROIDS
The number of patients who were taking, or who had previously
taken systemic corticosteroids for their chest complaint in groups A,
B, and H are shown in table 58. In all but one patient (who used
A.C.T.H. and therefore indirect therapy) this was oral treatment. Over
a half of the patients in group A either took or had taken systemic
corticosteroids in the past, whereas this applied to less than a fifth
of patients in group B. Nearly all the asthmatics in group H were
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X1 11.6 DF1 p<0.001
10(10%) 9(22%)
X* 3.6 DF1 NS
1(1%) 3(20%)
XZ 16.8 DF1 p<0.001
Table 57.
The number(%) of patients who were taking or had previously
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taking or had taken systemic corticosteroids in the past. The dosages
and lengths of time on treatment of the 33 patients in groups A and B,
and 19 in group H who were currently taking this drug are analysed in
table 59. The majority used less than 10mg of prednisolone or
equivalent daily and most patients in groups A and B had been taking
the drug for at least 5 years.
The medical surveillance of patients using regular systemic
corticosteroid in groups A and B-
Hie attendances of 33 patients using regular systemic
corticosteroids in groups A and B are illustrated in table 60. The
majority (73%) had attended a hospital outpatient clinic within the
previous 12 months and only one patient had had no recent medical
surveillance either in a hospital clinic or by the general
practitioner.
Hie use of inhaled corticosteroid with the oral drug-
14 of 33(42%) patients in groups A and B did not use inhaled
corticosteroid with the oral drug, and 10(30%) had never had inhaled
corticosteroid at any time. Patients attending their general
practitioner alone (A-GP and B-GP) were more likely to use oral
corticosteroid without inhaled corticosteroid (6 out of 9, 66%) than
those who also attended a hospital clinic (A-OPD ard B-OPD) (8 out of
24,33%). 2 out of the former group used prednisolone as their only
therapy for airways obstruction, with no available bronchodilator. In
group H only 1 out of 1 9 patients using oral corticosteroid did not
also use the inhaled form.
Hie use of "booster" doses by patients on regular systemic
corticosteroids-
23(70%) patients in groups A and B and 12(63%) in group H had
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The frequency of attendance by 33 patients in
groups A and B using oral corticosteroids in










No. of attendances at the
general practice surgery
in the previous 6 months
Never Once 2-5 >5 Total
1 2 3 3 9
0 1 12 5 18
0 1 4 0 5
0 0 1 0 1
1 4 20 8 33
Table 60.
used raised "booster" courses for troublesome symptoms. The majority
usually did so without a doctor's supervision and the increases taken
were usually small (<20mg of prednisolone daily or equivalent) and
were usually for periods of less than one week. A summary of
"booster" dosage is included in table 61.
Side effects of systemic corticosteroids-
Of 52 patients in groups A, B, and H taking regular systemic
corticosteroids 29(56%) had noticed weight gain, 23(44%) facial
changes, 15(29%) indigestion, 4(8%) had symptoms associated with
documented osteoporosis, 4(8%) complained of bruising easily and 1
was a diabetic. A further 24 patients in groups A and B and 2 in H
had had a prolonged course of oral corticosteroids (>6 weeks) in the
past. The incidence of side effects in these patients was similar.
Hie use of short courses of systemic corticosteroids-
Of patients not taking regular systemic corticosteroids,
67(33%) in group A, 14(12%) in group B, and 23(48%) in group H had
had a previous short course of the drug. The details of dosage,
frequency, and outcome of these courses and whether they were usually
prescribed by their own general practitioner or a hospital doctor is
included in table 62. More patients in group H were normally
prescribed these courses by a hospital doctor than those in groups A
and B. Threequarters of the patients were prescribed a cumulative
dose of at least 100mg of prednisolone (or equivalent) and
approximately a half received the drug for at least a week; in only a
seventh of patients did the symptoms relapse after the course.
Although patients in groups A, B, and H appeared to have been
prescribed similar courses, when the patients were split into two
groups- firstly those in whom the courses were normally prescribed by
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The prescription of short courses of systemic corticosteroids-
the dosage, length of course, and frequency of courses
prescribed to 81 patients in groups A and B, and 23 in group H.
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Table 62
the general practitioner, and secondly those in whom the courses were
normally prescribed by a hospital doctor, more of the latter were
prescribed a cumulative dose of at least 100mg of prednisolone (35
out of 36, 97%) than the former (42 out of 61,69%) (Xa 11.1 DF1
p<0.01 )(in 7 patients the dosage was unknown).
d) DISCUSSION
Although two thirds of the asthmatics seen in general
practice were using prophylactic agents, it is likely that nearly
half the remainder would have benefitted from this group of drugs, as
many had frequent symptoms and low PEFRs. It was interesting to see
that the use of prophylactic drugs appeared to be independent of the
PEER grade at interview. This could be due to the poor correlation
between respiratory function and symptoms in asthma (Rubinfield and
Pain 1976) or the fluctuation of airways obstruction in this
condition. In the younger asthmatic the identification and treatment
of persistent airways obstruction may be important if permanent
disability is to be avoided (McNicol and Williams 1976).
The type of prophylactic drugs used in those patients who
attended their general practitioners alone and those who also
attended a hospital clinic differed markedly. Seme specialist clinics
have a policy of never discharging patients using long term oral
corticosteroids, and this may explain the high proportion of patients
in groups A-OPD and H using these drugs. Patients using sodium
cromoglycate were younger and tended to have higher PEFRs than those
using inhaled corticosteroids. This suggests that those asthmatics
using the former had less severe disease, though it is noticeable
that their symptom scores were similar to those using inhaled
corticosteroid. There was a trend for the general practitioner rather
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than a hospital specialist to prescribe sodium cromoglycate, with the
reverse trend being applicable to inhaled corticosteroid. It was
noticeable, however, that there were marked differences in the use
of these two agents between the practices.
Although up to 70% of adult asthmatics may respond to sodium
cromoglycate (Northern General Hospital Brompton Hospital and MRC
collaberative trial 1976), relapse after a period of good control is
not uncommon (Godfrey 1975). In general inhaled corticosteroid is a
more potent suppressing drug in adult asthma, and it is likely that
many of the patients who were symptomatic on sodium cromoglycate
would have achieved better control using inhaled corticosteroid.
Sodium crcmoglycate has little steroid sparing effect (Toogood et al
1981) and it is unlikely that the 8 patients in group A using the
combination of corticosteroid and sodium cromoglycate were deriving
benefit from the latter. Despite the observed popularity of sodium
crcmoglycate compound rather than the plain preparation there is
little evidence to support its value (Brompton Hospital MRC
collaborative trial 1972) and the frequent use of this drug on demand
supports the theory that the immediate relief obtained from the
isoprenaline in the compound may lead the patient to be confused as
to the role of the drug (Gregg 1982).
Poor compliance was the major problem with the use of
prophylactic inhalers and its incidence of 39% was similar to that
found in a recent hospital outpatient study (James et al 1982). Two
types of poor compliance were identified: firstly those patients who
took regular treatment but always at below the prescribed dose, and
secondly those patients who used the drug on demand; of course in
some patients these two errors co-existed. The first type of poor
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compliance, unlike the second, was not related to a poor level of
knowledge of the prophylactic function of the drug. The practical
implications of this is that while patients may be taught not to use
therapy on demand, many would continue to regularly emit doses. These
findings are substantiated by a study of antihypertensive therapy in
which a careful education progrartme failed to improve the level of
poor compliance (Sackett et al 1975). It may be considered that many
patients were poor compilers because, as in hypertension, they felt
well. However, nearly a half of this group had troublesome symptoms.
There is now evidence that twice daily dose regimes using higher
individual doses axe as efficacious as the four times daily regime
for inhaled corticosteroid (Munch et al 1982). Though the effect of
twice daily dose regimes on compliance requires further study, there
seems little doubt that such regimes would be more convenient.
Patients attending hospital clinics were more compliant than those
attending their general practitioners alone, but this was not
associated with an increased knowledge of the function of the drugs.
This improved compliance may have been associated with the stimulus
of a more severe underlying disease, though it has been noted
previously that symptoms need not stimulate good compliance.
Although the majority of patients can be controlled on
standard doses of inhaled prophylactic drugs same may benefit from
larger doses of sodium cromoglycate (Bernstein 1981) and inhaled
corticosteroid (Toogood et al 1977). Certainly it is difficult to
defend the prescription of below standard doses in symptomatic
patients. In contrast to groups A and B nearly all patients attending
hospital clinics (group H) were prescribed at least standard dosage
(400mcg beclcmethasone diproprionate or equivalent).
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When combining the problems of prophylactic inhaler use over
half the patients in groups A and B took inefficient therapy.
Although the corresponding figure in group H was less, this group may
not have been representative of the impact of hospital clinics on the
care of patients with airways obstruction, as groups A-OPD and B-OPD
were similar in terms of the incidence of inefficient therapy to
groups A-GP and B-GP.
The incidence of oral thrush in patients using inhaled
corticosteroids has been variably reported between 4.5% when based on
a single examination (Willey et al 1976), to 77% for cumulative
incidence (Brampton Hospital MRC oollaberative trial 1974). Obviously
the difference in these figures may be in part due to the different
criteria used for diagnosing oral thrush. However, there seems little
doubt that the incidence of oral thrush is dose related (Milne and
Crompton 1974) and this may explain the higher incidence of oral
thrush in group H in when higher doses of inhaled corticosteroids
were prescribed. Although hoarseness and sore throat are the usual
symptoms of oral thrush, the former may occur without thrush (Willey
et al 1976) and may be associated with the local effects of
corticosteroid on the musculature on the larynx.
It is well known that the dry powder of sodium cromoglycate
in the spinhaler may cause throat irritation, cough and occasionally
wheeze. Because of the latter complaint a compound of isoprenaline
with cromoglycate was developed. Though a half of the patients in
this study had noted coughing with the spinhaler there was no
difference in the incidence between those patients using cromoglycate
plain and those using the compound.
Nearly a third of patients using oral corticosteroids in
112
groups A and B were supervised by their general practitioners alone,
although in the majority of cases it had been commenced initially by
a hospital doctor. The level of medical surveillance of this group
was impressive with only one patient having had no recent general
practitioner or hospital clinic attendance.
The use of inhaled rather than oral corticosteroids where
feasible is now established practice and 400mcg of beclcmethasone
diproprionate and 7.5mg of prednisolone are roughly equivalent
(British Thoracic and Tuberculosis Association 1975). It was a
surprise, therefore, to find that 42% of patients using oral
corticosteroids were not also using the inhaled form. Though this may
have been the policy of the local specialist clinic, it is noticeable
that the use of oral corticosteroids without the inhaled drug
occurred more frequently in those patients attending their general
practitioner alone. In groups A and B it is likely that substantial
reductions in the use of oral corticosteroids could have been made by
an increased use of the inhaled drug. This is important because of
the high incidence of side effects which can be associated with the
long term use of these drugs. Despite the moderate dosages used by
patients in this study, at least a half had noticed weight gain and
facial changes and nearly a tenth had symptoms of underlying
osteoporosis. The side effects are dose related, and therefore
attempts to keep doses to a minimum are wise.
In order to maximise control, patients using oral
corticosteroids should be well educated, and discretion should be
entrusted to then as to dose changes. The majority of patients in
this study took booster doses without medical supervision,
illustrating a large degree of self management. Though the dose
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increases were usually only modest in most cases they were successful
in alleviating symptoms and as such are difficult to criticise.
Short courses of oral corticosteroids are prescribed for two
main reasons, firstly to treat exacerbations of symptoms and secondly
as a trial to elucidate whether a patient with chronic airways
obstruction is "corticosteroid responsive". The majority of chronic
bronchitics seen in this survey had severe symptoms, and yet only 1
in 10 had had a previous course of oral corticosteroids. Such "trial"
treatment could be considered to have been underused in this group of
patients. As previously discussed sane of the patients had medical
conditions which may have made the general practitioner reluctant to
prescribe the drug, however, the possible benefits often outweigh the
risks involved. This study has demonstrated a group of patients with
typical symptoms of chronic bronchitis with a good response to oral
corticosteroids, whose control may have beeen greatly improved by the
use of regular inhaled corticosteroids. There has been concern that
general practitioners do not prescribe large enough doses of
corticosteroids in short courses. Evidence from this study, however,
suggests that this is uncommon, with the majority (69%) being
prescribed a cumulative dose of at least 100mg of prednisolone.
Nevertheless patients receiving courses from a hospital clinic were








The first part of this study was concerned with the diagnosis
of patients with airways obstruction. General practitioners have been
criticised in the past for misdiagnosing patients with asthma,
labelling then instead as having chronic bronchitis or emphysema
(Seaten 1978). There is an impression that the airways obstruction in
chronic bronchitis is often considered to be irreversible, and
therefore, is undertreated. Usually only the symptomatic history is
used in making a diagnosis, however, it is unclear how reliable the
symptomatic history is in identifying patients with variable (or
reversible) airways obstruction. Gregg has demonstrated hew simple
reversibility studies may be undertaken in general practice using
peak flow meters to identify patients with reversible airways
obstruction (Gregg 1964). Such studies may be of great value in the
diagnosis and assessment of patients with obstructive airways disease
but in practice are frequently omitted. The value of undertaking
reversibility studies using bronchodilators and corticosteroids was
examined.
In general practice two main diagnoses were used- asthma and
chrome bronchitis. In the absence of any quantifiable abnormality,
such as in diabetes mellitus or thyrotoxicosis, it was impossible to
either prove or disprove a diagnosis of asthma. It was not the aim of
the study, therefore, to criticise the general practitioners'
diagnoses, but to examine the validity of the separation of patients
into these two diagnostic categories. Because of the selection
methods used in the study, patients with "simple" chronic bronchitis
(chronic cough and expectoration only) were not included, and only
those with symptomatic airways obstruction were seen. Such cases were
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more likely to have been mistaken for the asthmatic patient.
Two aspects of the patient's condition were examined: firstly
the symptomatic history, and secondly, the reversibility of the
patient's airways obstruction to drug therapy. The relationship
between these two features was assessed. Finally, the drug therapy of
those patients with demonstrable airways reversibility was examined.
After consideration of the results of this part of the study some
simple guidelines for general practitioners dealing with patients
with obstructive airways disease are suggested.
The following conclusions were made: -
1) The symptoms that were most valuable in separating patients
diagnosed as having asthma from those having chronic bronchitis were,
in order:- a) an absence of chronic cough and expectoration, b) a
history of hayfever, c) a history of exercise induced wheeze, d) a
history of episodic symptoms, e) an early onset of symptoms, f) an
absence of cigarette smoking.
General practitioners should enquire into the presence of
these symptoms when considering the diagnosis of asthma.
2) Patients could be separated into the two groups, asthma and
chronic bronchitis, using the symptomatic history. However, there was
considerable overlap between the groups, such that in clinical
practice approximately a third of the patients would be difficult to
diagnose accurately using the symptomatic history. The cause of this
overlapping of symptoms in asthma and chronic bronchitis has been
discussed earlier in the thesis. Simply it may be due to the fact
that in some patients asthma (variable airways obstruction) and
chronic bronchitis (chronic expectoration due to atmospheric
pollution or smoking) co-exist.
117
The general practitioner should be aware that for scrae
patients the symptomatic history is not a reliable basis for
diagnosis.
3) There was little difference in the degree of bronchodilator
reversibility between those patients diagnosed by their general
practitioners as having asthma and those having chronic bronchitis.
Only very large responses were specific for a symptomatic diagnosis
of asthma. An analysis of the symptomatic history in patients with
good and poor bronchodi lator reversibility emphasised the poor
correlation between the two.
Corticosteroid reversibility is often considered to be
synonymous with asthma. In this study there were no characteristic
symptoms with which one could predict good corticosteroid
reversibility and sane patients with symptoms typical of asthma had a
poor response to oral corticosteroids whereas sane with symptoms
typical of chronic bronchitis had a good response. In conclusion
there are ranges of reversibility to bronchodilators and
corticosteroids in patients with asthma and chronic bronchitis and
these correlate poorly with their symptoms.
The general practitioner should realize that it is impossible
to reliably predict a patient's response to bronchodilators or
corticosteroids using the symptomatic history.
4) About a third of patients who were given a trial of high dose oral
corticosteroids responded well to this form of therapy and nearly all
these patients had moderate or severe symptoms. Less than a quarter
of the responsive patients used inhaled corticosteroids and almost
all who did take this drug used belcw standard doses. All the
responsive patients could be considered to have been undertreated.
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The study has demonstrated, therefore, the value of
undertaking trials of high dose oral corticosteroids, to identify
those patients who would benefit from prophylaxis with this drug
(preferably in the inhaled form). These can easily and safely be used
in general practice. Bronchodilator reversibility studies are a
useful simple way of demonstrating variable airways obstruction and
the value of this form of therapy to the patient. They may be
insensitive, however, and a poor response should not necessarily
militate against the use of a bronchodilator.
General practitioners should be aware that patients with
demonstrable airways reversibility are undertreated, because of an
inadequate assessment of their reversibility to corticosteroids. As
responsiveness to this drug cannot reliably be predicted from the
symptomatic history, trials of this therapy should be undertaken more
readily.
b) PART 2
Ihe second part of the study examined the type and efficacy
of therapy used by patients in general practice and compared those
seen by their general practitioners alone with those who also
attended specialist clinics. When criticising drug therapy allowances
have to be made for individual prescribing habits. As in most other
conditions, there is more than one correct way to treat obstructive
airways disease. In assessing therapy, therefore, care is required
not to be prejudiced in favour of one's own therapeutic practice. On
the other hand individual therapy can be compared with standard
therapeutic practices that are advised by most modern reference
works, that are undertaken in most asthma clinics, and that are
taught in our medical schools. By examining care in several general
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practices it was hoped that the general prescribing trend was
emphasised rather than that pertaining to individuals.
Audits of care in asthma clinics have been undertaken
previously, but how representative of the care of asthma in this
country are they? Obviously they are dominated by the clinical
practice of the clinic involved and this study has shewn that only a
quarter of asthmatics requiring treatment are likely to attend such a
clinic. Unfortunately there are difficulties in comparing disease
severity and efficiency of disease control between patient groups.
For instance one group with severe underlying disease but with
optimal treatment may have similar symptoms and PEFRs as a group with
mild underlying disease which is badly treated. Bearing this in mind,
apart from having slightly higher PEFRs and fewer previous hospital
admissions, asthmatics who attended their general practitioners alone
had a similar severity of symptoms as those attending specialist
clinics. Thus the bulk of the care of asthma occurs in general
practice and this applies to all grades of severity. In the case of
chronic bronchitis the dominance of general practice care is even
greater. It may be considered that attendance at a specialist clinic
would replace general practice care, but this was not so as there
were similar general practitioner attendance rates in those patients
who attended specialist clinics and those who did not.
Audits in asthma clinics may be a false indicator of the
impact of specialist care on the patient's management and, therefore,
two groups were assessed: firstly a consecutive series of asthmatics
attending a hospital clinic (in which the patient was interviewed at
the clinic), and secondly those patients who were seen in general
practice but had also attended a specialist clinic within the
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previous 12 months. This study has shewn that although the first
group usually used more efficient therapy than those seen by their
general practitioner alone, this did not always apply to the second
group.
What specific conclusions can be drawn form the detailed
analysis of drug therapy used in general practice?
1) Approximately a tenth of the patients used corticosteroid or
sodium crcmoglycate alone without an available bronchodilator. In
most cases this was inappropriate.
2) Patients attending specialist clinics were more likely to use
inhaled bronchodilators than those attending their general
practitioner. The majority of patients using oral bronchodilators
alone had never used inhalers, but of those who could choose between
the two methods of delivery the majority preferred inhalers. This
suggests that it is the doctor rather than the patient who is
responsible for this prescribing trend of oral bronchodilators.
3) Chronic bronchitics, unlike asthmatics, were more likely to be
prescribed oral rather than inhaled bronchodilators. This may have
been because general practitioners associated oral therapy with
regular treatment and inhaled therapy with treatment on demand. This
is illogical, as inhaled therapy can be used regularly and would have
benefitted many asthmatics and chronic bronchitics in this study.
When comparing patients with a similar severity of symptoms, those
attending specialist clinics were much more likely to use regular
inhaled therapy than those attending their general practitioner
alone.
4) Very few patients were found to be using large doses of inhaled
bronchodilators, and this was more likely to be associated with
121
uncontrolled asthma requiring prophylactic treatment rather than
inhaler abuse. Underuse of inhalers was more common and was often
associated with poor inhaler technique.
5) Poor inhaler technique was a major problem in the use of aerosol
inhalers. Although improved by tuition older patients were less
capable than the younger. Patients seen in the specialist clinic were
much better in this respect, however, this did not apply to those
seen in general practice who had also recently attended a specialist
clinic.
6) There were marked differences between the practices in the
prescription of oral bronchodilators. Mixed oral drugs (containing
theophylline, and ephedrine with or without a barbiturate) continue
to be used, though only infrequently in most practices.
7) Slow release methylxanthines were usually prescribed by the
general practitioners in lew dosage. It is likely that some of the
patients would have benefitted from larger doses. Despite being
unsuitable for demand usage over a quarter of patients used the drug
in this fashion, often because a more suitable bronchodilator was not
available.
8) Approximately a sixth of asthmatics with moderate or severe
symptoms did not use inhaled or oral corticosteroids or sodium
cromoglycate. A half of this group also had PEFRs below 60%
predicted. This represents underuse of these agents.
9) Unlike inhaled corticosteroids, sodium cromoglycate was more
likely to be initiated by the general practitioner than a hospital
doctor. Relatively few patients attending specialist clinics used
sodium cromoglycate. Half the patients using this drug had moderate
or severe symptoms and may have been helped by increased doses or a
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change to inhaled corticosteroids.
10) Poor compliance was a major problem in the use of inhaled
prophylactic drugs and occurred in 4 in 10 patients. Although less
common in patients attending specialist clinics, these differences
were not marked. Two main types were identified: firstly the use of
the drugs on demand, which was associated with a poor understanding
of the function of the drugs, and secondly the omission of drugs
every day in an otherwise regular user. This study emphasises the
importance of non-ccmpl iance as many of these patients had
troublesome symptoms. These results implied that education would not
be entirely successful in eradicating the problem. Less frequent
daily dose regimes might be valuable in irrproving compliance.
11) Sate compliant patients were prescribed below standard doses of
inhaled corticosteroid or sodium cromoglycate despite being
symptomatic. Patients attending specialist clinics were usually
prescribed higher doses of inhaled corticosteroid.
12) Combining the problem of poor compliance, poor inhaler technique,
and underprescription half of the patients using inhaled
corticosteroids or sodium cromoglycate were using inefficient
therapy. Though patients seen in a specialist clinic were more likely
to be using efficient therapy, this did not apply to those seen in
general practice but who had recently attended a specialist clinic.
13) Nearly a third of patients using oral corticosteroids did not use
concomitant inhaled corticosteroids. This was more likely to occur in
those patients attending their general practitioners alone. A
substantial reduction in the use of oral corticosteroids may have
been possible with the increased use of inhaled corticosteroids.
14) Despite the high incidence of incapacity in the chronic
123
bronchitics only about a tenth had previously had a short course of
oral corticosteroids. It is likely that this form of treatment both
for assessment and treatment of exacerbations was underused. Patients
receiving short courses of oral corticosteroids from hospital doctors
tended to be prescribed higher doses for longer periods than those
from the general practitioners.
This study has illustrated considerable differences in the
management of obstructive airways disease between practices. Single
practice audits, therefore, do not accurately reflect general
standards of care in the community. Although it is an improvement to
study several practices, it is a fault of this study that these were
not chosen at random. Unfortunately this problem would be difficult
to overcome. It is interesting that audits in asthma clinics may also
fail to give a true reflection of their impact on patient management.
Many therapeutic problems have been highlighted in this
summary. How can they be avoided? Obviously awareness of their
occurrence is the first step. Seme of the problems could be
eradicated by repeated instruction of the patient. However, seme of
the fault lies with inappropriate prescribing and the main message
from this study is the undertreatment of patients both with the
appropriate drugs and their dosages. What is the cause of this
undertreatment? It is possible that some patients were undertreated
because of the use of the disease label- chronic bronchitis, however,
many asthmatics were also undertreated. It is likely that this was
caused by an anxiety about the safety of asthma therapy, and
ignorance concerning the indications and optimal use of the various
therapies. Much work is required, therefore in demonstrating the





I declare that the work reported in this thesis was
originated and perfarmed by me, with the exception of assistance in
computing detailed in the acknowledgments. I also declare that this
thesis was composed entirely by myself.
126
PUBLICATIONS ARISING FROM WORK IN THIS THESIS
Wardman A.G., Birms V., Clayden A.D. Cooke N.J.
The use of prophylactic drugs for asthma in general practice, what
are the problems?
J. R. Coll. Physicians Lond. 1985; 19(1): 45-47.
Wardman A.G., Cooke N.J.
Bronchodilator therapy in general practice - what are the problems ?
Practitioner 1985; 229: 631-635.
Wardman A.G., Binns V., Clayden A.D., Cooke N.J.
The diagnosis and treatment of obstructive airways disease in general
practice.
Br. J. Dis. Chest 1986; 80: 19-26.
127
ACKNOWLEDGMENTS
I would like to gratefully acknowledge the help, advice, and
encouragement given by Dr. N. J. Cooke during the preparation of this
wcrk.
I would also like to thankfully acknowledge the following:-
Miss Valerie Binns- for her help in computer progranming.
Dr. A. D. Clayden- for help and advice in computing and statistics,
and for allowing me to use his computing facilities.
Dr. A. G. Arnold- for help and advice.
Dr. S. B. Pearson- for constructive criticism of the work.
Miss Kathryn Marsden- for her secretarial help.
Yorkshire Regional Health Authority and Allen and Hanburys LID- for
financial support.
I would like to offer sincere thanks to the general
practitioners who offered unconditional and unselfish support to this
study. Their enthusiastic attitude could only lead to optimism for
the improvement of the care of patients with obstructive airways
disease in the community.
Finally I would like to thank all the patients who gave up
time to participate in this study.
128
Adams, F. (1844-7)
Hie seven hooks of Paulus Aegineta.
Sydenham Society: London.
Mams, F. (1856)
Hie extant works of Aretaeus the Cappadocian.
Sydenham Society: London.
Ahlquist, R.P. (1948)
A study of the adrenotropic receptors.
Am. J. Physiol. 153, 586-600.
Albert, R.K., Martin, T.R., Lewis, S.W. (1980)
Controlled clinical trial of methylprednisolone in patients with
chronic bronchitis and acute respiratory insufficiency.
Ann. Intern. Med. 92, 753-758.
Altounyan, R.E.C. (1967)
Inhibition of experimental asthma by a new compound - Disodium
crcmoglycate "intal".
Acta Allergologica 22, 487.
Anderson, S.D., Seale, J.P., Rozea, P., Bandler, P., Theobald, G.,
Lindsay, D.A. (1976)
Inhaled and oral salbutamol in exercise-induced asthma.
Am. Rev. Respir. Dis. 114, 493-500.
Anonymous. (1981)
Drug inhalation systems for asthmatics.
Drug. Ther. Bull. 19, 41-43.
Armitage, P. (1971)
Statistical methods in medical research.
Blackwell Scientific Publications: Oxford.
Badbam, C. (1808)
Observations on the inflammatory affectations of the mucous membrane
of the branchiae.
Callow: London.
Barger, G., Dale, H.H. (1910-11)
Chemical structure and sympathomimetic action of amines.
J. Physiol (Lend). 41, 19-59.
Barter, C.E., Campbell, A.H. (1976)
Relationship of constitutional factors and cigarette smoking to
decrease in 1-second forced expiratory volume.
Am. Rev. Respir. Dis. 113, 305-314.
Bernstein, L. (1981)
Cromolyn sodium in the treatment of asthma: changing concepts.
J. Allergy Clin. Immunol. 68, 247-253.
129
Blackley, C.H. (1873)
Experimental researches on the causes and nature of catarrhus
aestivus (Hayfever or hayasthma).
Balliere, Tindall and Cox: London.
Bordley, J.E., Carey, R.# McGehee Harvey, A., Howard, J.E., Kattus,
A.A., Newman, E.A., Winkenwerder, W.L. (1949)
Preliminary observations on the effect of adrenocorticotropic hormone
(A.C.T.H.) in allergic diseases.
Bull, of the John Hopkins Hospital 85, 395-398.
Brewis, R.L. (1976)
Lecture notes on respiratory disease.
Blackwell Scientific Publishers: Oxford, London, Edinburgh.
British Thoracic and Tuberculosis Association. (1975)
Inhaled corticosteroids compared with oral prednisone in patients
starting long terra corticosteroid therapy for asthma.
Lancet 2, 469-473.
British Thoracic Association. (1982)
Death from asthma in two regions of England.
Br. Med. J. 285, 1251-1255.
Broder, I., Barlow, P.P., Horton, R.J.M. (1962)
The epidemiology of asthma and hayfever in a total community,
Tecumseh, Michigan.
J. Allergy 33, 513-531.
Brampton Hospital/ Medical Research Council Collaborative Trial.
(1972)
Longterm study of disodiura cromoglycate in treatment of severe
extrinsic or intrinsic bronchial asthma in adults.
Br. Med. J. 4, 383-388.
Brampton Hospital/ Medical Research Council Collaborative Trial.
(1974)
Double blind trial comparing two dose schedules of beclcmethasone
diproprionate aerosol in the treatment of chronic bronchial asthma.
Lancet 2, 303-307.
Brown, P.G., Greville, H.W., Finucane, K.E. (1984)
Asthma and irreversible airflow obstruction.
Thorax 39,131-136.
Burr, M.L., St.Leger, A.S., Bevan, C., Merrett, T.G. (1975)
A community survey of asthma characteristics.
Thorax 30, 663-667.
Burr, M.L., Charles, T.J., Roy, K., Seaton, A. (1979)
Asthma in the elderly: An epidemiological survey.
Br. Med. J. 1, 1041-1044.
130
Burrows, B., Fletcher, C.M., Heard, B.E., Jones, N.L., Wootliffe,
J.S. (1966)
The emphysematous and bronchial types of chronic airways obstruction.
Lancet 1, 830-835.
Campbell, I.A., Schonell, M. (1984)
Respiratory medicine.
Churchill Livingstone: Edinburgh, London.
Camps, P.W.L. (1929)
Inhalation treatment of asthma.
Guy's Hospital Reports 79, 496-498.
Carmichael, J., Paterson, I.C., Diaz, P., Crompton, G.K., Kay, A.B.,
Grant, I.W.B. (1981)
Corticosteroid resistance in chronic asthma.
Br. Med. J. 282, 1419-1422.
CIBA Foundation Guest Symposium. (1959)
Terminology, definitions and classification of chronic pulmonary
emphysema and related conditions.
Thorax 14, 286-299.
Clarkson, D.M., Lamb, E.M., McHardy, G.T.R. (1978)
Computer assisted display and analysis of sequential peak flew data.
Br. J. Clin. Pharmacol. 5, 273-275.
Coca, A.F., Cooke, R.A. (1923)
Qi the classification of the phenomena of hypersensitiveness.
J. Iimtunol. 8, 163-182.
Cochrane, G.M. (1983)
Systemic steroids in asthma.
In Clark, T.J.H. ed.
Steroids in asthma: a reappraisal in the light of inhalation therapy.
ADIS press: Auckland.
College of General Practitioners. (1961)
Chronic bronchitis in Great Britain.
Br. Med. J. 2, 973-979.
Golmer, L.J., Pereira Gray, D.J. (1983)
An audit of the care of asthma in a general practice.
Practitioner 227, 271-279.
Cornelian, S.J., Joyce, H., Holland, F., Carson, R., Pride, N.B.
(1982)




Diurnal rhythms in airway obstruction.
Br. J. Dis. Chest 73, 357-366.
131
Connolly, C.K. (1983)
Management of asthma in outpatients.
J. Roy. Coll. Physicians Lend. 17, 115-120.
Cooke, R.A. (1918)
The uses and limitations of desensitization.
N.Y. Medical Journal 107, 577-583.
Cotes, J.E. (1979)
Lung function.
Blackwell Scientific Publications: Oxford.
Crofton, J.E., Douglas, A.C. (1981)
Respiratory Diseases.
Blackwell Scientific Publications: Oxford.
Crompton, G.K. (1968)
A comparison of responses to bronchodilator drugs in chronic
bronchitis and chronic asthma.
Thorax 23, 46-55.
Crampton, G.K. (1980)
Diagnosis and management of respiratory diseases.
Blackwell Scientific Publications: Oxford.
Crompton, G.K. (1983)
The use of inhaled steroids in the management of asthma.
In Clark, T.J.K. ed.





Curtis, J.K., Liska, A.P., Rasmussen, H. K., Cree, E.M. (1966)




The story of a great consultation.
Annals of Medical History 3, 122-135.
Dawkins, K.D., Muers, M.F. (1981)
Diurnal variation in airflow obstruction in chronic bronchitis.
Thorax 36, 618-621.
Dobell, H. (1886)
On asthma: Its nature and treatment.
•Smith, Elder & Co.: London.
Editorial. (1958)
Steroids in the treatment of asthma.




Br. Med. J. 281, 1088-1089.
Editorial. (1981a)
The proper use of aerosol bronchodilators.
Lancet 1, 23-24.
Editorial. (1981b)
Asthma- a challenge for general practice.




Ellul-Micallef, R., Borthwick, R.C., McHardy, G.J.R. (1974)
The time course of response to prednisolone in chronic bronchial
asthma.
Clin. Sci. Mol. Med. 47, 105-117.
Epstein, S.K., Manning, C.P.R., Ashley, M.J., Corey, P.N. (1979)
Survey of the clinical use of pressurized aerosol inhalers.
Can. Med. Assoc. J. 120, 813-816.
Evans, J.A., Morrison, I.M., Saunders, K.B. (1974)
A controlled trial of prednisone, in lew dosage, in patients with
chronic airways obstruction.
Thorax 29, 401-406.
Fanta, C.H., Ingram, R.H. (1981)
Airway responsiveness and chronic airway obstruction.
Med. Clin. North. Am. 65, 473-485.
Fitch, K.D., Morton, A.R. (1971)
Specificity of exercise in exercise induced asthma.
Br. Med. J. 4, 577-581.
Flenley, D.C., Warren, P.M. (1980)
Chronic bronchitis and emphysema
In Flenley D.C., ed.
Recent advances in respiratory medicine 2.
Churchill Livingstone: Edinburgh and London, 205-224.
Fletcher, C.M., Hugh-Jones, P., McNichol M.W., Pride, N.B. (1963)
The diagnosis of pulmonary emphysema in the presence of chronic
bronchitis.
Q. J. Med. 32, 33-49.
Fletcher, C.M. (1971)
Difficulties in diagnosis.
In Porter, R., Birch, J., eds.
Identification of asthma.
CUBA Foundation study group No. 38.
Churchill Livingstons: Edinburgh and London .
133
Fletcher, C.M., Peto, R., Tinker, C., Speizer, F.E. (1976)
Natural history of chronic bronchitis and emphysema.
Oxford University Press: Oxford, New York, Toronto.
Fletcher, C.M., Pride, N.B. (1984)
Definitions of emphysema, chronic bronchitis, asthma, and airflow
obstruction: 25 years on from the CIBA symposium.
Thorax 39, 81-85.
Floyer, J. (1717)
A treatise of the asthma
Wilkin & Irmys: London.
Fraser, P.M., Speizer, F.E., Waters, S.D.M., Doll, R, Mann, N.M.
(1971)
The circumstances preceding death from asthma in young people in 1968
to 1969.
Br. J. Dis. Chest 65, 71-84.
Fry, J. (1983)
Common diseases- their nature, incidence and care.
MTP press: Lancaster.
Gandevia, B. (1973)
Pressurized sympathomimetic aerosols and their lack of relationship
to asthma mortality in Australia.
Med. J. Aust. 1, 273-277.
Godfrey, S., Balfour-Lynn, L., Konig, P. (1975)
The place of cromolyn sodium in the long term management of childhood
asthma based on a 3-5 year follcw-up.
J. Pediatr. 87, 465-473.
Godfrey, S. (1983a)
Anti-allergic agents.









Inhalation therapy of bronchial asthma.
J.A.M.A. 112, 1223-1226.
Gregg, I. (1964)
The measurement of peak expiratory flew rate and its application in
general practice.
J. Coll. Gen. Pract. 7, 199-214.
134
Gregj, I, Nunn, A.J. (1973)
Peak expiratory flew in normal subjects.
Br. Med. J. 3, 282-284
Gregg, I. (1982)
Asthma and bronchitis.
In Hart, C. ed.
Child care in general practice. Churchill Livingstone: Edinburgh.
Gregg, I. (1983a)
Epidemiological aspects




Role of the family doctor in management.




What is this thing called love? Or defining asthma.
Am. Rev. Respir. Dis. 121, 203-204.
Harding, S.M., Freedman, S. (1978)
A comparison of oral and inhaled steroids in patients with chronic





Herrmann, G., Aynesworth, M.B. (1937)
Successful treatment of extreme dyspnoea "status asthmaticus". Use of
theophylline ethylene diamine (Aminophy11 ine U.S.P.) intravenously.
J. Lab. Clin. Med. 23, 135-148.
Herxheimer, H. (1946)
Dosage of ephedrine in bronchial asthma and emphysema.
Br. Med. J. 1, 350-352.
Hetzel, M.R., Williams, I.P., Shakespeare, R.M. (1979)
Can patients keep their own peak flow records reliably?
Lancet 1, 597-598.
Hetzel, M.R., Clark, T.J.H. (1980)




Hetzel, M.R., Clark, T.J.H. (1983)
Mult asthma
In Clark, T.J.H., Godfrey, S. eds.
Asthma
Chapman Hall: London.
Higenbottam, T.M., Feyeraband, C., Clark, T.J.H. (1980)
Cigarette smoking in asthma.
Br. J. Dis. Chest 74, 279-283.
Hogg, J.C., Macklem, P.T., Thurlbeck, W.M. (1968)
Site and nature of airway obstruction in chronic obstructive lung
disease.
N. Engl. J. Med. 278, 1355-60.
Hughes, D.T.D., Ehpey, D.W. (1972)
Ten years experience in running a pulmonary function laboratory.
Br. Med. J. 4, 470-472.
Hume, K.M., Gandevia, B. (1957)
Forced expiratory volume before and after isoprenaline.
Thorax 12, 276-278.
Hume, K.M., Rhys-Jones E. (1960)
Bronchodi lators and corticosteroids in asthma.
Lancet 2, 1319-1322.
Hutchinson, J. (1846)
Ch the capacity of the lungs and on respiratory functions.
Med. Clin. Trans. 29, 137-252.
Inman, W.H.W., Melstein, A.M. (1969)
Rise and fall of asthma mortality in England and Wales in relation to
use of pressurised inhalers.
Lancet 2, 279-285.
Ishizaka, K., Ishizaka, T. (1971)
Mechanisms of reaginic hypersensitivity. A review.
Clin. Allergy 1, 9-24.
James, P., Henry, J., Cochrane, G.M. (1982)
Compliance with therapy in patients with chronic airflow obstruction.
Thorax 37, 778-779.
Jones, R.S., Buston, M.H., Wharton, M.J. (1962)
The effect of exercise on ventilatory function in the child with
asthma.
Br. J. Dis. Chest. 56, 78-86.
Kennedy, M.C.S., Thursby-Pelham, D.C. (1956)
Cortisone in the treatment of children with chronic asthma.
Br. Med. J. 1, 1511-1515.
136
Laennec, R.T.H. (1846)
A treatise on mediate auscultation, and of diseases of the lungs and
heart.
Translated from the latest edition by a member of the College of
Physicians.
Balliere: London.
Lam, W.K., So, S.Y., Yu, D.Y.C. (1983)
Response to oral corticosteroids in chronic airflow obstruction.
Br. J. Dis. Chest 77, 189-198.
lands, A.M., Arnold, A., McAuliffe, J.P., Luduena, F.P, Brcwn, T.G.
(1967)
Differentiation of receptor systems activated by sympathomimetic
amines.
Nature 214, 597-598
Lee, H.Y., Stretton, T.B. (1972)
Asthma in the elderly.
Br. Med. J. 4, 93-95.
Leopold, S.S., Miller, T.G. (1927)
The use of ephedrine in bronchial asthma and hayfever.
J.A.M.A. 88, 1782-1786.
McFadden, E.R., Ingram, R.H. (1979)
Exercise induced asthma- observations on the irritating stimulus.
N. Engl. M. J. 301, 763-769.
McNiool, K.N., Williams, H.B. (1973)
Spectrum of asthma in children - 1 Clinical and physiological
components.
Br. Med. J. 4, 7-11
Medical Research Gouncil. (1956)
Controlled trial of effects of cortisone acetate in chronic asthma.
Lancet 2, 798-803.
Medical Research Council. (1959)
Field trial of influenza virus vaccine in patients with chronic
bronchitis during the winter 1957-8.
Br. Med. J. 2, 905-908.
Medical Research Council. (1965)




Bronchial asthma as a phenomenon of anaphylaxis.
J.A.M.A. LV, 1021-1024.
137
Milledge, J.S., Morris, T. (1979)
A comparison of slow release salbutamol with slow release
aminophylline in nocturnal asthma.
J. Int. Med. Res. 7 Supp.(1), 106-110.
Milne, L.J.R., Crompton, G.K. (1974)
Beclomethasone diproprionate and oropharyngeal candidiasis.
Br. Med. J. 3, 797-798.
Mitchell, D.M., Gildeh, P., Rehahn, M., Dimond, A.H., Collins, J.V.
(1984)
Effects of prednisolone in chronic airflow limitation,
lancet 2, 193-195.
Morrison Smith, J. (1983)
A recent history of the treatment of asthma- a personal view.
Thorax 38, 244-253.
Morrow Brown, H., Storey, G., George, W.H.S. (1972)
Beclomethascne diproprionate: a new steroid aerosol for the treatment
of allergic asthma.
Br. Med. J. 1, 585-590.
Mjnch, E. P., Tandorf, E., Weeke, B. (1982)
Dose frequency in the treatment of asthmatics with inhaled steroid.
Eur. J. Respir. Dis. 63 (Suppl 122), 143
Nicklaus, T.M., Burgin, W.W., Taylor, J.R. (1969)
Spirometric tests to diagnose suspected asthma.
Am. Rev. Respir. Dis. 100, 153-159.
Nie, N.H., Hull, C.H., Jenkins, J.G., Steinbrenner, K., Bent, D.H.
Statistical package for the social sciences.
McGraw-Hill: New York.
Noon, L. (1911)
Prophylactic inoculation against hayfever.
Lancet i, 1572-1573.
Northern General Hospital, Brampton Hospital, and Medical Research
Council collaborative trial. (1976)
Sodium cromoglycate in chronic asthma.
Br. Med. J. 1, 361-364.
Office of Populations Censuses and Surveys. (1970)
Classification of occupations. H.M.S.O.: London.
Office of Populations Censuses and Surveys. Annual
Hospital inpatient enquiry. Series MB4
H.M.S.O.: London.
Office of Populations Censuses and Surveys. Annual




Asthma: a study in prognosis of 1000 patients.
Thorax 17, 183-189.
Oliver, G., Schafer, E.A. (1895)
The physiological effects of extracts of the suprarenal gland.
J. Physiol. 18, 230-276.
Qrie, N.G.M., Sluiter, H.J., de Vries, K., Tanmeling, G.J., Witkop,
J. (1961)
The host factors in bronchitis.
In Bronchitis. An international symposium, University of Groningen.
Royal Van Gorcum: Assen. 43-59.
Oswald, N.C., Harold, J.T., Martin, W.J. (1953)
Clinical pattern of chronic bronchitis.
Lancet 2, 639-643.
Palmer, K.N.V., Legge, J.S., Gaddie, J. (1971)
Comparison of drugs for asthma.
Br. Med. J. 1, 727
Paterson, J.C., Crampton, G.K. (1976)
Use of pressurised aerosols by asthmatic patients.
Br. Med. J. 1, 76-77.
Paterson, J.W., Shenfield, G.M. (1974)
Bronchodilators
Tubercle B.T.T.A. Review Vol IV 55, 25-40, 61-74.
Pearson, R.S.B. (1968)
Asthma- allergy and prognosis
Proc. Roy. Soc. Med. 61, 467-470.
Pepys J. (1975)
Atopy
In Gell, P.G.H., Coombs, R.R.A., Lachmann, P.J. eds.
Clinical aspects of inrrtunology
Blackwell Scientific: Oxford
Petty, T.L., Brink, G.A., Miller, M.W., Corsello, P.R. (1970)
Objective functional improvement in chronic airway obstruction.
Chest 57, 216-223
Poppius, H., Muittari, A., Kreus, K-E., Korhonen, 0., Viljanen, A.
(1970)
Exercise asthma and disodium cromoglycate.
Br. Med. J. 4, 337-339.
Poppius, H., Salorinne, Y. (1973)
Comparative trial of a new anticholinergic bronchodilator Sch1000,
and salbutamol in chronic bronchitis.
Br. Med. J. 4, 134-136.
139
Porter, R., Birch, J. eds. (1971)
Identification of asthma. CIBA Foundation Study Group No. 38
Churchill Livingstone: Edinburgh and London
Pratt, H.F. (1982)
Abuse of salbutamol inhalers in young people.
Clin. Allergy. 12, 203-208
Prior, J.G., Cochrane, G.M. (1980)
Hsme-monitering of peak expiratory flew rate using a MiniWright peak
flew meter in the diagnosis of asthma.
J. R. Soc. Med. 73, 731-733
Prior, J.G., Cochrane, G.M. (1982)
Assessment of optimum dose of inhaled terbutaline in patients with
chronic asthma: the use of simple cumulative dose response curves.
Br. J. Dis. Chest 76, 266-268
Rackemann, F.M. (1927)
Hayfever and asthma
in Osier, W., McCrae, T. eds.
Modern Medicine Volume IV
Henry Kimpton: London.
Rackemann, F.M. (1947)
A working classification of asthma
Am. J. Med. 3, 601-606
Randolph, T.G., Rollins, J.P. (1950)
The effect of cortisone on bronchial asthma.
J. Allergy 21, 288-295
Rees, H.A., Williams, D.A. (1962)
Long terra steroid therapy in chronic intractable asthma.
Br. Med. J. 1, 1575-1579
Richet, C. (1908)
De L'anaphylaxie et de toxogenines.
Annals de l'lnstitut Pasteur 22, 465-495.
Royal College of General Practitioners (O.P.C.S.) (1979)
Morbidity statistics from general practice 1971-2. Second National
Survey. Studies on Medical and Population Subjects No 36
H.M.S.O.: London.
Royal College of Physicians Carmittee on Thoracic Medicine. (1981 )
Disabling chest disease: prevention and care.
J. Roy. Coll. Physicians Lend. 15, 69-87




Sackett, D.L., Haynes, R.B., Gibson, E.S., Hackett, B.C., Taylor,
D.W., Roberts, R.S., Johnson, A.L. (1975)
Randomised clinical trial of strategies for improving medication
compliance in primary hypertension.
Lancet 1, 1205-1207
Sahn, S.A. (1978)
Corticosteroids in chronic bronchitis and pulmonary emphysema.
Chest 73, 389-395
Salter, H.H. (1868)
On asthma: Its pathology and treatment.
Churchill and Sons: London.
Scadding, J.G. (1971)
Definition of asthma.
In Identification of asthma. CIBA Foundation study group No 38.
Porter, R., Birch, J. eds
Churchill Livingstone: Edinburgh and London.
Scadding, J.G. (1983)
Definition and clinical categories of asthma.




Asthma- contrasts in care.
Thorax 33, 1-2.
Shee, C.D., Poole, D., Cameron, I.R. (1980)
Treatment of asthma in general practice.
Thorax 35, 236
Shenfield, G.M., Hodson, M.E., Clarke, S.W., Paterson, J.W. (1975)
Interaction of corticosteroids and catecholamines in the treatment of
asthma.
Thorax 30, 430-435
Shepherd, G.L., Hetzel, M.R., Clark, T.J.H. (1981)
Regular versus symptomatic treatment of asthma.
Br. J. Dis. Chest. 75, 215-217
Shim, C., Stover, D.E., Williams, M.H. (1978)
Response to corticosteroids in chronic bronchitis.
J. Allergy Clin. Immunol. 62, 363-367
Speight, A.N.P. (1978)
Is childhood asthma being underdiagnosed and undertreated?
Br. Med. J. 2, 331-332
Speizer, F.E., Doll, R., Heaf, P. (1968)
Investigation into the use of drugs preceding death from asthma.






The clinical assessment of inhaled corticosteroids
in Mygind, N., Clark, T.J.H.
Tbpical steroid treatment for asthma and rhinitis.
Balliere Tindall: London.
Stellman, J.L., Spicer, J.E., Cayton, R.M. (1982)
Morbidity from chronic asthma.
Thorax 37, 218-221
Stokes, T.C., Shaylor, J.M., O'Reilly, J.F., Harrison, B.D.W. (1982)





In Clark, T.J.H., Godfrey, S., eds.
Asthma
Chapman Hall: London.
Taylor, R.G., Gross, E., Joyce, H., Holland, F., Pride, N.B. (1985)
Bronchial reactivity to inhaled histamine and the annual rate of
decline in FEV1 in male smokers and ex-smokers.
Thorax 40, 17-22
Thurlbeck, W.M., Simon, G. (1978)
Radiological appearance of the chest in emphysema.
Am. J. Roentgenol. 130, 429-440
Toogood, J.H., Lefooe, N.M., Haines, D.S.M., Jennings, B., Errington
N., Baksh, L., Chuang, L. (1977)
A graded dose assessment of the efficacy of beclomethasone
diproprionate aerosol for severe chronic asthma.
J. Allergy 59, 298-308
Tbogood, J.H., Lefcoe, N.M., Haines, D.S.M., Chuang, L., Jennings,
B., Errington, N., Baksh, L., Cauchi, M. (1978)
Minimum dose requirements of steroid dependent asthmatic patients for
aerosol beclomethasone and oral prednisone.
J. Allergy. Clin. Imnunol. 61, 355-364
Tbogood, J.H., Jennings, B., Lefooe, N.M. (1981)
A clinical trial of combined cromolyn/beclomethasone treatment for
chronic asthma.
J. Allergy Clin. Immunol. 67, 317-324
U2
Tamer-Warwick, M. (1957)
Study of theophylline plasma levels after oral administration of new
theophylline compound.
Br. Med. J. 2, 59-67
Turner-Warwick, M. (1977)
On observing patterns of airflow obstruction in chronic asthma.




Immunology of the lung
Arnold: London.
Ttoeeddale, P.M., Merchant, S., Leslie, M., Alexander, F., McHardy,
G.J.R. (1984)
Short term variability in FEV1: relation to pretest activity, level
of FEV1 and smoking habits.
Thorax 39, 928-932
Ullah, I., Cuddihy, V., Saunders, K.B., Addis, G.J. (1983)
How many blows really make an FEV1, FVC, or PEFR.
Thorax 38, 113-118
Van Helmont J.B. (1662)
Oriatrike or physick refined.
Lodcwick Lloyd: London.
Walker, S.R., Evans, M.E., Richards, A.J., Paterson, J.W. (1972)
The clinical pharmacology of oral and inhaled salbutamol.
din. Pharmacol. Ther. 13, 861-867
Walsh, S.D., Grant, I.W.B. (1966)
Corticosteroids in treatment of chronic asthma.
Br. Med. J. 2, 796-802
Webb, J., Clark, T.J.H., Chilvers, C. (1981a)
Time course of response to prednisolone in chronic airflow
obstruction.
Thorax 36, 18-21
Webb, J., Clark, T.J.H. (1981b)
Recovery of plasma corticotrophin and Cortisol levels after a
three-week course of prednisolone.
Thorax 36, 22-24
Weinberger, M., Hendeles, L. (1983)
Use of theophylline for asthma




Willey, R.F., Milne, L.J.R., Crompton, G.K., Grant, I.W.B. (1976)
Beclomethasone diproprionate aerosol and oropharyngeal candidiasis.
Br. J. Dis. Chest 70, 32-38
Williams, I.P., McGavin, C.R. (1980)
Corticosteroids in chronic airways obstruction: can the patients
assessment be ignored?
Br. J. Dis. Chest 74, 142-147
Willis, T. (1679)
Pharmaceutice rationalis or, an excitation of the operations of
medicines in humane bodies.
Dring, Harper, Leigh: London.
Wilson, J.D., Sutherland, D.C., Thomas, A.C. (1981)
Has the change to beta-agonists combined with oral theophylline
increased cases of fatal asthma?
Lancet 1 , 1235-1237
Wolfe, J.D., Tashkin, D.P., Calvarese, B., Simmons, M. (1978)
Bronchodi lator effects of terbutaline and aminophylline alone and in
combination in asthmatic patients.
N. Engl. J. Med. 298, 363-367
World Health Organisation. (1971)
International classification of diseases.
World Health Organisation. (1978)
International Classification of Diseases.
Wright, B.M., McKerrow, C.B. (1959)
Maximum forced expiratory flow rate as a measure of ventilatory
capacity.
Br. Med. J. 2, 1041-1047.
Wright. B.M. (1978)
A minature Wright peak flew meter.








Date: Date as Postmark
Dear Sir or IIadam
I am a doctor currently working with your general practice, with
the aim of assessing the treatment and control of wheezy chest
conditions. At present you are receiving treatment for your
chest. I would be most grateful, therefore, if you could help
me by attending the surgery at the time and date shown below for
a short interview (approx. 20 minutes), in which we will discuss
how troublesome your symptoms are and what treatment you take.
Should your symptoms be severe it may be useful to give you a
short course of tablets to see if your wheeze responds.
Unless you have especially troublesome symptoms please do not
take treatment in the four hours before the interview.
Time Date
If this time is not suitable I would be grateful if you could
contact at the surgery and a more
convenient appointment will be made for you.
In anticipation of your kind co-operation.
Yours faithfully












1. SEX 1 2
H P
2. AGE 1 2 3 4
18-30 VM01 VJ1o 51-70 70+
3. SOCIAL CLASS 1 2 3 4 5
I II III IV V
4. ARE YOU TROUBLED WITH WHEEZE 1 2 3
YES HO DON'T
KNOW
5. IP YES FOR HOW LONG 0 1 2 3 4
NO <1 Yr 1-5 5-10 >10
TROUBLE Yrs. Yrs. Yrs.
6. IS IT 1 2 3
Continuous wheezing







7. IS IT 1 2 3
Seasonal Perennial (most
months) NEITHER








<20 Yr 20-40 >40 Yr
2
PATIENT ASSESSMENT PROFORMA
9. DO YOU ASSOCIATE YOUR WHEEZE
a) with occupation - Present 1 2 3
YES 110 DON'T KNOW
10. Past 1 2 3
YES NO DON'T KNOW
If YES what occupation
11. b) Hobbies
If YES what hobbies
1 2 3
YES NO DON'T KNOW
12. c) Contact with Animals
13. d) URTI
1 2 3
YES NO DON'T KNOW
1 2 3
YES NO DON'T KNOW
14. Do/Did you suffer from hayfeve: 1 2 3
YES NO DON'T KNOW
15. Do/Did you have eczema 1 2 3
YES NO DON'T KNOW
16. Have you a family history of
hayfever and or asthma
1 0 3
YES NO DON'T KNOW
17. What time of day is your
wheesing worse
0 1 2 3 4
NO
CHANGE
HORNING DAY EVENING NIGHT
13. Do you have cough and sputum
most days for at least three
months out of the year in the
past two years
19. Do/Did you smoke regularly
1 2 3
YES NO DON'T KNOW
1 2 3 4




19A What form of tobacco do/did
you 3moke mostly
0 •1 2 3
NONE CIGARETTE PIPE CIGAR
3
20. How many if a cigarette
smoker?
(cigarettes/day)
21. Did/does smoking affect
your wheeze?
0 1 2 3 4
None no don't
smoker Better Worse change know
0 1 2 3
NIL <10 10-20 >20
22. Have you been warned
about smoking by your
doctor?





23. If you have stopped
smoking, why?








28. What chest condition do you have?
0 1 2 3
Not Own Own Medical
applic¬ volition volition Warning






0 1 2 3
NIL <2 2-5 >5
0 1 2 3
NIL < 2 2-5 >5
1 2 3 4 5
Asthma Chronic Emphysema C.O.A.D. Don't
Bronchitis know
29. G.P. Diagnosis:
1 2 3 4 5
Asthma Chronic Emphysema C.O.A.D. Don't
Bronchitis know
30. Hospital Diagnosis:
1 2 3 4 5
Asthma Chronic Emphysema C.O.A.D. Not
Bronchitis Recorded
ASSESSMENT OF WEE7TE CONTROL
31. Axe you satisfied with youx wheeze contxol 1 2
YES NO
32. Is youx condition: 1 2 3
Static Deteriorating Improving
33. How often have you seen uoux GP with wheeze
in the past six months?
0 1 2 3
NIL <2 2-5 >5
34. Have you required emergency housecalls by youx
G.P. in the past six months fox wheeze?
0 1 2 3
NIL < 2 2-5 >5
35. Have you required injections by
youx G.P. in past 6 months? 1 2
YES NO
How many weeks off School/work have you had
in the past yeax?
0 1 2 3
NIL <2 2-5 >5
37. If episodic how many episodes of wheeze lasting
moxe than 1 houx have you had in the past month?
0 1 2 3 4
NIL <5 5-20 20+ NOT
EPISODIC
33. If you have moxning tightness how long does it
normally last?
0 1 2 3 4
NIL <i hr A-l hr 1-2 hrs 2 hrs+
39. Do you have more severe wheeze on exercise (continuing





Does this regularly interfere with
your activity?




































Cough suppressants, expectorants, antihistamines
1 2
YES NO
62. Which method of therapy do you prefer:









63. Are you using an aerosol inhaler? 1 2
YES NO
64. Were you shown how to use the inhaler
a) by your G.P. 1 2
YES NO
65. b) by pharmacist 1 2
YES NO






































73• Are (were you) using a bronchodilator aerosol inhaler?
1 2 3
YES NO IN PAST
PEESEL7T
74. DHUG:-




76. Is it used on demand? 1 2
YES NO
77. Average Dosage - Puffs/day:
1 2 3 4 5
<2 2-8 9-16 17-24 >24
78.
before exercise? 1 2
YES NO
79« Is it beneficial before exercizing?
1 2 3
YES NO HOT USED
80. Hoy; long does relief from the inhaler last?
0 1 2 5 4
NO <1 1-2 2-4 DON'T
RET.TEF hour hours hours KNOW
81. Hoy; long does an inhaler normally last?









82. Have you noticed side effects:
Tremor 1 2
YES NO
83. Palpitations 1 2
YES NO
84. Other: 1 2
YES 110
If yes, please specify
If inhaled bronchodilators used in the past, why was the drug stopped?
85. DR7JG:-



















If yes, please specify:
92. Worry about danger 1 2
YES NO




94. Do you use Salbutanol Rotacaps 1 2 3
YES HO IN PAST
95. Dose of capsule 1 2
200 Tig 400 ug
9- - Is it used regularly without
regard to wheeze 1 2
YES NO
97. Is it used on demand
93. Average dose per day:
1 2
YES NO
1 2 3 4
400}ig 400-1 fOOjig i;'oo-3200jig > 3200pg
99. Do you use the drug before exercise





101. How long does relief from the inhaler normally last?
0 1 2 3 4
NO
RET, I KH'
<1 hr 1-2 hrs 2-4 hrs 4 hrs
102. Have you noticed side effects:








If yes, please specify:
10
105. Have you tried an aerosol inhaler? 1 2
YES 170





107. Used in the past - why was drug stopped?
1 2 3 4 5
Cause Difficulty Lack of Side Other



























113. Do you use the drug
before exercising
114. Is it beneficial?





115- How long does relief last with tablets?
0 1 2 3 4
NO < 2 2-4 4-3 >8
RELIEF hrs hrs hrs hrs
116. If used at bedtime does it stop nocturnal
wheeze?
0 1 2 3
























If yes, please specify
PAST
121. Why was the drug stopped?
DRUG:
122. Cause unknown














127. Worry about danger 1 2
YES NO
128. Other cause 1 2
YES NO
Please specify





















132. Do/did you find them beneficial? 1 2 3
YES NO NOT
USED
133. Did you experience any













135* Do you take the drug regularly














137. Are doses missed?
1 2 3 4
RARELY ONCE PER ONCE PER AT LEAST
WEEK DAY TWICE A
DAY
138. Is it used on demand
for wheezy attacks? 1 2
YES NO
139. Is it helpful? 1 2
YES NO
140. Do you use Intal
before exercise











143. Were you shown how to use the spinhaler:
1 2 3
YES NO TAKING AEROSOL
15
144. Do you find the spinha],er technique usage
















14'--. Was the drug commenced 1 2




Why was Intal stopped?
147. Cause unknown




















153. Are you using (have you used)
a Becotide/Bextasol inhaler?
1 2 3
YES ITO HI PAST
154. PRESENT




155. Dose: 1 2 3 4
<2 2-4 4-8 8-16
Puffs per Puffs per Puffs per Puffs per
day day day day
156. Are doses missed?
1 2 3 4
RARELY OITCE PER ONCE PER AT LEAST
WEEK DAY TWICE PER
DAY
157. Is it used on demand for v/heesy attacks?
158. Is it helpful? 1 2
YES no
159 • Do you use the inhaler before exercise?













162. How long does an inhaler last?









163. Have you had hoarseness with the inhaler? 1 2
YES NO
Have you had sore throat
with inhaler? 1 2
YES 110
Have you required treatment
for oral thrush? 1 2
YES NO
Was the drug commenced? 1 2
BY G.P. BY HOSPITAL
DOCTOR
PAST
Why was Becotide stopped?
1 2 3 4 5
Cause Lack of Side effects- Worried Other




168. Are you talcing (have you taken)
oral steroids for wheeze?
1 2 3
YES NO EI PAST
PRESENT
169. Vas the drug first prescribed by? 1 2
G.P. HOSPITAL
DOCTOR
170. How long have you been talcing steriods?
1 2 3 4 5
< 1 1-6 6 months 1 year >5
month months - 1 year -5 years years
171. What dose of steroids do you take
(Prednisolone equivalent)
1 2 3 4
<5mgs 5-10mgs 10-15nigs >15mgs
172. Do you alter your steroid dose
with respect to your wheeze? 1 2
YES HO
173* Is this on your doctors recommendation?
1 2 3 4
RARELY USUALLY ALWAYS NEVER
ALTER
174. By how much do you increase your steroid dose for an
exacerbation of wheeze (in Prednisolone equivalent)?
1 2 3 4 5
<10mgs 10-20mgs 20-40ngs >40mgs never
alter
175. How long do you normally take the raised dose?
1 2 3 4 5
(3 day3 3-7 day3 1-2 wks >2 wks never
alter
19
17^. When lowering the dose to "baseline treatment









178. How often do you take raised
courses (per year)
1 2 3 4 5
<2 2-6 6-12 >12 never
alter
179 • Have you noticed any of the following
since steroid therapy?
Weight gain 1 2 3
YES NO DON'T
KNOW
180. G.I. effect 1 2 3
YES NO DON'T
KNOW
181. Changes in facial appearance 1 2 3
YES NO DON'T
KNOW






183. Were the steroids commenced
1 2
BY G.P. BY HOSPITAL
DOCTOR
184. PAST (short course)
Was the drug used in one or more





185. IF YES - How many courses have been given
in the past 1 year?
1 2 3 4
<2 2-6 >6 Course given
over 1 year.
186. How much 3teroid is normally given in
total (Prednisolone equivalent)
1 2 3 ' 4 5
<50 50-100 100-300 >300 don't
mgs mgs mgs mgs know








188. How long has the course lasted usually?









189. Does your wheeze relapse after the course?
1 2 3
Often rarely never




191 - Is the course ever commenced by the patient




192. PAST (Long course)
Was the drug ever used in a course lasting
longer than 6 weeks?
1 2
YES NO
193« What daily dose was used?
(Prednisolone equivalent) 1 2 3 4
<5mg 5-10mg 10-15mg >15mg
21
194. Why was the drug stopped?
Cause unknown





















Are you taking (have you taken)
Ketotifen
1 2 3
YES HO HI PAST
202. PRESENT
Do you use the drag regularly
without regard to wheeze? 1 2
YES NO
203. Dose per day: 1 2 3
<2mgs 2-4uigs >4mgs.
204. Are doses missed? 1 2 3 4
Rarely once per once per at least
week day twice a
day
205. Is it used on demand for wheezy attacks?



















209. Did you experience drowsiness? 1 2
YES NO
210. PAST
Why was the drug stopped?









How many courses of antibiotics have you had
for your wheeze in the past year?
212. DESENSITISATION
Have you had desenaitisation
for your chest?
1 2 3 4
NIL <2 2-4 >4
1 2
YES NO
213. EXPECTORANTS & ATJPTHTSTAMINES
Do you take the above for wheeze





214. Please grade your wheeze control by marking the line below
at an appropriate site:
215. Please grade your wheeze as an average in the
month before interview:
0 No wheeze - able to do all activities
1 Slight wheeze - able to do most activities
2 Moderate wheeze - activities limited regularly
by frequent wheeze





216. 0 No nocturnal wheeze
1 Slight nocturnal wheeze (woken occasionally - less than
once per week)
2 Moderate nocturnal wheeze (woken frequently - 1-3 times
per week - with wheeze)
3 Severe nocturnal wheeze (very frequently woken - more than







PEFR (best of 3)
Predicted fefk
% Predicted
PEFK post Salbutamol if below{80J4
predicted
°/o Reversal (from predicted)
Prednisolone reversibility if PEFR
<6C5o predicted,or grade 3 assess¬
ment
217. % predicted PEFR:
1 2 3 4 5 6
>9055 81-90 71-30 61-70 51-60 41-50
7 3
31-40 21-30
218. Salbutamol reversibility done - 1 2
YES NO
219. % reversal 1 2 3 4
<1055 10-2C55 21-305o >3055
220. Prednisolone reversibility done - 1 2
YES NO
221. Prednisolone reversibility:
1 2 3 4












8 Rimiterol Auto (Pulmadil Auto)
9 Isoetharine (Bronchodilator)
10 Isoprenaline (isoautohaler, Medihaler Iso (Duo) PUB, Brontosil, Aleudrin)
11 Adrenaline (Asna-Vydrin, Brovon, Silbe, Medihaler-Epi)
12 Ipratropium Bromide (Atrovent)
B) Dry Powder Inhaled Bronchodilators
13 Salbutaool Rotacaps
Oral Bronchodilators
14 Salbutamol (Syrup or Tablet)
15 Salbutamol Spandet
16 Terbutaline (S or T)
17 Terbutaline SA
18 Orciprenaline (S or T)
19 Reproterol (t)
20 Isoetharine T (Numotac)
21 Isoprenaline (Aleudrin)
22 Ephedrine + Theophylline + Barbiturate (Amesec, AsnapaZj CAM, Expansyl
Spansule, Nethaprine, Tedral, Pranol)
23 Theophyllines (Choledyl, Labophylline, Monotheamin, Nuelin, Silbephylline,
Theodroz).
24 Theophylline (sustained release) (Nuelin SA, Phyllocontin Continuing,




Intal 26 Intal (Sodium Cronoglycate) Plain Spincap
27 Intal ( " " ) Compound Spincap
28 Intal ( " " } Aerosol
Inhaled Steroids
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